Without directly observed sex, what's a microbicide trialist to do? Adherence and adherence measurement as a

clinical trial design issue in vaginal microbicide

trials for HIV prevention. by Miller, L
LSHTM Research Online
Miller, L; (2017) Without directly observed sex, what’s a microbicide trialist to do? Ad-
herence and adherence measurement as a clinical trial design issue in vaginal microbicide tri-
als for HIV prevention. PhD thesis, London School of Hygiene & Tropical Medicine. DOI:
https://doi.org/10.17037/PUBS.03817569
Downloaded from: http://researchonline.lshtm.ac.uk/3817569/
DOI: https://doi.org/10.17037/PUBS.03817569
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
WITHOUT
DIRECTLY OBSERVED SEX,
WHAT’S A MICROBICIDE TRIALIST
TO DO?
adherence and adherence measurement as a
clinical trial design issue in vaginal microbicide
trials for hiv prevention
LORI MILLER
Department of Infectious Disease Epidemiology
Faculty of Epidemiology and Population Health
London School of Hygiene & Tropical Medicine
Thesis submitted in accordance with the requirements for the degree of
Doctor of Philosophy
University of London
2016
financial or in-kind support for this PhD researchwas
provided by:
Economic and Social Research Council
Tropical Epidemiology Group, LSHTM
HIV Prevention Unit’s Capacity Development Programme of the South African
Medical Research Council
Mwanza Intervention Trials Unit
Tongaat Child Welfare
Anonymous donors
Self-funding
A B S T R AC T
Background
This research examined past microbicide effectiveness trials to better understand how ad-
herence and adherence assessment could be improved in future vaginal microbicide trial
design. No product is currently available despite decades of clinical trials of candidate
microbicides, yet the need for women to have a method to reduce their risk of sexual
transmission of HIV that does not rely on male partner agreement remains urgent. Low
product adherence and inaccurate adherence reporting has inhibited the ability of trials
to accurately assess the biological efficacy of candidate products.
Methods
Three different studies were conducted to examine adherence as a clinical trial design is-
sue. The comparative study examined how five trials measured, calculated, and reported
microbicide adherence. The quantitative study used latent class and latent profile analysis
and multinomial logistic regression to examine if patterns of adherence could be identi-
fied in four trials and, if so, what individual-level factors were associated with the pat-
terns. The qualitative study sought opinions from former trial participants about how
to improve adherence and adherence reporting in future microbicide trials through focus
group discussion workshops in South Africa and Tanzania.
Results
There was diversity in methods used to collect and calculate adherence among the in-
cluded trials. Two methods to calculate averages of overall adherence were identified. Trial
documentation and publications lacked clarity in exact methods used to calculate adher-
ence estimates.
Latent structure analysis identified different patterns of adherence in all included trials,
and these patterns were similar. Multinomial logistic regression identified factors associ-
ated with adherence patterns in all trials.
Women join and stay in microbicide trials for their own needs, which are not necessarily
related to interest in using the investigational product. Key reasons for joining and stay-
ing in trials included access to health care and financial reimbursements. Fear of adverse
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effects from the investigational product was the most important reason why participants
did not use the gel. Participants reported that male partners can act as barriers to gel use
and the key reason for inaccurate reporting of gel use was fear of removal from the trial.
This study demonstrated that trial teams and participants can work together to develop
improved trial designs.
Recommendations
There are improvements to be made in how trialists plan, conduct, analyse and report re-
sults of microbicide trials. Trial teams can improve the clarity of their trial materials, and
use analysis methods to identify patterns of adherence. To improve adherence and trial
implementation, trials can test applicators for evidence of vaginal insertion and report re-
sults to participants, better engage male partners, develop a less watery gel, and create an
atmosphere of transparency and respect between research teams and participants.
Identifying HIV prevention products for women requires better understanding of the
lives of women asked to join these trials, and application of that understanding to collab-
oratively develop innovative trial designs that meet both the needs of the research and the
needs of participants.
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ABIC Sample-size adjusted Bayesian information criterion
ACASI Audio computer-assisted self-interview
AIC Akaike information criterion
AOR Adjusted odds ratio
ARV Antiretroviral
ASPIRE A Study to Prevent Infection with a Ring for Extended Use
AVAC Global Advocacy for HIV Prevention
BAT24 Before-after-two-24; gel-use regimen for CAPRISA 004
BIC Bayesian information criterion
CAB Community advisory board
CAG Community advisory group
CAPRISA Centre for the AIDS Programme of Research in South Africa
CI Confidence interval
COL-1492 Nonoxynol-9 vaginal gel; also the name of the multi-country trial
CONRAD Formerly: Contraceptive Research and Development Program
CRFs Case report forms
CS Cellulose sulphate
CVL Cervical vaginal lavage
DNA Deoxyribonucleic acid
DSA Dye stain assay
DSMB Data and safety monitoring board
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EM Expectation-maximisation
ESRC Economic and Social Research Council
FACTS Follow-on African Consortium for Tenofovir Studies
FEM-PrEP Preexposure Prophylaxis Trial for HIV Prevention among African Women
FGD Focus group discussion
FGDW Focus group discussion workshop
FHI Formerly: Family Health International
FIML Full information maximum likelihood
FTC Emtricitabine
FTFI Face-to-face interview
GCP Good clinical practice
GPP Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials
HIV Human immunodeficiency virus
HPTN HIV Prevention Trials Network
HR Hazard ratio
IC Informed consent
IDI In-depth interview
IPM International Partnership for Microbicides
iPrEx Pre-exposure Prophylaxis Initiative (iPrEx) trial
IPV Intimate partner violence
LCA Latent class analysis
LPA Latent profile analysis
LRT Likelihood ratio test
LSHTM London School of Hygiene and Tropical Medicine
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MAR Missing at random
MDP Microbicides Development Programme
MIRA Methods for Improving Reproductive Health in Africa trial
MITU Mwanza Intervention Trials Unit
MRC Medical Research Council
MTN Microbicide Trials Network
N-9 Nonoxynol-9
OR Odds ratio
pH Potential of hydrogen
PhD Doctor of Philosophy
PK Pharmacokinetic
PrEP Pre-exposure prophylaxis
PSA Prostate-specific antigen
RA Research assistant
RR Relative risk
RRR Relative risk ratio
RSID-Semen Rapid Stain Identification of Human Semen
SA South Africa
SAP Statistical analysis plan
SOP Standard operating procedures
STI Sexually transmitted infection
TDF Tenofovir disoproxil fumarate
TVF Tenofovir gel
TZ Tanzania
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UK United Kingdom
UNAIDS Joint United Nations Programme on HIV/AIDS
US United States of America
UTC University of Cape Town
UTI Urinary tract infection
UVL Ultraviolet light
VIREA Visual inspection of returned empty applicators
VOICE Vaginal and Oral Interventions to Control the Epidemic
WHO World Health Organization
ZAR South African Rand
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this work is dedicated to my mother
I am woman, hear me roar
In numbers too big to ignore
And I know too much to go back and pretend
Cause I’ve heard it all before
And I’ve been down there on the floor
No one’s ever going to keep me down again
Oh, yes, I am wise
But it’s wisdom born of pain
Yes, I’ve paid the price
But look how much I gained
If I have to I can do anything
I am strong
I am invincible
I am woman
You can bend but never break me
Cause it only serves to make me
More determined to achieve my final goal
And I’ll come back even stronger
Not a novice any longer
Cause you’ve deepened the conviction in my soul
Oh, yes, I am wise
But it’s wisdom born of pain
Yes, I’ve paid the price
But look how much I gained
If I have to I can do anything
I am strong
I am invincible
I am woman
I am woman, watch me grow
See me standing toe-to-toe
As I spread my loving arms across the land
But I’m still an embryo
With a long, long way to go
Until I make my brother understand
Oh, yes, I am wise
But it’s wisdom born of pain
Yes, I’ve paid the price
But look how much I gained
If I have to I can face anything
I am strong
I am invincible
I am woman
∗Helen Reddy, 1971
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1 
introduction
1
I N T RO D U C T I O N
1.1 introduction
In many places and relationships worldwide, women may not have control over how and
when they have sex. Use of condoms, which prevent sexual transmission of HIV, requires
the knowledge and agreement of male sexual partners. HIV continues to be a global prob-
lem, with young women aged 15–24 years, in particular, at high risk for HIV infection.
Young women represent 11% of the population globally but accounted for 20% of new
HIV infections in 2015.1 Efforts to reduce sexual transmission of HIV based on absti-
nence, faithfulness, and correct and consistent use of condoms do not take into account
the fact that individuals’ risk may depend not only on their own behaviours but also on
the behaviours of their sexual partners, of which they may have no knowledge or control.
Such individual behaviour-based prevention messaging does not take into account gen-
der dynamics in intimate relationships, structural factors which may put women at risk
of HIV, and inequalities in how sexes are treated in societies.2,3,4,5,6
The concept of vaginal microbicides resulted from the need for women to have a method
to reduce their risk of sexual transmission of HIV that they can control themselves and
does not rely on male partner agreement.7 The concept of a vaginal microbicide called for
a topically applied product which could be developed in different formulations such as
a gel, film, ring, or suppository. Preferably, the product would reduce a woman’s risk of
HIV acquisition as well as other sexually transmitted infections and would be available in
contraceptive and non-contraceptive forms. To have the broadest impact, microbicides
would be available without prescription and could be used without the need for clinical
monitoring.
The field of vaginal microbicide research was born in the 1990s, when candidate prod-
ucts began to be tested in clinical trials in populations at risk of HIV infection. However,
designing, conducting, and analysing results of clinical trials for vaginal microbicides is
challenging for a complex set of reasons.8,9,10,11,12,13,14 After 26 years of clinical trials, a mi-
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crobicide product is still not available on the market.
A central challenge of microbicide trials, unlike many clinical trials that test investigational
drugs, is that the end result of a late-stage microbicide trial does not give an estimate of
product efficacy, or biological effect of the product. Microbicides are user-controlled prod-
ucts: they are used around the time of sex or inserted vaginally at specific times, during
the normal lives of clinical trial participants, rather than in a controlled setting such as a
research clinic. Therefore, the final result of a microbicide trial is influenced by a combi-
nation of factors. These include the biological effects of the product, participants’ adher-
ence, and other factors which may inhibit a trial’s ability to detect an efficacious product;
for example, anal sex, lubrication effect of the placebo gel, and time off product due to
pregnancy.11,15,16,17 In addition, rather than an estimate of efficacy, late-stage clinical trials
of vaginal microbicides give an estimate of the effectiveness of the study product. Fur-
ther complicating the situation are the absence of a gold standard or consistently reliable
way in clinical trials to measure adherence to using microbicides or exposure to HIV. His-
torically, microbicide trials have largely relied on participants reporting their own sexual
behaviour and microbicide use; both areas are known to be subject to recall bias and social
desirability bias.18,19
Microbicide trials are conducted to test whether a candidate microbicide is effective at re-
ducing HIV transmission and whether it is safe for human use. If research teams are not
sure to what extent trial participants have used the candidate product, then it is difficult to
interpret the results of microbicide trials. A trial result that does not indicate a beneficial
effect of the product could be due to the fact that the product is actually biologically inef-
fective at reducing HIV transmission, or it could be due to the fact that trial participants
did not use the product enough for protective properties to be detected. Conversely, it
is possible that a candidate product could increase the risk of HIV if used correctly. Yet
this effect would not be observed if product use by trial participants is low. Similarly, if
results of a microbicide trial show an equal number of adverse events in the experimental
and placebo arms, one explanation could be that the product is safe for human use. An
alternative explanation could be that participants did not use the product enough for ad-
verse events to be observed at an adequate level for detection.
In 2012, at the start of this PhD research, 12 vaginal microbicide effectiveness trials had
been conducted,20,21,22,23,24,25,26,27,28,29,30,31 with only one trial, CAPRISA 004,31 a phase
IIb study of 1% tenofovir gel, showing an effect of reducing HIV transmission (Table 1.1.1).
Due to the large size and cost of microbicide trials, once a phase III trial is completed and
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an investigational product is not found to be effective, it is typically discarded from the
product development pipeline, even if there is lack of confirmation that it is biologically
non-efficacious. This is a disadvantage to women worldwide who would benefit from
a product they could use to reduce their chance of becoming infected with HIV. In the
biomedical HIV prevention field, there has been great concern that low adherence may
have been the cause of some of the null findings in the effectiveness trials. Thus, this
significant challenge of adherence in microbicide trials has emerged as a key topic in the
microbicides field.
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Reference Product Trial/Sponsor
Key results
HIV vs. Placebo
[95% confidence interval]
Locations
Participants 
contributing to key 
results
Years conducted
First generation
Kreiss, 1992
N-9 Sponge, 1000mg vs. 
placebo suppository
FHI
Hazard ratio HIV 1.7 [0.9–3.0],                      
[Genital ulcer relative risk 3.3 p<.001]
Kenya 116 January 1987–June 1990
Roddy, 1998 N-9 Film, 70 mg FHI Rate ratio 1.0 [0.7–1.5] Cameroon 1170 March 1994–December 1996
Richardson, 2000 N-9Gel, 52.5 mg FHI Relative risk 0.7 [0.3–1.5] Kenya 278 July  1996–February 1998
Van Damme, 2002 N-9 Gel, 52.5 mg COL-1492 UNAIDS
Hazard ratio 1.5 [1.0–2.2]                                    
For women using >3.5 applicators per 
day: HR 1.8 [1.0–3.2]
Benin, Cote d’Ivoire, South Africa, 
Thailand
765 September 1996–June 2000
Peterson, 2007 C31G, SAVVY Gel Savvy Ghana FHI Hazard ratio 0.9 [0.3–2.3] Ghana 2038 March 2004–February 2006
Feldblum, 2008 C31G, SAVVY Gel Savvy Nigeria FHI Hazard ratio 1.7 [0.9–3.5] Nigeria 2082 September 2004–August 2006
Second generation
Van Damme, 2008 Cellulose sulphate CS CONRAD
Hazard ratio 1.61 [0.86–3.01], final 
analysis; Interim result at independent 
data monitoring committee: HR 2.3 
[1.05–5.03]
Benin, India, South Africa, 
Uganda
1398 July 2005–March 2007
Halpern, 2008 Cellulose sulphate CS FHI Hazard ratio 0.8 [0.3–1.8] Nigeria 1506 November 2004–March 2007
Skoler-Karpoff, 2008 Carraguard
Carraguard 
Population Council
Hazard ratio 0.87 [0.69–1.09] South Africa 6004 March 2004–March 2007
Abdool Karim, 2011
BufferGel,                            
0.5 % PRO 2000
HPTN 035
Hazard ratio 1.10 [0.75–1.62]                      
Hazard ratio 0.70 [0.46–1.08]
Malawi, South Africa, Zambia, 
Zimbabwe, US
3087 February 2005–September 2008
McCormack, 2010
 0.5% PRO 2000,                
2% PRO 2000
MDP 301 Hazard ratio 1.05 [0.82–1.34]
South Africa, Tanzania, Uganda, 
Zambia
8859 (6268 for 0.5% + 
placebo)
October 2005–September 2009 
(2% dropped February 2008)
Third generation
Abdool Karim, 2010 1% tenofovir gel CAPRISA 004 Hazard ratio 0.63 [0.42–0.94] South Africa 889 May 2007–March 2010
Table 1.1.1: Microbicide effectiveness trials through 2012
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With the completion of each trial, more experience is gained and that knowledge is shared
within the field so future trials can be improved.8,10,11,32 However, despite concerns around
adherence, the study design of microbicide trials has largely remained the same. Improve-
ments in trial design have been incremental and have not looked fundamentally at the
design of the trials in the context of the needs of trial participants or in terms of how best
to understand and report adherence-related data.
Clinical trials are bound by the realities of science and donor budgets, and must be con-
ducted within the context of research ethics. Healthy individuals volunteer their bodies,
their lives, and their time to participate in trials. They are exposed to potential risks of
the study product and study participation. In the case of effectiveness or late-stage micro-
bicide trials, tens of millions of dollars, often from taxpayers, are invested in these multi-
country, multiyear studies.33,34 These trials are bound by the ethical obligation of scien-
tific quality. Trials must be designed in a way that maximises, to the best extent possible,
the ability to achieve their research objectives. If adherence is known to be an important
issue in interpreting results of microbicide trials, then it is an ethical obligation to under-
stand how to facilitate good adherence and more accurate adherence estimation in these
trials.35 There is a scientific and ethical need to fully consider adherence as a critical micro-
bicide trial design issue so that future trials will be better able to answer their research ques-
tions and equipped to identify an efficacious vaginal microbicide.8,13,19,24,25,26,32,36,37,38
1.2 purpose of this phd research
The goal of this PhD research was to critically examine, from different perspectives, ex-
periences of past vaginal microbicide effectiveness trials to better understand how adher-
ence and adherence assessment can be improved in future microbicide trial design. In
this context, adherence assessment refers to the measurement of adherence and sexual be-
haviour, and to the analysis and reporting of those data. The goal of this PhD research
was accomplished by conducting three different studies, each with a different objective
and methodology, to examine adherence as a clinical trial design issue from a different
perspective.
Objective one of this PhD research was to critically examine how five completed effec-
tiveness microbicide trials measured, calculated, and reported microbicide gel adherence.
To accomplish this objective, trial-related materials were systematically reviewed and com-
parative analysis methods were used to identify how trial teams collected adherence and
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sexual behaviour data and how trial teams reported adherence in their primary results
manuscripts. Trial materials were also reviewed to identify the specific choices and calcu-
lations that trial teams used to characterise adherence.
Objectivetwo of this PhD research was to examine, using self-reported adherence data
from four completed effectiveness microbicide trials, if longitudinal patterns of adherence
are evident, and if so, what individual level factors are associated with these patterns of ad-
herence. This objective was accomplished using quantitative methods to conduct latent
class and latent profile analysis, followed by multinomial logistic regression.
Objective three of this PhD research was to use the expertise of former microbicide
trial participants to understand barriers to adherence and accurate adherence reporting,
and to seek their opinions about how to improve adherence and adherence reporting in
future microbicide trials. Qualitative methods were used to conduct focus group discus-
sion workshops to engage former participants in concepts around microbicide trial design,
adherence, and their own experiences of trial participation. Eight focus group discussion
workshops were conducted in Tongaat, Durban, South Africa, and Mwanza, Tanzania.
Table 1.2.1 provides a summary of this PhD research by listing each objective as well as
corresponding research questions and methods.
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Objective Research questions Methods
Comparative study
A. How are overall adherence estimates reported in primary trial results 
publications? 
• Obtain protocols, CRFs, and statistical analysis plans from trial 
teams.
B. What are the different adherence and sexual behaviour adherence 
measures used to collect source data?
• Review primary results publications and extract overall adherence 
estimates.
C. How are adherence and sexual behaviour data used to calculate 
overall adherence estimates?
• Extract source questions used for adherence and sexual behaviour 
measurement from CRFs.
• Analyse overall adherence estimates, statistical analysis plans, and 
CRFs to determine exact methodology used to calculate adherence 
measures; summarize findings in diagrams.
• Conduct survey with trial teams to check results of analysis, clarify 
specific methods, and provide rationale for measurement and 
analysis methods used. 
Quantitative study
A. Can longitudinal patterns of adherence be identified in self-reported 
data in four completed effectiveness trials?
• Review CRFs and protocols from trials to determine appropriate 
variables to request for quantitative study.
B. If patterns can be identified, how do patterns of adherence compare 
across the trials?
• Obtain and manage data sets for analysis.
C. If patterns are identified, what individual-level factors are associated 
with the different patterns of adherence, and how do these compare 
across trials? 
• Conduct latent class and latent profile analysis on data from four 
trials to identify patterns of adherence.
• Conduct multinomial logistic regression with latent trajectories as 
outcome using data from four trials.
Qualitative study
A. What are the reasons why women join and stay in microbicide trials?
• Develop participatory tools to engage former trial participants in 
thinking about microbicide trial design, the importance of adherence, 
and factors affecting adherence and adherence reporting in 
microbicide trials.
B. What are former participants’ experiences with regard to barriers to 
product use?
• Obtain required ethical approvals for qualitative study. 
C. What are former participants’ experiences with regard to barriers to 
accurate adherence reporting?
• Recruit former microbicide trial participants in Tongaat, Durban, 
South Africa; and Mwanza, Tanzania.
D. What are former participants’ feelings and needs?
• Conduct focus group discussions workshops with former 
microbicide gel trial participants. 
E. What are former participants’ perceptions of trial staff and the 
research?
• Gain former participants’ feedback on how to improve adherence 
and adherence reporting in future microbicide trials.
F. How would former participants design future microbicide trials with 
respect to improving adherence and adherence reporting? 
The goal of this PhD research was to critically examine, from different perspectives, experiences of past vaginal microbicide effectiveness trials to better understand how adherence and adherence assessment can 
be improved for future microbicide trial design. 
To critically examine how five completed effectiveness microbicide trials 
measured, calculated, and reported microbicide gel adherence.
To examine, using self-reported adherence data from four completed 
effectiveness microbicide trials, if longitudinal patterns of adherence are evident 
and, if so, what individual-level factors are associated with patterns of 
adherence.
To use the expertise of former microbicide trial participants to understand 
barriers to adherence and accurate adherence reporting and seek their opinions 
about how to improve adherence and adherence reporting in future microbicide 
trials.
Table 1.2.1: PhD research
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1.3 thesis structure
Chapter 2 provides background and context to the field of microbicides at the start of
this PhD research in 2012. It describes microbicide trial design and its challenges, gives a
brief history of effectiveness trials completed through 2010, and provides an overview of
the primary methods used to measure adherence and sexual behaviour in those trials.
Chapters 3, 4, and 5 comprise the research content of the thesis, which was designed
in 2012. Each chapter includes one study which corresponds to a particular PhD research
objective. Research chapters are written in paper style, meaning that specific study results
are contextualised within the format of an introduction, methods, results, and discussion.
Chapter 3, “What do we really mean by adherence? A comparative study of measur-
ing, calculating, and reporting adherence in five microbicide effectiveness trials,” contex-
tualises and reports results of the comparative study to address the first objective of this
PhD research.
Chapter 4, “Hidden heterogeneity: Uncovering patterns of adherence in microbicide
trials,” contextualises and reports results of the quantitative study, using latent class and
latent profile analysis and multinomial logistic regression to address the second objective
of this PhD research.
Chapter 5, “Design your own microbicide trial: Opinions of former microbicide trial
participants on how to improve adherence and adherence reporting in future microbicide
trials,” contextualises and describes results of the qualitative study to address the third ob-
jective of this PhD research.
Chapter 6, the overall discussion, contains a summary of the key findings of this PhD
research as well as an update on the microbicide field, and provides a discussion of the
PhD research results contextualised within research results published through 2015.
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background
2
W H Y A R E M I C RO B I C I D E T R I A L S S O C O M P L I C AT E D ?
Chapter 2 gives overall background on the complexities of phase IIb and phase III vaginal
microbicides. The first section, 2.1, provides a general description of how microbicide tri-
als are designed and implemented. The following section, 2.2, explains why phase IIb and
phase III trials are unable to test product efficacy, and the importance of sexual behaviour
measurement for interpreting trial results. Section 2.3 gives a brief history of microbicide
effectiveness trials up to the start of the PhD research in 2012. Section 2.4 provides an
overview of methods to measure adherence used in those trials. The final section, 2.5,
provides a brief summary of the microbicide trials that are included in this PhD research.
2.1 vaginal microbicide clinical trial design and methodology
As with other biomedical HIV prevention trials, microbicide trials must be conducted in
populations of healthy HIV-negative individuals where incidence of HIV is high. The dif-
ference between HIV seroconversion rates among the group of trial participants assigned
to the investigational product and the group of trial participants assigned to the control
product is how investigational products are evaluated. If trials are conducted among pop-
ulations in which HIV incidence is low, trials would not be feasible due to the time it
would take to answer their research questions. Even within populations where there is
high HIV incidence, HIV seroconversion is a rare event. Effectiveness trials typically en-
rol 800–9000 women and follow them for 1–3 years to accrue the required number of
HIV seroconversions in order to have suitable power to detect a difference between the
experimental and control arms.
From an ethical standpoint, it is important that investigational products be tested for
safety and efficacy in populations that need and will use the products.39 For these reasons,
the majority of microbicide trial participants are located in sub-Saharan Africa. Economic,
social, educational, and other structural factors which put women at risk for HIV are
the same factors which make them vulnerable in other important ways.40 Women who
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may be interested and eligible to join microbicide trials may lack economic independence,
and may have limited access to education and other opportunities where they live. Thus,
women who enrol in microbicide effectiveness trials are a particular population with par-
ticular needs and circumstances that are different from the circumstances and needs of
those who fund, design, and conduct the microbicide trials.
To achieve the number of required seroconversions, microbicide trials are generally multi-
site studies and usually involve collaboration between several countries. Donors are often
from the United States (US) or United Kingdom (UK); partnerships are formed across
countries to design, conduct, and analyse results from the trials.40 Conducting microbi-
cide trials to meet the needs of all the stakeholders requires extensive planning and coor-
dination. Trials also require regulatory and ethical approval from multiple bodies before
recruitment is allowed to commence. The power inequalities and cultural and linguistic
differences between stakeholders add further layers of complexity. Research teams recruit
healthy populations of people to volunteer to use investigational products that may be
harmful. Understandably, without careful consideration of how trials are communicated
to local communities, controversy can emerge, especially around concerns of exploitation.
Such controversies can put the research at risk if not addressed sensitively.41,42,43
Recruitment of trial participants requires liaising with local authorities and communities.
Community advisory boards or groups (CABs or CAGs) are developed or engaged with to
help bridge trial sites and local communities. Populations of sexually active, healthy HIV
negative women are identified and recruited. As it takes time to enrol the required num-
ber of participants at each site, screening and enrolment of participants is staggered and
can take place over long periods of time until accrual targets are met. Because enrolment
in microbicide trials includes eligibility requirements that require clinical and laboratory
tests, there is typically a two-stage informed consent process. Generally, prospective par-
ticipants are invited to provide informed consent to complete the screening procedures,
which include asking participants about themselves and their sexual history as well as con-
ducting clinical and laboratory procedures to check their health, pregnancy, HIV, and STI
status. Once participants are deemed eligible per pre-defined protocol criteria, they are in-
vited to enrol in the clinical trial.
The informed consent process for enrolment in microbicide trials is lengthy. Key aspects
of the process include informing participants about the voluntary nature of participation,
the investigational nature of the product, that ability to protect against HIV is not known,
that adverse effects are not all known, how the product is expected to be used, trial pro-
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cedures, clinical and laboratory tests, collection of behavioural data, protection of data,
reimbursement, and their rights as participants.44 Reimbursement varies from site to site
and must be approved by local ethics committees. The reason for local approval is to help
ensure that the reimbursement amount is not coercive, meaning that, it is not so large that
individuals in the local population would feel compelled to join a trial that exposes them
to potential adverse effects of an investigational product because the amount of money
being offered is so attractive. In most sub-Saharan countries, the value of the amount is
not substantial. South Africa, however, requires that clinical trial participants receive 120
ZAR per trial visit,45 which may be a significant motivating factor for women in South
Africa to join microbicide trials.
Participants who enrol are randomly assigned to one of the arms of the trial, where they
receive the intervention or control plus an HIV risk reduction package. The HIV risk
reduction package changes as new ways to prevent HIV are discovered. Microbicide trials
through 2012 have typically included HIV risk reduction counselling, provision of con-
doms, and STI screening and treatment. In some trials, participants are encouraged to
invite their partner or partners to come to the clinic for HIV testing and counselling, or
to learn about the study itself.
Participants who consent to enrol are expected to use the study product per the required
regimen. At the start of this PhD research, all regimens of completed effectiveness micro-
bicide trials required use of the product around the time of sex, referred to as a “coitally de-
pendent” regimen. Participants are generally asked to return to the study clinic monthly
for product refills, adverse event reporting, pregnancy tests, HIV and STI screening, risk
reduction counselling, and to report product use and sexual behaviour. Trials may divide
some of the procedures into “shorter” (monthly) visits, and “longer” (quarterly) visits.
Regular visits are generally scheduled on a particular day each month, and there is an al-
lowable “window period” around that day (for example, 7 days before or after the sched-
uled date) for which attendance during that time would be considered a successful visit
and data collected at that visit would be entered into the database as that month’s data for
that participant. If a participant has a visit outside of the allowable window for a particu-
lar period, then the visit may be considered “missed.” As clinical trials must minimise loss
to follow-up, when participants do not show up for their appointment, dedicated staff
typically follow up with them to remind them about the missed appointment. Once a
participant has completed the amount of time required for her participation, or the trial
has stopped for other reasons, she will attend a final visit. Some trials have included spe-
cial exit questionnaires to ask more detailed questions about trial participation, product
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use and acceptability, and behavioural or other information.
Trials are monitored by independent safety and data committees44 which are composed
of experts who are not staff on the particular trial. The committees check the progress of
the trial at designated time points and will make recommendations that a trial continue as
planned, be stopped for futility, be stopped for harm, or in the case of a substantial ben-
efit, be stopped as it would no longer be ethical to provide participants with the control
product.
Main trial results are typically reported at large international conferences, which may or
may not be coordinated with publication of the primary results manuscripts in journals.
Further analyses are then conducted and published. Trial results, either at the planned
end of a trial or following important findings from an independent data and safety moni-
toring committee meeting, need to be disseminated quickly as results are relevant to both
ongoing trials in the field and planned trials. Clinical trials are conducted within the con-
text of equipoise; if a product is found to be harmful, trials testing that product may need
to stop. If a product is found to be highly effective, it may no longer be ethical to continue
ongoing trials of that product. Results of other biomedical interventions for HIV are also
relevant. If another HIV prevention method is found to be effective, this may affect the
informed consent process and package of HIV prevention options potentially offered to
trial participants.
2.2 specific methodological challenges in microbicide trials:
effectiveness versus efficacy and how to interpret trial
results
Phase III clinical trials traditionally assess biological efficacy of an investigational prod-
uct in a population of healthy human volunteers. In an ideal scenario, any difference in
HIV incidence between participants using the investigational product and those using the
placebo product would be due to the biological effect of the investigational drug. Phase
IIb and phase III trials of vaginal microbicides for the prevention of sexual transmission of
HIV are faced with a number of unique methodological challenges, discussed below, that
affect the ability of a trial to detect a difference in HIV incidence between the arms, and
to identify a potentially efficacious (or harmful) product.8,10,11,12,13,16,46,47,48 Therefore,
phase IIb and phase III trials are unable to provide results that indicate biological efficacy
of an investigational product; rather, results provide an estimate of product effectiveness.
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As microbicide trials estimate effectiveness rather than efficacy, it is particularly important
to measure the factors which limit the ability of trials to estimate product efficacy, to the
best extent possible, in order to optimise results interpretation. These methodological
challenges, which affect how phase IIb and phase III trials are designed and conducted,
and how results can be interpreted, are briefly summarised below.
2.2.1 pregnancy
As candidate microbicides are investigational, the effects of the drugs on a foetus are un-
known. For this reason, trial protocols usually require that if a participant has a positive
pregnancy test, she not use the study product until a negative pregnancy test is observed.
This means that a substantial period of time during a woman’s follow-up may be without
product use, especially in locations where fertility is high, thereby decreasing the power
of the trial.8,11,46
2.2.2 placebo gel
Microbicide gel trials use placebo gels in the comparator arm. Due to the lubricating and
possible barrier effects of a placebo gel, the “placebo” used in microbicide trials may not be
truly inert and may have some ability to reduce HIV transmission for participants using
the placebo gel.8,11,46 Also relevant is that some placebo gels and investigational products
have different pH levels and ingredients,23 such as preservatives which may affect vaginal
flora. Presence of a gel in the vagina will also dilute semen—which, if the partner is HIV
positive, will contain HIV. For these reasons, placebo gels may affect the incidence of HIV
in the control arm compared to no use of gel at all. This is the reason that the HPTN 035
trial team chose a clinical trial design with two control arms: one blinded with a placebo
gel, and the other unblinded with no gel intervention, using only condoms for HIV pre-
vention.12
2.2.3 anal sex
Vaginal microbicide effectiveness trials to date have only tested products that were de-
signed for vaginal use. Participants were instructed not to use the microbicides rectally
when engaging in anal sex. If all participants used their study products exactly as in-
structed, but also engaged in anal intercourse without condoms, it is likely that some of
the HIV seroconversions in the trial would be due to anal rather than vaginal transmis-
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sion of HIV, thus limiting the ability to detect a protective effect of the investigational
product on vaginal HIV transmission of HIV.8,11,48 This possibility is particularly likely
given the higher rate of HIV transmission associated with anal sex, despite lower rates of
anal sex than vaginal sex in most microbicide trial populations.48
2.2.4 condom
Another dilemma faced in microbicide trial design is that, from an ethical standpoint, par-
ticipants must be provided with risk reduction counselling and condoms,49 yet exposure
to HIV while using the investigational product versus the placebo is how a difference is
detected between the two products. If intact condoms are used correctly during each sex
act, no HIV transmission will take place, and it will not be possible to test the effect of a
microbicide. As long-term perfect condom use within a population is rare, and indeed is
one of the reasons microbicides are needed, most populations recruited into microbicide
trials will experience HIV serocoversions over time. However, the patterns of condom
use, in combination with the study product, may be important for interpretation of re-
sults.11,13 If participants tend to use condoms and the study products together, and use of
the gel alone during sex is rare, it will be difficult for a trial to detect a difference in HIV
rates in the trial arms.
2.2.5 product adherence
The most significant threat to trial results and their interpretation is adherence to the
study product. If women do not use the study products to a sufficient extent, HIV rates
in the different trial arms will be similar and it will not be possible for a trial to detect a pro-
tective effect of a truly efficacious drug.10,11,13,16 There are multiple reasons why women
might not use study products, including the fact that women enrolled in trials are aware
that they might be assigned to the placebo gel which has no active drug. Therefore, some
form of measurement of product adherence is critical in microbicide trials so that trial
results can be interpreted optimally.
In order to interpret results, a microbicide trial should measure product use, condom use,
vaginal sex, and anal sex. Coitally dependent microbicides create an even more challeng-
ing situation because gathering data on product use, by definition, also requires gathering
data about sexual behaviour. This translates into collecting data about each vaginal sex
act, each anal sex act, condom use for each vaginal sex act, condom use for each anal sex
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act, and gel use for each vaginal sex act.32,50
Sexual behaviours are private, often stigmatised for women to discuss, and are not di-
rectly observable in a trial setting; these realities comprise another major challenge to con-
ducting and analysing microbicide trials. Research teams, not able to directly observe
behaviours around exposure to HIV and use of the study product, must therefore seek
alternative ways to gain as much information as possible about those behaviours. Mul-
tiple methods to gather these data have been developed and continue to be developed,
but these data, for the most part, cannot be fully validated because of the private and
complicated nature of the behaviours being studied.50 Different methods for measuring
adherence used in effectiveness trials prior to the start of this PhD research are described
in Section 2.4.
2.3 summary of microbicide effectiveness trials through 2012
At the start of this PhD research, 12 effectiveness trials of candidate microbicides had been
completed (Table 1.1.1). Eleven of the trials used a coitally dependent regimen that asked
participants to use one dose of microbicide prior to sex. CAPRISA 004, the last trial to
be completed before this PhD research, used a coitally dependent regimen with a pre-sex
and a post-sex dose of microbicide. Microbicide trials began with products that had al-
ready been developed and marketed as spermicides.51 Most products tested in trials com-
pleted by 2012 were gels applied vaginally with applicators. Different products had dif-
ferent properties, including different viscosities, volume, and applicator types. The first
generation of products were surfactants whose method of action was disruption of cell
membranes of sperm and pathogens causing sexually transmitted infections, including
HIV.33,51 Between 1987 and 2000, the four trials testing the effectiveness of Nonoxynol-9
(N-9), a licenced spermicide, in reducing transmission of HIV were conducted.
The first trial tested an N-9-infused sponge against a placebo suppository among sex work-
ers in Kenya.20 The trial did not find a significant difference in HIV infections between
the active product and placebo arms (hazard ratio 1.7; 95% CI 0.9–3.0).20 The trial team
did, however, observe a trend towards increased risk of HIV and of genital ulcers among
participants using the 1000 mg N-9 sponges. For these reasons, in July 2002, the data and
safety monitoring committee recommended termination of the trial. N-9 was then tested
as a vaginal film among a sex worker population in Cameroon.21 This trial, which used a
70 mg dose, did not find a significant reduction in HIV (rate ratio 1.0; 95% CI 0.7–1.5).21
The next trial used 52.5 mg of nononoxyl-9 (N-9) in a gel formulation to test the effect
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of N-9 in reducing STIs, including HIV, among a population of sex workers in Kenya.22
This trial did not find a difference in the incidence of genital ulcers between the N-9 and
placebo groups and was unable to find a difference in HIV transmission due to lack of
power.22 The final clinical trial to test N-9 as an HIV microbicide was the COL-1492
study, a phase II/III trial which enrolled sex workers in Benin, Cote d’Ivoire, South Africa,
and Thailand.23 This study found an increased risk of HIV infection among women ran-
domised to N-9 gel (hazard ratio 1.5; 95% CI 1.0–2.2), and this risk was higher among
women who used more applicators of N-9 gel per day.23 Based on results of the COL-1492
trial, N-9 was discarded as a possible vaginal microbicide for preventing sexual transmis-
sion of HIV.
The second drug to be tested as a possible vaginal microbicide was C3IG, an amphotetric
surfactant, called SAVVY. Two phase III trials were conducted in West Africa: SAVVY
Ghana and SAVVY Nigeria.24,25 Both trials used 1.0% C31G in the form of a coitally de-
pendent gel and both were stopped early due to futility as the HIV incidence was much
lower than anticipated.24,25 However, the SAVVY Nigeria team noted that their results
could not be interpreted as confirmation of no harm because a trend towards harm was
observed (hazard ratio 1.7; 95% CI 0.9–3.5). In both trials there was concern, based on self-
reported behaviour of participants, that adherence to the gel when no condom was used
was low. Trialists also suspected that self-reported data on gel use and condom use were
inaccurate because pregnancy rates did not correspond with behavioural reports of partic-
ipants given the contraceptive effects of condoms and C31G.52 The SAVVY Ghana team
suggested that future microbicide trials require participants to use effective non-barrier
methods of contraception to increase the ability of future trials to answer their research
questions. Surfactants as vaginal microbicides for HIV prevention were thus discarded
for further evaluation.
The second generation of microbicides subsequently went into late-stage trials; this gen-
eration included polyanions, negatively charged polymers which were shown to inhibit
HIV-1 replication,51,53,54,55 and buffering agents which aimed to maintain a high pH in
the vagina, thereby potentially inactivating HIV and preventing entry into lymphocytes
and macrophages.51,56,57,58,59,60,61,62
Cellulose sulphate (CS) was tested in two phase III effectiveness trials: a multi-country
trial sponsored by CONRAD and a trial conducted in Nigeria, sponsored by FHI.27,28
The CS CONRAD trial, which was conducted in Benin, India, South Africa, and Uganda,
tested 6% CS gel against a placebo gel. An independent data monitoring committee re-
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viewed data after 35 incident HIV cases and found a hazard ratio of 2.23 (95% CI 1.0–
5.03). They recommended that the trial be halted due to harm. The final results included
6 additional HIV infections, giving a hazard ratio of 1.61 (95% CI 0.86–3.01). Due to
results of the multi-country CS CONRAD results, the CS Nigeria study was also halted
over concern for potential harm, although their results did not suggest harm (hazard ratio
0.8; 95% CI 0.3–1.8). As with previous studies, trial teams were concerned that use of the
gel during condom-less sex was low. Pregnancy rates were similar in both groups, despite
CS having contraceptive properties.63
The CS CONRAD trial team noted that there are potentially two mechanisms of biolog-
ical effect with candidate microbicides. The first is the biological effect of the candidate
gel related to HIV prevention used during a specific sex act. The second biological effect
of a candidate gel might be related to the candidate gel’s effect on the vaginal environ-
ment with repeated use over time, which could degrade the vaginal epithelium and thus
put a participant at greater risk of HIV infection over time, with more product use. The
trial team noted that although a per sex act-specific effect of a candidate gel would be dif-
ficult to identify if adherence was low, this difficulty would not preclude a cumulative
adverse effect of product exposure which could lead to an increased risk of HIV.28 The
CS CONRAD trial team raised the question of the need to assess microbicides in differ-
ent populations: those who have very high use, for cumulative exposure, and those with
less coital frequency.28
The CS FHI trial team suggested that phase I trials test candidate products at greater ex-
posure rates than the typical 1–2 doses per day for 14 days, to help identify the potential
adverse effects of high frequency use.27 The CS FHI team noted that by recruiting women
who were at high risk for HIV, they were also selecting a population that was highly mo-
bile. They lost one-third of their participants from each study arm to follow-up. This loss,
although non-differential, highlights the dilemma in microbicide trials between recruit-
ing populations of women with high HIV incidence versus women who are less mobile
and more able to fulfil study procedures, but may have lower rates of HIV.
Carraguard (PC-515), a second-generation, seaweed-derived product, is a sulphated polysac-
charide33,51 developed by the Population Council. A phase III trial tested Carraguard gel
against a placebo gel in South Africa. The trial did not find a protective effect of the in-
vestigational product (hazard ratio 0.87; 95% CI 0.69–1.09).26 Carraguard was the first
microbicide effectiveness trial in which a novel technology was developed to assess prod-
uct adherence without relying solely on participant self-report. This technology, a dye
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stain assay (DSA),64,65 which tests if used applicators have been vaginally inserted, in-
volves identifying, by a staining procedure, a mucosal enzyme’s presence on the gel ap-
plicator. Presence or absence of the characteristic blue pattern indicates if the applicator
was “used” or not. There are limitations with the DSA: a woman can insert the applicator
vaginally but still expel the gel externally; a positive dye pattern indicating vaginal use does
not confirm if the gel was expelled in the correct participant’s vagina; and the assay was
not validated in the context of applicators being washed by participants before returning
them to the clinic.66 Self-reported data from trial participants indicated 96.1% gel use at
last sex act. Results of the DSA, however, together with self-reported sexual behaviour
data, indicated that participants used the gel in approximately 42.1% of sex acts. Results
from the Carraguard trial had a large impact on the microbicide community, as it was the
first trial to confirm that self-reported adherence data were significantly overreported and
also highlighted the extent to which participants might not be using the study products.
PRO 2000, a synthetic naphthalene sulphonate derivative,51,67,68,69 was tested in two dif-
ferent microbicide trials. The first trial was a phase II/IIb trial, HIV Prevention Trials
Network (HPTN) 035, which tested 0.5% PRO 2000 gel. HPTN 035 found an indi-
cation of a protective effect (hazard ratio 0.7; 95% CI 0.46–1.08)29 when compared to a
placebo gel. However, the larger phase III trial, Microbicides Development Programme
(MDP) 301,30 did not find a protective effect (hazard ratio 1.05; 95% CI 0.82–1.34). The
MDP 301 trial, in addition to testing a 0.5% formulation, also tested a 2% formulation of
PRO 2000 gel. This arm was discontinued early, however, due to futility.
BufferGel, an acid-buffering product, was also tested in the HPTN 035 trial. It was also
not found to reduce HIV transmission in the phase II/IIb trial (hazard ratio 1.10; 95% CI
0.75–1.62).29 MDP 301 and HPTN 035 were the last effectiveness trials to test products
within the second generation of microbicides. While trial participants in both studies
reported high adherence, it is possible that low adherence may have played a role in the
null results observed. HPTN 035 measured adherence by asking participants about their
product use in face-to-face interviews. MDP 301 asked participants about their adherence
in face-to-face interviews and requested that participants return their applicators to study
clinics. MDP 301 also conducted an intensive social-science sub-study, which included
asking a subsample of participants to complete coital diaries and participate in in-depth
interviews and a reconciliation process for discrepant adherence data. Based on those stud-
ies, the MDP 301 trial team estimated that product use was high.30,70 However, there was
no way to verify the actual adherence of either the HPTN 035 or MDP 301 trial partic-
ipants. The microbicide field then shifted focus to specific acting antiretroviral (ARV)
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drugs in vaginal formulations for the prevention of HIV.
Tenofovir gel, a nucleotide reverse transcriptase inhibitor, was the first ARV to reach ef-
fectiveness trial testing in the third generation of candidate microbicides. ARVs have the
advantage of being specific and potent, and have demonstrated safety in the context of
clinical use. An ARV-based microbicide, however, would not likely meet the original call
for a female-controlled product that would be available without a prescription. Users of
ARVs need to be tested regularly for HIV, monitored for HIV drug resistance should they
seroconvert while using the ARV microbicide, and also monitored for long-term adverse
effects of the ARV. While ARVs are highly potent against HIV, they do not provide broad
protection from transmission of other STIs (although the CAPRISA 004 trial, discussed
below, did find a 51% reduction of Herpes simplex virus type 2 transmission31). An ad-
vantage of ARV-based microbicides is that biomarkers are available to detect the drug in
biological samples, which can greatly aid the interpretation of trial results.
The CAPRISA 004 trial, which began in May 2007, tested 1% tenofovir gel against a
placebo gel in South Africa.31 The phase IIb trial was the first effectiveness trial to test
both an ARV microbicide and a coitally dependent regimen that included a pre and post
coital dose of gel. The regimen was called “BAT24” because trial participants were in-
structed to use an applicator of gel before sex and after sex, and not to use more than two
applicators of gel in a 24-hour period. The trial results, released in 2010, were the first to
show a statistically significant reduction in HIV transmission (hazard ratio 0.63; 95% CI
0.42–0.94). Analyses of self-reported adherence, along with applicator assessments, indi-
cated a dose effect with participants having higher adherence achieving greater protection
from HIV transmission.31
At the start of this PhD research, a number of new microbicide trials were in the field or
the planning stage. Results of those trials are discussed in Chapter 6.
2.4 methods for adherence measurement in microbicide trials
As discussed in Section 2.2, a critical reason to measure adherence and sexual behaviour
in microbicide trials is to help interpret trial results. This section provides a brief overview
of some of the adherence and sexual behaviour measurement methods available for mi-
crobicide studies prior to the start of this PhD research in 2012.
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While adherence data can support interpretation of research results, there are other impor-
tant reasons to have accurate estimates of adherence in microbicide trials. If research teams
can identify issues around poor product adherence or inaccurate reporting of adherence,
there may be ways to adjust study procedures to improve those outcomes prospectively,
during trial implementation, thus increasing the chance of finding an effect of the study
product if it is indeed efficacious. Understanding the issues around participant adher-
ence and participant reporting of adherence in completed trials can be used to improve
the design of future trials. Although trial participants who use an experimental product
which is not yet known to be effective, and their motivations and behaviour, are likely
different from populations who use already licensed products, it is useful to understand
factors which affect product adherence in a clinical trial so that programmatic rollout of
the product can be designed in an optimal way, thereby increasing the likelihood of prod-
uct uptake in the population.8,32
2.4.1 self-report
Measures of adherence in microbicide trials have relied heavily on self-report data about
sexual behaviour and product use.20,21,22,23,24,25,26,27,28,29,30,31 With self-report measure-
ments, the participant directly provides information about her use of the study product
and sexual behaviours, including condom use. Self-report is a simple and inexpensive
method, but relies on a participant’s ability to remember her behaviour accurately and
thus is subject to recall bias. The amount of detail requested and the length of time over
which a participant is asked to recall behaviour will affect the accuracy of a participant’s
self-reported information.18,32,71 Microbicide trials, which often employ coitally depen-
dent regimens, are particularly challenging because measuring adherence requires a par-
ticipant to recall specific past sex acts and to recall for each of those sex acts whether she
used the study gel, or a condom, or both.
Self-report is also subject to social desirability bias because individuals are asked to answer
sensitive questions about sexual behaviour and stigmatised behaviours.18,71 Participants
responding to questions may not feel comfortable telling the truth and may give answers
they think will be more acceptable to the interviewer and less likely to cause a negative
effect, such as jeopardising their participation in the trial, or answers that they think de-
scribe themselves in a way with which they are more comfortable.
How to reduce both recall bias and social desirability bias is critical to obtaining more
accurate measures of sexual behaviour and product adherence. Different time periods of
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recall and modes of seeking self-reported data can potentially facilitate or hinder a par-
ticipant’s ability to remember details and to feel comfortable reporting her behaviours
accurately.18,71,72,73,74
2.4.1.1 face-to-face interviews (ftfis)
Fate-to-face interviews (FTFIs) with structured questionnaires have been the most com-
mon format of self-report in microbicide trials. With this method, for coitally dependent
regimens, participants are asked about their product and condom use in relation to sexual
activity by study staff, during monthly or quarterly visits. Face-to-face interviews are easy
to integrate into trial visits as staff collect other data using case report forms (CRFs). The
quantitative data can easily be tabulated for one participant across her study participation
or aggregated with data from other study participants to summarise adherence data over
the entire trial.
Face-to-face interviews, however, may increase the chance of social desirability bias as par-
ticipants are asked to answer very personal questions directly to members of research
teams. Overall measures of adherence from data obtained from FTFIs in microbicide
trials have been consistently high, ranging from 70% to 96.2%.75 These data cannot be di-
rectly validated, however; thus it is difficult to know if and by how much those estimates
differ from the truth.
One small study (n=132),72 conducted within the context of a phase II trial of Carraguard,
attempted to assess if microbicide trial participants intentionally misreported behaviours
in FTFIs during the trial. Seventy-nine percent (79%) of participants in the study re-
ported they had misled interviewers at least once. Reasons given for misreporting were
politeness (34%), seeking approval or fear of criticism (24%), and embarrassment (18%).72
As trials have integrated additional methods of adherence measurement into trial designs,
they have shown discrepancies in results of the different adherence measurement tools,
demonstrating the limitations of relying solely on FTFIs.36,31
2.4.1.2 audio computer-assisted self-interview (acasi)
Audio computer-assisted self-interview (ACASI) is a method of data collection that al-
lows a participant to use a computer to answer the same types of questions that would be
asked in FTFIs. Typically, the participant is seated alone; the computer speaks the ques-
tion audibly and can show pictures on the screen to help the participant understand the
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question and choose answers. Microbicide research teams have been interested in ACASI
as a method to reduce social desirability bias due to some of the successes observed with in-
creased reporting of sensitive behaviours using this mode.76,77,78,79,80 As trial participants
do not give their answers directly to another human, ACASI may be a better format for
asking sensitive questions. ACASI provides perceived greater privacy and thus may reduce
participants’ feelings of embarrassment or stigma, facilitating their comfort in answering
questions accurately.
ACASI, however, has limitations. Trial teams may believe a system like ACASI might
provide more privacy, but trial participants may not be confident that their answers are
truly confidential and may, therefore, not change how they report their information in
ways that trial teams hope. ACASI requires financial investment in software and hard-
ware and is dependent on electricity; source data are recorded electronically and can be
lost if there is a system failure. A self-administered, electronic system can also increase
the chance that participants provide answers without actually understanding the ques-
tions, an event which would be difficult to identify. Most importantly, ACASI might not
be appropriate or easy to implement in settings where trial participants have low literacy
or exposure to electronic devices. Successful use of ACASI may require substantial ori-
entation of trial participants to facilitate proper use of the device and ability to answer
questions using it.
One study73 specifically attempted to compare the accuracy of ACASI versus FTFIs in
reporting sensitive behaviours in a simulated microbicide trial using a placebo gel. Re-
sponses from questions about sexual behaviour and product adherence were validated by
an applicator stain test and a test for the presence of semen, Rapid Stain Identification
of Human Semen (RSID-Semen). Results indicated that participants were more likely
to report sexual behaviours accurately via ACASI; however, this difference diminished
over time. Importantly, results from questions about product adherence did not show a
difference between ACASI and FTFI modes.73
2.4.1.3 coital diaries
Coital diaries are paper-based tools that a participant is given to take home and use to
record sexual behaviour and product use as they occur. Participants are oriented on how
to complete them and, at specified intervals, the diaries are collected so that the informa-
tion can be transferred into databases by research staff. Coital diaries may be advantageous
in reducing recall bias as they allow participants to record their behaviours as they occur.
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Social desirability bias may also be reduced because a participant can complete the diary
independently and is not required to directly report answers to a research staff member,
a situation that potentially facilitates greater comfort.
Coital diaries, however, are dependent on participants being at least semi-literate and re-
quire that participants be taught how to use them. The pictures used in the diaries, and
how to complete the diaries, may be complicated and understood in different ways. It can
be difficult to know if diaries have been completed in a way that is consistent with how
the research team understands the diary and intends it to be completed. An additional
concern about coital diaries is that participants might not complete the diaries as sex acts
occur but may instead complete them immediately before they are collected by research
staff, which means they are not necessarily documenting an accurate record of their ongo-
ing behaviours.23 It is also possible that while participants fill out coital diaries privately,
they are aware that their answers will be reviewed by research staff and that this awareness
may influence the answers they provide.
Data from three studies examining the utility of coital diaries in the context of microbicide
trial populations indicate that coital diaries may decrease social desirability bias compared
to FTFIs.81,82,83 Sexual activity was reported more frequently, gel use less frequently, and
stigmatised behaviours such as sex during menstruation and lack of vaginal washing more
frequently in coital diaries than in FTFIs.
2.4.1.4 in-depth interviews (idis)
An IDI is a type of face-to-face interview that typically produces qualitative data. In mi-
crobicide trials, quantitative data can also be gathered with IDIs, but in a conversational
manner rather than by asking questions in a structured format as with the case report
forms used in FTFIs. In-depth interviews can therefore facilitate greater rapport between
the trial participant and the staff member. This style of interviewing may put participants
more at ease and thus they may feel freer to provide candid information about their cir-
cumstances. In-depth interviews can be used to collect information on sexual behaviour
and product use, and to reconcile discrepant answers from other modes of data collection.
The phase III MDP 301 trial used IDIs as a method in a subsample of trial participants
to collect sexual behaviour and product use data.30,70,74 As with FTFIs, IDIs are still sub-
ject to social desirability and recall biases. IDIs are labour intensive and thus expensive to
complete; they require highly trained staff members; and they produce data that are more
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difficult to extract and analyse compared to more structured interviews.
2.4.1.5 recall timing
An important consideration in determining the optimal way to ask for self-reported be-
haviours is recall timing. Time periods commonly used in microbicide trials are last sex act,
last 7 days, and last 30 days. There are benefits and drawbacks to different time frames.
Asking about last sex act will likely diminish recall bias, as it is easier to remember be-
haviours that were recent rather than further back in time. However, participants might
be inclined to change their behaviour just before attending a study visit, as they know
they will be asked about use of the study product. Last sex act also captures information
about one sex act as opposed to usage over time. Longer periods of recall might provide
a less biased estimate, as they can capture more typical behaviour, but might be difficult
for participants to remember.32
2.4.2 non self-report methods
Non self-report methods entail methods of collecting adherence data, such as applicator
counts and biomarkers, that do not rely on the participant directly providing verbal or
written report about her behaviour.
2.4.2.1 applicator counts
Some effectiveness microbicide trials36,30,31 asked participants to bring their unused, or
used and unused gel applicators back to the clinic to be counted. Theoretically, applicator
counts can provide some indication about how much study product a participant has
used since her last study visit. As a further example of social desirability bias, however, a
participant might choose which applicators to bring back, or expel study product from
applicators not used vaginally around the time of sex. In addition, participants can insert
the gel vaginally without having sex and can choose to share their study product with
other people. Thus, counts of applicators are also not an objective or a highly reliable
measure of product adherence. Applicator counts for coitally dependent regimens must
be paired with data on sexual behaviour to obtain estimates of adherence, a requirement
which adds additional complexity and opportunity for bias. Another consideration is
that in settings where microbicide trials are typically conducted, keeping and returning
applicators may be difficult for some participants.
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2.4.2.2 applicator dye stain assay (dsa)
For their Carraguard trial, the Population Council developed a unique method which
involved using an assay to try to determine which applicators were inserted vaginally.26
Using a staining procedure, the assay identifies a mucosal enzyme’s presence on the appli-
cator thus indicating that the applicator has been vaginally inserted. According to tests
by the developers, the assay has 97.5% sensitivity and 96% specificity.26,64,65 However,
the DSA cannot confirm whose vagina it was inserted into, and was not validated in the
context of washed applicators.66 It also cannot determine if gel was inserted per regimen
instructions, around the time of sex.
2.4.2.3 biomarkers for sexual intercourse
In the context of microbicide trials, biomarkers for sexual intercourse can provide infor-
mation about a participant’s sexual behaviour, in the form of exposure to semen. Tests
for the presence of semen can help corroborate reports of vaginal sex or condom use. The
most commonly used assays are prostate specific antigen (PSA), Rapid Stain Identifica-
tion of Human Semen (RSID-Semen) and Y-chromosome DNA.8,32,50,73 While all can
be used to detect the presence of semen, positive results of the Y-chromosome DNA as-
say may be due to sources of male DNA other than semen which may enter the woman’s
vagina. The limitation of these assays is that they are only able to detect markers of semen
exposure for relatively short periods of time: about 48 hours for PSA, 3 days for RSID-
Semen, and 4–15 days for Y-chromosome DNA.50,84
2.4.2.4 biomarkers for use of microbicide products
The fact that biomarkers were not available for first- and second-generation microbicides
is one of the reasons for heavy reliance on self-reported data in those trials. Biomarkers
for ARVs, as well as other technologies specific to measuring adherence in microbicide
trials, are currently being developed. ARV-based microbicides, such as tenofovir, can be
detected in the human body using biological specimens. Both plasma and cervico-vaginal
fluid can be used to detect levels of tenofovir from vaginal dosing of 1% tenofovir gel.85,86
ARV-based biomarkers for microbicides tend to provide information about use very prox-
imate to a sample being collected.85 This information, however, does not provide direct
information about whether the drug was biologically available at the right location at the
time of exposure to HIV. With coitally dependent microbicides, adherence measurement
will always need to include information about sexual behaviour, which at this time in
effectiveness trials is achieved by asking a woman about her behaviour. Collection and
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analysis of specimens can be expensive and time-consuming. Moreover, some biomark-
ers can be manipulated by the participant, in that participants can alter their use of the
study product in anticipation of a specimen being collected.50,85,87 As biomarker assays
improve and become less expensive, they will undoubtedly greatly aid the understanding
of adherence in future microbicide trials.
In the context of microbicide effectiveness trials, specimens are generally taken at study
visits. As specimens at visits can only be collected episodically, biomarkers may tend to
cover either very specific points in time such as hours preceding a study visit, or general
periods in time such as a period of weeks or months. Because of the complicated nature of
sexual behaviour—which includes specific sexual acts, use of product and condoms, and
how all of these behaviours play out in an individual act of sexual intercourse or rounds of
sexual intercourse—data from specimen analysis will not provide a complete set of data
with which to examine exposure to study product and exposure to semen.50
Finally, if one of the objectives of biomarker use is to prospectively utilise information
about adherence to improve study outcomes, then biomarkers that identify the investiga-
tional product will compromise double blinding if done on an individual basis. Analyses
using biomarkers which identify the study product must be done retrospectively, after
data collection has completed. Alternatively, biomarker data used to alter study proce-
dures to improve adherence during follow-up can be examined at the group (often site)
level.
2.4.3 other strategies
2.4.3.1 mixed methods
A mixed methods approach can refer to a trial design that gathers data about sexual be-
haviour and product adherence using several different sources such as quantitative and
qualitative methods.32,70,74 This term can also be used to describe the use of different
sources to measure adherence. Examples of mixed methods could include using FTFIs
and applicator counts, FTFIs and a biomarker, or FTFIs, ACASI, and applicator returns.
As no gold standard exists to measure sexual behaviour and product adherence in micro-
bicide trials, employing mixed methods is a useful way to attempt to gauge the level of
adherence. In the Carraguard trial, self-reported product use was 96% at last sex act.26
However, the applicator DSA indicated that overall product use for the study was only
42%.26 A mixed methods approach will not ensure accurate adherence data; however, it
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can help research teams better understand and interpret the data they do have. While it
is more expensive to use several methods to collect sexual behaviour and adherence data,
utilisation of mixed methods is likely to be the most successful approach in the absence
of a gold standard.38,70,74
2.4.4 triangulation of data
Data triangulation occurs when results from different methods of data collection are com-
pared and discrepancies examined and reconciled to produce an improved estimate of
sexual behaviour and product adherence.74 The inclusion of qualitative methods in the
triangulation process can also help research teams have a greater understanding of how
their questions are being understood by the trial participants, which may be different
from how the questions are understood by the research team.70,74
MDP 30130 pioneered this methodology in microbicide trials, creating a comprehensive
approach of mixed methods and triangulation of data for a subsample of the trial popu-
lation. MDP 301 used FTFIs, applicator returns, coital diaries, and IDIs to compare and
reconcile responses about sexual behaviour and product adherence.30,70,74 Incorporating
a substantial social science component in a trial takes time, money, and extremely skilled
interviewers. While the extensive social science component used in MDP 301 is not likely
feasible in all or even most microbicide trials, it is quite possible that reconciliation of
different methods of adherence measurement could be done at standard interviews with
participants at regular clinic visits.74
2.5 trials included in this thesis
This PhD research includes data from six effectiveness microbicide trials. A brief sum-
mary of each trial is given below. Table 2.5.1 provides a summary of the trials included in
this PhD research.
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Trial Product
Number of 
participants
Locations Years conducted
HPTN 035
BufferGel,                                                             
0.5% PRO 2000
3101
Malawi, South Africa, Zambia, 
Zimbabwe, US
February 2005–September 
2008
MDP 301
 0.5% PRO 2000,                                              
2% PRO 2000
9385
South Africa, Tanzania, Uganda, 
Zambia
October 2005–September 
2009 (2% dropped February 
2008)
Carraguard 
Population 
Council
Carraguard 6202 South Africa March 2004–March 2007
CS CONRAD Cellulose sulphate 1398
Benin, India, South Africa, 
Uganda
July 2005–March 2007
CAPRISA 004 1% tenofovir gel 889 South Africa May 2007–March 2010
VOICE
1% tenofovir gel                                             
(plus oral tenofovir disoproxil 
fumarate, oral 
tenofovir–emtricitabine)
5029 (all regimens) South Africa, Uganda, Zimbabwe 
September 2009–August 
2012
Table 2.5.1: Trials included in this PhD research
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HPTN035was a four-arm phase II/IIb randomised placebo-controlled trial testing 0.5%
PRO 2000 gel and BufferGel for the prevention of sexual transmission of HIV against
a placebo gel and a condom-only arm. The three gel arms were double-blinded; the
condom-only arm was not blinded. A total of 3101 women were enrolled in Malawi,
South Africa, Zambia, Zimbabwe, and the US. Results indicated no preventive effect for
BufferGel and a non-significant 30% reduction in HIV for 0.5% PRO 2000. HPTN 035
is included in the comparative and latent structure studies of this PhD research (Chapters
3 and 4).
MDP 301 was a three-arm phase III randomised, double-blind placebo-controlled trial
testing 0.5% and 2% PRO 2000 for the prevention of sexual transmission of HIV against
a placebo gel. In total, 9385 women were enrolled in South Africa, Tanzania, Uganda,
and Zambia. The 2% PRO 2000 arm was closed early due to futility. Trial results for
0.5% PRO 2000 did not indicate an effect on HIV incidence. MDP 301 is included in the
comparative, latent structure, and qualitative studies in this PhD research (Chapters 3, 4,
and 5).
Carraguard was a phase III randomised, placebo-controlled, double-blind trial to test
the effect of Carraguard gel for the prevention of sexual transmission of HIV. It enrolled
6202 women in South Africa. Carraguard was not shown to reduce HIV transmission in
this trial. Carraguard is included in the comparative and latent structure studies in this
PhD research (Chapters 3 and 4).
CS CONRAD was a phase III randomised, placebo-controlled, double-blind trial to test
the effect of cellulose sulphate gel for the prevention of sexual transmission of HIV. CS
CONRAD enrolled 1398 women in Benin, India, South Africa, and Uganda. CS CON-
RAD was halted early due to evidence that CS increased the risk of HIV transmission.
Final trial results, however, did not show a statistically significant increase in HIV trans-
mission for participants using the CS gel. CS CONRAD is included in the comparative
and latent structure studies within this PhD research (Chapters 3 and 4).
CAPRISA 004was a phase IIb randomised, placebo-controlled, double-blind trial to test
1% tenofovir gel for the prevention of sexual transmission of HIV. CAPRISA 004 en-
rolled 889 women in South Africa. Trial results showed that 1% tenofovir gel reduced
HIV acquisition in the tenofovir arm by about 39%. CAPRISA 004 is included in the
comparative study of this PhD research (Chapter 3).
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VOICE (Vaginal and Oral Interventions to Control the Epidemic) was a
5-arm, randomised, placebo-controlled phase IIb trial to assess daily use of 1% tenofovir
(TFV) vaginal gel, or oral tenofovir disoproxil fumarate (TDF), or oral tenofovir–emtricit-
abine (TDF/FTC) against HIV infection. Women in South Africa, Uganda, and Zim-
babwe were enrolled. At the start of this PhD research, VOICE was an ongoing trial
actively collecting data. At the start of the qualitative study for this PhD research, the
VOICE trial had completed its follow-up and its study participants had exited; therefore,
former VOICE gel trial participants were eligible for inclusion in the qualitative study
conducted for this PhD research (Chapter 5).
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what dowe really mean by
adherence?
measuring, calculating and reporting adherence
in five trials
objective
To critically examine how five completed effectiveness microbicide trials measured,
calculated, and reported microbicide gel adherence
included trials
HPTN 035
MDP 301
Carraguard
CS CONRAD
CAPRISA 004
3
W H AT D O W E R E A L L Y M E A N B Y “A D H E R E N C E ” ?
3.1 introduction
Trial population adherence to the investigational product regimen is a critical factor in
interpreting results of microbicide trials. How adherence is measured and calculated is,
therefore, equally critical. In the field of biomedical HIV prevention research, trial teams
determine study procedures and methods of analysis. Consequently, each microbicide
trial team may choose different ways to assess adherence and calculate adherence estimates.
Each trial team also chooses how to report adherence findings in their primary trial results
publication. Because methods of data collection, modes of analysis, and ways of reporting
results are not standardised, comparisons across trials can be challenging. This difficulty
can be compounded when adherence information provided in publications is minimal
or lacking clarity. Lack of ability to make comparisons across trials is particularly prob-
lematic when the same experimental product is tested. The importance of implementing
common methods of measurement and analysis so that results can more easily be com-
pared has been recognised as an issue in the field.38,32,37,88,89
To understand the extent of the similarities and differences in adherence assessment across
different trials, it is necessary to look in detail at the methods trial teams used. The purpose
of this study was to critically examine and compare how five effectiveness trials of coitally
dependent microbicide gels collected adherence data, how the summary estimates of ad-
herence in primary results manuscripts were reported and characterised, and how those
summary estimates of adherence were actually calculated.
3.2 methods
Eligibility criteria for included trials in this study were post-surfactant microbicide candi-
dates being tested in effectiveness trials (phase IIb or later) and willingness and ability of
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trial teams to provide required information about their trial. Trial teams from six com-
pleted microbicide gel trials were invited in the spring of 2012 to participate in this com-
parative study. Five trials were able to participate: HPTN 035, MDP 301, Carraguard,
CS CONRAD, and CAPRISA 00429,30,26,28,31 (Table 3.2.1). All trials included in this
study tested coitally dependent regimens of vaginal microbicide gels, meaning that par-
ticipants were instructed to use the gel each time they had vaginal sex. Trial protocols,
case report forms (CRFs), and statistical analysis plans (SAPs) were provided by each trial
team. These trial materials, as well as the primary results publications for each trial, were
examined for this study.
CHAPTER 3. what do we really mean by “adherence”? 54
Trial Product
Number of 
participants
Locations Years conducted
HPTN 035
BufferGel,                                                             
0.5 % PRO 2000
3,101
Malawi, South Africa, Zambia, 
Zimbabwe, US
February 2005 – September 
2008
MDP 301
 0.5 % PRO 2000,                                              
2 % PRO 2000
9,385
South Africa, Tanzania, Uganda, 
Zambia
October 2005 – September 
2009, (2% dropped 
February 2008)
Carraguard 
Population 
Council
Carraguard 6,202 South Africa March 2004 – March 2007
CS CONRAD Cellulose sulphate 1,398
Benin, India, South Africa, 
Uganda
July 2005 – March 2007
CAPRISA 004 1% Tenofovir gel 889 South Africa May 2007 – March 2010
Table 3.2.1: Trials included in the comparative study
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As the purpose of this study was to accurately report how the included trials collected
adherence data, how adherence estimates were reported in publications, and how those
estimates were actually calculated, care has been taken in the results section to report in-
formation using the terminology and language that the trial teams used. The discussion
section provides interpretation and criticism of terminology, methods, and language used
by the trial teams.
The sections below describe the methods used to determine trial teams’ methods for col-
lecting adherence data, how overall estimates of adherence were reported in primary re-
sults publications, and how source data were specifically used to calculate the reported
adherence estimates.
3.2.1 source data
The term “source data” refers to specific pieces of information collected from participants
and used by trial teams as the foundation of calculations to estimate adherence to study
products and exposure to HIV. Because all of the trials in this study tested coitally de-
pendent microbicides, adherence must be calculated by combining information about
the occurrence of specific sex acts and whether gel was used as directed for those sex acts.
Information on the occurrence of sex acts can only be provided by participants, as they
cannot be directly observed by trial teams. Source data are collected from participants in
a number of ways that usually involve questionnaires during face-to-face-interviews (FT-
FIs). As discussed in Chapter 2, source data can also be collected through means such as
applicator returns or biological samples that are tested for biomarkers.
For each trial, protocols and CRFs in English were examined to identify what informa-
tion was collected from participants, including any information related to sex acts, gel use,
and condom use. All source data for each trial were identified and placed into a common
spreadsheet. Source data were categorised as self-reported or non self-reported. Recall pe-
riod, frequency of the measurement, and particular wording of the questions, if relevant,
were documented.
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3.2.2 overall adherence estimates
To understand how trial teams initially reported overall adherence to the investigational
gels, first the primary results publication for each trial was reviewed. Next, written state-
ments that provided estimates of adherence for each trial were extracted; the wording
found in the publications was retained. Finally, overall adherence estimates were docu-
mented in a comparison table across all trials.
3.2.3 calculations of overall adherence estimates in manuscripts
The next step in this study was to understand how source data were used to calculate the
overall adherence estimates that were reported in the primary results publications. This
was accomplished through a multi-step procedure. First, trial protocols, CRFs, SAPs, and
the primary results publications were reviewed.
Second, a schematic figure was developed to track the information and the flow of infor-
mation for each trial. The schematic figure for each trial included three sections: an area
to list source data, an area to describe intermediate calculations, and an area to list the
actual overall adherence estimates. Intermediate calculations refer to sums of source data
or equations using source data that are subsequently used in equations to calculate over-
all adherence estimates. Each different piece of source data, intermediate calculation, and
overall adherence estimate is presented in its own box within the schematic figure for each
trial, with source variables placed at the left, intermediate calculations in the middle, and
overall adherence estimates at the right.
The third step was to complete the schematic figures to represent how source data are
transformed into the published overall estimates. This was accomplished by reviewing
each overall estimate published and the description of how that estimate was calculated in
the publication (if available), reviewing the SAP, reviewing the available source variables
for the trial, and reviewing the trial protocol to understand study procedures, timing, and
frequency of source data collection.
Based on this information, along with the available source data for each trial, equations
were developed to characterise how source data were transformed to overall adherence es-
timates. These equations were placed within the schematic figures. Each piece of source
data was described within an individual box, represented by a lower-case letter. Each in-
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termediate calculation was represented by an upper-case letter, and an equation if appli-
cable. Upper-case letters representing intermediate calculations were then arranged in
equations, to convey how they could be used to give the final adherence estimates pro-
vided in the primary results publications.
Finally, a trial team survey was conducted to share the schematic diagrams with trial team
representatives and check that the interpretations of how adherence was measured, cal-
culated, and reported were correct. All five trial teams responded with clarifications and
corrections. Last of all, schematic figures were revised based on corrections from trial
teams; these are presented in the results section.
3.2.4 comments and lessons learned from trialists
In the trial team survey, trial teams were invited to provide comments about considera-
tions and choices they made regarding adherence measures, calculations, and overall esti-
mates. They were also invited to share lessons learned and to make recommendations on
adherence in future microbicide trials.
3.3 results
3.3.1 source data
This section summarises the types of source data that were collected in HPTN 035, MDP
301, Carraguard, CS CONRAD, and CAPRISA 004. The types of source data described
in this section are divided into three categories. The first category describes how self-
reported data were collected in FTFIs. The second section describes methods that trials
used to collect source data that were not verbally self-reported by participants. The third
category describes methods of collecting source data that may have been novel at the time
and were only used with a subset of participants within the trial using that method.
Table 3.3.1 provides a summary of all of the types of source data collected across the five
clinical trials. Figures 3.3.1–3.3.5 provide a more detailed description of the type of source
collected for each trial, including aspects of the specific wording of questions used to col-
lect information in FTFIs.
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Last sex act
Applicator 
count
DSA Biomarker
Coital 
diary
Comparison 
form 
In-depth 
interview
ACASI
1. Gel use at last 
sex act
Number of sex acts
1. Number of times gel 
used
Number of sex acts
1. Number of times gel 
used
Number of sex acts
1. Number of times gel 
used
2. Condom use 
at last sex act
2. Number of times 
condom used
2. Number of times 
condom used
2. Number of times 
condom used
(Wording of question) (Wording of question) (Wording of question) (Wording of question) (Wording of question) (Wording of question)
(Frequency of 
question)
(Frequency of question)
(Frequency of 
question)
(Frequency of 
question)
(Frequency of question) (Frequency of question) (Frequency of question)
(Frequency of 
data 
collection)
(Frequency 
of data 
collection)
(Frequency of data 
collection)
1. Yes                                                      Yes                                                                               1. Yes                                                No No No No No No No No No No Subset
2. Yes 2. Yes
("Past week") ("Past week")
(Quarterly) (Quarterly) (Quarterly)
1. Yes                                                                           Yes                                                     1. Yes                                                          (Yes)                                                                                                                               (1. Yes) (Yes)    (1. Yes) Yes                                                                   No No Subset Subset Subset No
2. Yes 2. Yes (2. Yes) (2. Yes)
("Last week") ("Last week") (For those who had sex 
in the last 4 weeks but 
not last week)
(For those who had sex 
in the last 4 weeks but 
not last week)
(Last 4 weeks, for those 
who did not have sex in 
the last week)
(Last 4 weeks, for those 
who did not have sex in 
the last week)
(Monthly) (Weeks 4, 24, 40, 52) (Weeks 4, 24, 40, 52) (Weeks 4, 24, 40, 52) (Weeks 4, 24, 40, 52) (Weeks 4, 24, 40, 52) (Weeks 4, 24, 40, 52) (Monthly)
1. Yes                                                      No No Yes                                                                                 1. No No No Yes                                                                   Yes No No No No No
2. Yes 2. No
("Past 2 weeks")             
(Month 1 + 
Quarterly)
(Month 1 + Quarterly) (Month 1 + 
Quarterly)
(Batched)
 No Yes                                                                              1. Yes                                                    No No No No No No No No No No No
2. Yes
("Past 7 days") ("Past 7 days")
(Monthly) (Monthly)
1. Yes                                                               Yes                                1. Yes, but did not ask 
about coverage of two 
doses: "How many of 
these sex acts had gel 
use?"                                                                                                                                                          
No No Yes                                                                                      1. Yes: "How many
study gels did you use?"
Yes                                                                No Yes                                                                                                        No No No No
2. Yes 2. No 2. No
(Last 7 days) (Last 7 days) (Last 30 days) (Last 30 days) Genital specimens   
(Monthly) (Monthly) (Monthly) (Monthly) (Monthly) (Monthly) (Baseline, months 3, 
12, 24, exit & at time 
of suspected 
seroconversion)
HPTN 035
MDP 301
Carraguard
CS CONRAD
CAPRISA 004    
(One gel before 
sex and one gel 
after sex)                                                        
Trial
Participant self-report at face-to-face interviews Non self-report  methods Methods used with subsample
Last 7 days Last 2 weeks Last 30 days 
Table 3.3.1: Source variables for the five trials
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HPTN 035: Source data at participant level 
The last time you had vaginal 
sex, did you or your partner use 
a  male condom?                            
In the past week, how many 
times did you use a male or 
femal condom and not the 
study gel during vaginal sex?                                                 
In the past week, how many 
times did you have 
vaginal sex?                       
In the past week, how many 
times did you use study gel and 
not a male or female condom 
during vaginal sex?
The last time you had vaginal 
sex, did you or your partner use 
a female condom?                           
In the past week, how many 
times did you use study gel 
with a male or femal condom 
during vaginal sex?                       
Participant self-report at face-to-face interviews Non self-report  methods
Last sex act Last 7 days Last 2 weeks Applicator countLast 30 days
Study exit questions
The last time you had vaginal 
sex, did you use  
study gel?                          
When was the last time you 
had vaginal sex? (used to 
count the total number of last 
sex acts in the trial)   
In the past week, how many 
times did you use neither study 
gel nor a male or female 
condom during vaginal sex?                                
In the past week, how many 
times did you use a male or 
female condom during vaginal 
sex?           
b
c
d
a e
f
g
h
i
j
Figure 3.3.1: HPTN 035 source variables
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MDP 301: Source data at participant level
Did you use a condom the last 
time you had sex?
(for each sex act in last week)
Did you use a condom during 
this sex act?
(for each sex event in last 4 
weeks) Did you use a condom 
during this sex
act?
How many times have you had 
sex in the last week?
(for each sex act in last week)
Did you use gel before this sex 
act?
Did you use the gel the last 
time you had sex?
Number of used applicators 
returned today 
(for each sex act in last week)
If you used gel, how long 
before sex did you insert it?
(for women who have not had 
sex in last week, but have had 
sex in past 4 weeks) Number of 
sex acts in the last 4 weeks 
Participant self-report at face-to-face interviews Non self-report  methods
Last sex act Last 7 days Last 2 weeks Applicator countLast 30 days
(for each sex event in last 4 
weeks) Did you use gel before 
this sex act?
(for each sex event in last 4 
weeks) If you used gel, how 
long before sex did you insert 
it?
Study exit questions
How often did you report using 
the gel during the interview 
when in fact you had not used
it? (often, occasionally, never)
In the last 4 weeks did you ever 
insert the gel and then not 
proceed to having sex? 
d
a c
b
e
f
g
h
m
j
i
k l
Figure 3.3.2: MDP 301 source variables
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Carraguard: Source data at participant level
The last time you had vaginal 
sex, did you use the study gel?
a
In the past two weeks how 
many times did you have 
vaginal sex?
c
The last time you had vaginal 
sex did you use a male 
condom?
b
Number of used applicators 
returned staining blue
d
Participant self-report at face-to-face interviews Non self-report  methods
Last sex act Last 7 days Last 2 weeks Applicator countLast 30 days
If there were reasons that you 
did not use the gel during sex, 
what was the reason(s)? 
One of the response options 
was:
“n/a always used the gel”
g
Study exit questions
In general how often did you 
use the gel during sex?
e
If you had more than 1 round 
of sex in a night, did you insert 
a new applicator before each 
round?
f
Figure 3.3.3: Carraguard source variables
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CS CONRAD: Source data at participant level
In the past 7 days how many 
vaginal sex acts using a new 
condom, but no new study gel, 
with other partners?
In the past 7 days how many 
vaginal sex acts using a new 
study gel, but no new condom 
with other partners?
In the past 7 days how many 
vaginal sex acts using both a new 
study gel and a new condom, 
with primary partner?
In the past 7 days how many 
vaginal sex acts with primary 
partner?
In the past 7 days how many 
vaginal sex acts with other 
partners?
In the past 7 days how many 
vaginal sex acts using a new 
condom, but no new study gel, 
with primary partner?
In the past 7 days how many 
vaginal sex acts using a new 
study gel, but no new condom 
with primary partner?
Participant self-report at face-to-face interviews Non self-report  methods
Last sex act Last 7 days Last 2 weeks Applicator countLast 30 days
Study exit questions
In the past 7 days how many 
vaginal sex acts using both a new 
study gel and a new condom, 
with other partners?
a
b
c
d
e
f
g
h
Figure 3.3.4: CS CONRAD source variables
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CARPISA 004: Source data at participant level
What was the last date you 
had sex?
Condom use at last sex act
(and all sex acts on that same 
day)
In the last 30 days, did you 
insert more than 2 gels in one 
day (24 hour
period)?
In last 7 days, how many times 
did you have sex?
e
In the last 7 days how many of 
these acts had gel use?
f
How many times did you have 
sex the last day you had it?
Number of used applicators 
(count, monthly)
j
Gel use before last sex act
and 
gel use after last sex act
(and all sex acts on that same 
day)
In last 30 days how many 
times did you have sex?
a
Participant self-report at face-to-face interviews Non self-report  methods
Last sex act Last 7 days Last 2 weeks Applicator countLast 30 days
In last 30 days, how many 
study gels did you use?
b
In the last 30 days did you use 
the gel before and after sex in
the
majority of times?
tenefovir concentration
(cellular level) ng/ml
k
Tenofovir concentration
g
h
i
l
c
d
Figure 3.3.5: CAPRISA 004 source variables
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3.3.1.1 self-reported gel and condom use during sex
All five trials included questions about sex acts, gel use during sex acts, and condom use
during sex acts, gathered in FTFIs conducted by trial staff. The trials combined these
questions in different manners and used different recall periods and frequency of data
collection.
last sex act
Four of the five trials asked in FTFIs about gel use and condom use at last sex act (HPTN
035, MDP 301, Carraguard, CAPRISA 004). CAPRISA 004 asked if one applicator of
gel was used before sex and one applicator after sex, per the BAT24 regimen that requires
an applicator of gel within 12 hours before sex, an applicator of gel as soon as possible after
sex and again within 12 hours, and not more than two applicators within a 24-hour pe-
riod. CAPRISA 004 also asked about all sex acts on the day of the “last sex act.” Two trials
(HPTN 035 and Carraguard) asked this question at quarterly visits. Two trials (MDP 301
and CAPRISA 004) asked this question at monthly visits. CS CONRAD was the only
trial of the five that did not ask about last sex acts.
last 7 days or last week
Four of the five trials (HPTN 035, MDP 301, CS CONRAD, CAPRISA 004) asked
about the proportion of sex acts covered by gel in the last 7 days or last week. Wording of
the time period varied from trial to trial, as did the format of the questioning (see example
in Figure 3.3.6). CAPRISA 004 asked how many sex acts had gel use, but did not ask how
many gels were used, or if a pre-dose and post-dose were used. Three trials (HPTN 035,
MDP 301, CS CONRAD) also asked about the proportion of sex acts covered by con-
doms with and without gel. CAPRISA 004 did not ask about condom use for the 7-day
recall period. Two trials (CS CONRAD, CAPRISA 004) asked this question at monthly
visits; one trial (HPTN 035) asked this question at quarterly visits; and one trial (MDP
301) asked this question four times over follow-up (weeks 4, 24, 40, and 52). Carraguard
did not use a 7-day recall period.
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HPTN 035
MDP 301
Figure 3.3.6: Wording of adherence questions in two trials
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last 2 weeks
Participants in Carraguard were asked how many times they had sex in the past 2 weeks.
There was no corresponding question to participants about how many of those sex acts
were covered by gel with and without condom. The data on the number of sex acts in
the past 2 weeks were later combined with gel applicator data to estimate adherence (see
section 3.3.3.3). Number of sex acts in the past 2 weeks was asked at month 1 and at quar-
terly visits in Carraguard.
Questions about the proportion of sex acts covered by gel in the last 2 weeks were not
explicitly asked by any of the five trials as a standard question. Sex acts covered by gel and
condom use in the last 2 weeks were incidentally captured with questions about sex acts
in the last 4 weeks in MDP 301 when a participant reported she had not had sex in the last
week, but had had sex in the last 4 weeks. There were potentially four times over follow-
up when a participant could answer this question (weeks 4, 24, 40, and 52).
last 30 days, last 4 weeks
CAPRISA 004, at monthly visits, asked participants how many sex acts they had in the
last 30 days and how many gels they used in the last 30 days. They did not ask about con-
dom coverage for those same sex acts. The proportion of sex acts covered by gel with and
without condom in the last 4 weeks were documented in MDP 301 when a participant
reported she had not had sex in the last week, but had had sex in the past 4 weeks. There
were potentially four times over follow-up when a participant could answer this question
(weeks 4, 24, 40, and 52).
3.3.1.2 non self-reported source data
This section describes how trials collected adherence-related data in ways that did not in-
volve participants answering questions in FTFIs.
applicator counts
Three trials asked participants to return applicators to the study clinics for counting (MDP
301, Carraguard, CAPRISA 004). Carraguard collected applicators at month 1 and at
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quarterly visits. MDP 301 and CAPRISA 004 collected applicators at monthly visits.
applicator dye stain assay (dsa)
Carraguard was the only trial of the five trials that developed a specific method for test-
ing if the returned gel applicators had evidence of being vaginally inserted. The dye stain
assay (DSA) was conducted on all returned applicators and was completed at the end of
the trial.
biomarkers
CAPRISA 004 collected genital specimens from participants at baseline; months 3, 12,
and 24; study exit; and at the time of suspected seroconversion. Genital samples were
tested for concentration levels of tenofovir, the antiretroviral drug being tested for pre-
vention of sexual transmission of HIV. All other trials included in this study tested inves-
tigational microbicides for which no biomarkers were available.
3.3.1.3 methods used with subsets of trial populations
The following methods were not used to collect adherence source data for all trial par-
ticipants. They were used in subsets of trial participants to help understand adherence
in the trials and test novel methods for adherence and sexual behaviour data collection.
HPTN 035 included a sub-study with audio computer-assisted self-interview (ACASI).
MDP 301 included a social science sub-study that used a number of methods to better un-
derstand adherence in the trial. MDP 301’s sub-study followed a subset of 725 randomly
assigned trial participants over time. Methods to assess adherence in this sub-study in-
cluded use of coital diaries, in-depth interviews, the standard gel accountability forms
used for all participants, the standard structured interviews used for all participants, and
a special comparison form to triangulate and reconcile adherence data from the various
sources.
coital diary
MDP 301 gave coital diaries to a subset of trial participants (725) to record their sexual
activity and gel and condom use over a 4-week period of time prior to study visits at weeks
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4, 24, and 52.
in-depth interviews
MDP 301 used in-depth interviews (IDIs) in two ways in order to understand adherence
in their social science sub-study. First, they used IDIs to ask trial participants about sex-
ual behaviour and gel adherence for the same time periods used in the CRFs for visits at
weeks 4, 24, and 52, but used open-ended questions. They then used the IDIs to reconcile
discrepancies in adherence data from answers at FTFIs on CRFs, returned gel applicators,
coital diaries, and answers received earlier in the IDIs.
comparison form for data triangulation
As noted above, MDP 301 used a special step to reconcile discrepant answers from dif-
ferent sources. A “comparison form” linked to study visits at weeks 4, 24, and 52 was
used with a subset of 725 trial participants. Prior to IDIs, data about gel use from CRFs,
returned gel applicators, and coital diaries were noted on the form. During the IDI, gel
use data gained through more open-ended questioning, were also recorded. Discrepan-
cies from these four different sources were discussed with participants and resolved. The
corrected gel use data was then noted on the comparison form.
acasi
Audio computer-assisted self-interview (ACASI) was used by HPTN 035 in a subset of
663 participants from Lilongwe and Blantyre, Malawi. Hand-held devices with pictures
and audio asked participants the same set of adherence and sexual behaviour questions as
used in the CRFs in FTFIs.
3.3.1.4 summary of source data
All trials used self-reported data to measure adherence. Different recall periods for sex
were used, with four out of five trials asking about more than one recall period (HPTN
035, MDP 301, Carraguard, CAPRISA 004). Four out of five trials asked about last sex
act (HPTN 035, MDP 301, Carraguard, CAPRISA 004). Frequency of questions var-
ied, with three trials collecting adherence data at monthly visits (MDP 301, CS CON-
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RAD, CAPRISA 004) and two trials collecting adherence data primarily at quarterly vis-
its (HPTN 035, Carraguard). Three trials included applicator returns as a part of their
data collection (MDP 301, Carraguard, CAPRISA 004). One trial tested returned appli-
cators using a special assay to better differentiate applicators that were vaginally inserted
from those where contents might have simply been expelled (Carraguard). One trial used
an ARV-based microbicide and was able to collect genital specimens for biomarker anal-
ysis (CAPRISA 004). Two trials collected adherence data using additional methods on
just a subsample within their trial populations (HPTN 035, MDP 301). MDP 301 had
a significant social science component where coital diaries, in-depth interviews and rec-
onciliation sheets were used. HPTN 035 included a sub-study where some participants
answered questions about sexual behaviour and gel use via ACASI.
3.3.2 overall adherence estimates in published manuscripts
This section describes the overall adherence estimates used by trial teams to describe trial
adherence in primary results publications. This results section, which describes the overall
adherence estimates, preserves the terminology and language chosen by trial teams used
in the publications, which may not be precise. Commentary on the language is provided
in the discussion section. A summary of overall adherence estimates for each trial is pro-
vided in Table 3.3.2.
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Trial Publication Summary estimate 1 Summary estimate 2 Summary estimate 3
HPTN 035 AIDS 2011 81% last sex acts covered by gel 61.3% sex acts with gel and condom
69.1% condom free last sex acts 
covered by gel
MDP 301 Lancet 2010
89% mean gel use at last sex act (95% 
CI: 86–91)
Carraguard 
Population 
Council
Lancet 2008 96.1% last sex acts covered by gel
Estimated average of 42.1% sex acts 
covered by gel
CS CONRAD
New England Journal of 
Medicine 2008
87% of all sex acts covered by gel in 
trial (reported in the 7 days before each 
follow up visit)
78% of sex acts with primary partners 
covered by gel (reported in the 7 days 
before each follow up visit)
45.8% condom free sex acts 
covered by gel (reported in the 7 
days before each follow up visit)
CAPRISA 004 Science 2010
72% (average), 60.2% (median) of self-
reported sex acts in the last 30 days 
covered by two doses of gel
61.3% (overall median) gel adherence 
for women who did not aquire HIV; 
59.2% (overall median) for women who 
did aquire HIV
About 40% of women had below 
50% gel adherence
Table 3.3.2: Overall adherence estimates in primary results publications
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3.3.2.1 hptn 035
HPTN 035 reported three summary estimates of adherence in their primary results pub-
lication.29 The first adherence summary estimate states the percentage of last sex acts cov-
ered by gel for the trial (81%). The second adherence summary estimate states the per-
centage of “sex acts” covered by gel and condom for the trial (61.3%). The third adher-
ence summary estimate states the percentage of last sex acts with no condom which were
covered by gel in the trial (69.1%). The methods section of their publication states that
adherence estimates were calculated using self-reported data for last sex act data.
3.3.2.2 mdp 301
MDP 301 reported one summary estimate of adherence in their primary results publi-
cation.30 The summary adherence estimate reported in the publication states the mean
percentage of last sex acts covered by gel (89%). The methods section in the publication
states trial participants were asked at each monthly visit about their gel use at their most
recent sex act.
3.3.2.3 carraguard
Carraguard reported two summary estimates of adherence in their primary results publi-
cation.26 The first adherence summary estimate states the average percentage of last sex
acts covered by gel (96.1%). It is clear in the publication that this estimate is derived from
self-reported data. The second adherence summary estimate states a different estimate
of sex acts covered by gel, based on results of the DSA of gel applicators and estimated
reported number of sex acts each week (42.1%). The methods section states this calcula-
tion was made by dividing the average number of applicator insertions per week (based
on the DSA results) by the average number of sex acts every week (based on participant
interviews).
3.3.2.4 cs conrad
CS CONRAD reported three summary estimates of adherence in their primary results
publication.28 The first adherence summary estimate states the percentage of all sex acts
covered by gel in the trial (87%). The second adherence summary estimate states the per-
centage of sex acts with primary partners that were covered by gel in the trial (78%). The
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third adherence summary estimate states the percentage of sex acts with no condom in the
trial that were covered by gel (45.8%). It is clear in the publication that these estimates are
derived from self-reported data based on the 7 days prior to each study visit.
3.3.2.5 caprisa 004
CAPRISA 004 reported three main summary estimates of adherence in their primary re-
sults publication.31 The first set of summary adherence estimates stated the average and
median percentage of “sex acts covered by two doses of gel in the last 30 days” (72% and
60.2%, respectively). The methods section defines the basis of these estimates as the num-
ber of returned applicators, divided by 2, divided by the number of sex acts reported that
month. The second set of summary adherence estimates were calculated in the same man-
ner as the first set of estimates, but segregated by HIV status: the median percentage of
gel adherence for the last 30 days for women who did not acquire HIV (61.3%) and the
median percentage of gel adherence for the last 30 days for women who did acquire HIV
(59.2%). The third summary estimate of adherence states the approximate percentage of
trial participants who had less than 50% adherence (40%).
3.3.2.6 summary of all trials
All five included trials presented summary adherence estimates for the trials as means or
medians. The type of means and medians are explained in the results section that describes
the calculation of published results (3.3.3) and in the discussion section under two types
of averages (3.4.4.1). Some trials had up to three estimates to describe adherence; one trial
reported one summary estimate of adherence. Three trials used averages based exclusively
on self-reported data (HPTN 035, MDP 301, CS CONRAD). Two trials combined appli-
cator data with self-reported data to produce summary estimates (Carraguard, CAPRISA
004).
While CAPRISA 004’s publication provided the most clarity on how the estimates were
calculated, in general the descriptions in the manuscripts do not provide enough speci-
ficity for the reader to understand exactly how the adherence estimates were calculated, as
there are different methods that can be used to produce overall averages from the source
data.
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Statistical analysis plans were consulted for more detailed explanations of how the esti-
mates were made. This resulted in less clarity, as descriptions offered in SAPs often did
not match the methods described in the publications or there was not enough specificity
in the SAP for the reader to understand the exact methods used for the published esti-
mates.
3.3.3 calculation of published results
This section explains in detail the mathematical process that each trial team used to calcu-
late the adherence estimates reported in their primary results publications. Review of the
SAPs and primary results publications did not provide confirmation on the exact meth-
ods used to calculate the adherence estimates published. All trial teams were contacted for
confirmation of their methods. Results presented below are based on trial teams’ reviews
and subsequent corrections and clarifications of the schematic diagrams describing the
adherence calculation process sent to them. The process of using source data to calculate
the overall adherence estimates is represented for each trial in figures 7–11. For complete-
ness, the detailed process is also described in text format below.
3.3.3.1 hptn 035
The first summary estimate of adherence reported by HPTN 035 was: 81% of last vaginal
sex acts were covered by gel. Figure 3.3.7 shows how this figure was calculated from the
source data. The total number of last vaginal last sex acts for the trial (D) was calculated
by summing the number of responses to the question “when was the last time you had
vaginal sex”? (d). The total number of last vaginal sex acts covered by gel for the trial (C)
was calculated by summing the number of “yes” responses to the question “The last time
you had vaginal sex, did you use study gel”? (c), aggregated across all sex acts across all
participants in the trial. The total number of last sex acts covered by gel for the whole
trial (C) was then divided by the total number of last sex acts for the whole trial (D), to
calculate the summary estimate of percentage of last vaginal sex acts covered by gel.
CHAPTER 3. what do we really mean by “adherence”? 74
When was the last time you had 
vaginal sex?
(used to count the total number of 
last sex acts in the trial)                                        
The last time you had vaginal 
sex, did you use study gel?
The last time you had vaginal sex, 
did you or your partner use a 
male condom?
Total last sex acts with "no" to a
and "no" to b =
Last vaginal sex acts 
without condom (for entire trial)
Total last sex acts with "yes" to c
and "no" to a and "no" to b =
Last vaginal sex acts with gel and 
no condom (for entire trial)
Total last sex acts with "yes" to c
and ("yes" to a or "yes" to b) =
Last vaginal sex acts with 
condom and gel (for entire trial)                                   
Total number of last vaginal
sex acts covered by gel trial wide 
(for the entire trial)
Total number of 
last vaginal sex acts in trial
(for the entire trial)
HPTN 035: Flow of source variables to summary adherence estimates
69.1% percent of last 
condom-free vaginal sex acts 
covered by gel 
61.3% percent of sex acts with 
gel and condom overall
81% percent of last 
vaginal sex acts covered by gel
Source data at 
participant level
Intermediate calculations:
responses on CRFs which have 
been summed across the trial
Overall adherence in primary 
results manuscript
The last time you had 
vaginal sex, did you use a 
female condom?
d
c
a
b
D
M
C
K
L
C/D
M/D
K/L
Figure 3.3.7: HPTN 035 calculation of summary adherence estimates
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The second summary estimate of adherence reported by HPTN 035 was: 61.3% of vagi-
nal sex acts were covered by gel and condom. While the estimate stated in the publication
did not state which type of sex act was used to make this calculation, the trial team con-
firmed the source data were last sex acts. Figure 3.3.7 demonstrates how this estimate was
calculated from the source data. The total number of last vaginal last sex acts for the trial
(D), aggregated across all sex acts across all participants in the trial, was calculated by sum-
ming the number of responses to the question “when was the last time you had vaginal
sex”? (d) and serves as the denominator for this estimate. The total number of last sex
acts with condom and gel (M), the numerator of the summary estimate, was calculated
by summing the total number of “yes” responses to “The last time you had vaginal sex
did you use study gel”? (c) and “yes” responses to “The last time you had vaginal sex did
you or your partner use a male condom”? (a) or “yes” responses to “The last time you
had vaginal sex did you use a female condom”? (b). The total number of last sex acts with
condom and gel (M) was then divided by the total number of last sex acts for the whole
trial (D), to calculate the summary estimate of percentage of last vaginal sex acts with gel
and condom for the trial.
The third summary estimate of adherence reported by HPTN 035 was: 69.1% of last
condom-free vaginal sex acts were covered by gel. Figure 3.3.7 shows how this estimate
was calculated from the source data. The total number of last vaginal sex acts without
condom for the trial (L) was calculated by summing the total responses of “no” to the
question “The last time you had vaginal sex did you or your partner use a male condom”?
(a) and the total number of responses of “no” to the question “The last time you had vagi-
nal sex did you use a female condom”? (b), aggregated across all sex acts for the trial. This
comprised the denominator of the summary estimate. The numerator of the estimate,
the total number of last sex acts in the trial with gel and no condom (K), was derived by
summing the total number of “yes” responses to the question “The last time you had vagi-
nal sex did you use the study gel”? (c) and “no” responses to the question “The last time
you had vaginal sex did you or your partner use a male condom”? (a) and “no” responses
to the question “The last time you had vaginal sex did you use a female condom”? (b).
The total number of last sex acts with gel and no condom (K) was then divided by the
total number of last vaginal sex acts without condom for the trial (L) to calculate the sum-
mary estimate of percentage of last condom-free vaginal sex acts covered by gel for the trial.
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3.3.3.2 mdp 301
The summary estimate of adherence reported in the main trial paper for MDP 301 was
89% gel use at last sex act. Figure 3.3.8 shows how this estimate was calculated from the
source data. The total number of last sex acts for each participant over her trial follow-up
(W) was calculated by summing the total number of “yes” responses with the total num-
ber of “no” responses to the question “Did you use the gel the last time you had sex”?
(b). The total number of sex acts covered by gel for each participant for her follow-up (Z)
was calculated by adding all of the “yes” responses to the question “Did you use gel the
last time you had sex”? (b). To calculate the percentage of sex acts covered by gel for each
participant over her follow-up (Y), her total number of “yes” responses to using gel at last
sex act (Z) was divided by her total number of sex acts over follow-up (W). To calculate
the average percentage of gel use at last sex act for the whole trial, the mean adherences (Y)
of the participants were added together and divided by the number of participants who
contributed values to the numerator (n).
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MDP 301: Flow of source variables to summary adherence estimates
Source data at 
participant level Intermediate calculations:
responses on CRFs which have been summed across the trial
Overall adherence in primary 
results manuscript
89%
Mean reported gel use at last sex act 
Y1+Y2+Y3+ Yn
n
Number of “yes” responses to “b”, per 
participant
=
Total number of last sex acts 
covered by gel per participant
Z
Number of “yes” responses to “b”, 
and number of “no” responses to “b”, 
per participant
=
Total number of last sex acts per 
participant
W
Z/W
=
Perecent reported gel use at last sex 
act, per participant over trial follow-
up 
Y
Did you use the gel the last time 
you had sex?
b
n = number of women contributing
Figure 3.3.8: MDP 301 calculation of summary adherence estimates
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3.3.3.3 carraguard
The first summary estimate of adherence reported by Carraguard was: 96.1% of last sex
acts were covered by gel. Figure 3.3.9 shows how this estimate was calculated from the
source data. The number of “yes” responses to the question “The last time you had vagi-
nal sex, did you use the study gel”? (a) was used to calculate the total number of last sex
acts covered by gel for the whole trial (G). The number of “no” responses to the same
question (a) was used to calculate the total number of last sex acts not covered by gel for
the trial, denoted as “H” in the figure. The total number of last vaginal sex acts for the
whole trial (Z) was calculated by summing the total number of last sex acts covered by gel
for the trial (G) with the total number of last sex acts not covered by gel for the trial (H).
To calculate the percentage of last vaginal sex acts covered by gel for the trial, the total
number of last sex acts covered by gel (H) was divided by the total number of last sex acts
for the whole trial (Z).
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Carraguard: Flow of source variables to summary adherence estimates
Source data at 
participant level
Intermediate calculations:
source data which have been summed across the trial
Overall adherence in primary 
results manuscript
42.1%
Percent of vaginal sex acts covered 
by gel, estimated
K1+K2+K3+...Kn
n
96.1%
Percent of last vaginal sex acts 
covered by gel, self report
G
Z
C/2
=
Average sex acts per week per participant
J
d
Total number of used applicators
staining blue per participant
weeks in study
=
Average weekly insertions per participant
I
Number of “yes” responses to a, trial wide
=
Total number of last sex acts covered by gel, 
trial wide
G
Number of “no” responses to a, trial wide
=
Total number of last sex acts not covered by 
gel, trial wide
H
The last time you had vaginal sex, 
did you use the study gel?
a
In the past two weeks how many 
times did you have vaginal sex?
c
Number of used applicators 
returned staining blue
d
Average weekly insertions per participant
Average sex acts per week per participant
I/J
=
Sex acts covered by gel for whole study, 
estimated
per participant
K
c1+c2+c3+...cn
number of times participant answered
=
Average number of sex acts in past two 
weeks, per particpant
C
G + H
=
Total number of last sex acts, trial wide
Z
n = number of women contributing
Figure 3.3.9: Carraguard calculation of summary adherence estimates
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The second summary estimate of adherence reported by Carraguard was: 42.1% of vagi-
nal sex acts coveded by gel. Figure 3.3.9 shows how this estimate was calculated from the
source data. Each trial participant returned her used applicators at regular trial visits. For
each participant, all returned used applicators were tested with the DSA to determine if
they were inserted vaginally, according to the assay. To estimate the average weekly inser-
tions of gel for each participant (I), the total number of used applicators staining blue
(d) for a trial participant over her follow-up was then divided by the number of weeks
she participated in the study. At each follow-up visit, each participant was asked “In the
past two weeks how many times did you have vaginal sex”? (c). For each participant, this
number was averaged over her follow-up to calculate her average number of sex acts in the
last 2 weeks (C). The average sex acts per week (J) for each participant was then calculated
by dividing the average number of sex acts in the last two weeks by 2. Sex acts covered by
gel over the study for each participant (K) was calculated by dividing her average weekly
insertions (I) by her average sex acts per week (J). To calculate the summary estimate for
the trial of the 42.1% of vaginal sex acts covered by gel, the estimated proportions of sex
acts covered by gel over the study for each person (K) were added together and divided by
the total number of participants participating who contributed to the numerator.
3.3.3.4 cs conrad
The first summary adherence estimate reported in the main trial paper for CS CONRAD
was: 87% of all sex acts in the trial were covered by gel. Figure 3.3.10 shows how this es-
timate was calculated from the source data. At every monthly visit, each participant was
asked “In the past 7 days how many vaginal sex acts with a primary partner”? (a). Each
participant was also asked “In the past 7 days how many vaginal sex acts with other part-
ners”? (b). To obtain the total number of vaginal sex acts for a participant for the past
7 days, the answers to (a) and (b) were summed to give “S,” the total number of vaginal
sex acts in the past 7 days. To obtain the number of vaginal sex acts covered by gel in the
past 7 days for an individual participant (J), the responses from the following 4 questions
were summed: “In the past 7 days how many vaginal sex acts using a new study gel, but
no new condom with primary partner”? (c); “In the past 7 days how many vaginal sex
acts using a new study gel, but no new condom with other partners”? (d); “In the past
7 days, how many vaginal sex acts using both a new study gel and a new condom, with
primary partner”? (g); and “In the past 7 days, how many vaginal sex acts using both a
new study gel and a new condom, with other partners”? (h). To obtain the percentage of
sex acts covered by gel for one participant’s monthly visit (Q), the total number of vaginal
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sex acts covered by gel (J) was divided by the total number of vaginal sex acts reported
by that participant at that monthly visit (S). To calculate each participant’s trial average
of gel adherence (N), each participant’s monthly visit’s reported percentage of gel cover-
age was added (Q1+Q2+Q3+...+Qn) and divided by the number of months contributed
in the numerator, to obtain an average adherence for each participant. Then all partic-
ipant averages were averaged across the trial by adding each participant’s contribution
(N1+N2+N3+...+Nn) and dividing by the total number of participants contributing to
the numerator, to obtain the average percentage of vaginal sex acts covered by gel for all
participants over the trial.
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CS CONRAD: Flow of source variables to summary adherence estimates
Source data at 
participant level
Intermediate calculations:
responses on CRFs which have been summed across the trial
Overall adherence in 
primary results 
manuscript
87%
Percent of all sex acts in trial covered 
by gel
N1+N2+N3+…Nn
n
78%
Percent of all sex acts with primary 
partners covered by gel
P1+P2+P3+…Pn
n
45.8%
Percent of condom free sex acts in 
trial covered by gel 
K1+K2+K3+…Kn
n
S-T
=
Total sex acts in past 7 days with no 
condom, for one participant for one 
month
V
J/S
=
Percent of sex acts in past 7 days 
covered by gel, for one participant for 
one month
Q
B/a
=
Percent of gel covered sex acts in 
the past 7 days with primary partner, 
for one participant for one month
M
W1+W2+W3+…Wn
n
=
Average percent of condom free sex 
acts in past 7 days covered by gel, for 
one participant over follow up
K
In the past 7 days how many 
vaginal sex acts with primary 
partner?
In the past 7 days how many
vaginal sex acts with other 
partners?
In the past 7 days how many 
vaginal sex acts using a new study 
gel, but no new condom with 
primary partner?
In the past 7 days how many 
vaginal sex acts using a new study 
gel, but no new condom with other 
partners?
X/V
=
Percent of condom free sex acts 
covered by gel, for one participant for 
one month
W
c+g
=
Total sex acts with primary partner 
with gel in the past 7 days for one 
participant in one month
B
c+d+g+h
=
Total sex acts coved by gel in the 
past 7 days for one participant in one 
month
J
e+f+g+h
=
Total sex acts with condom in past 7 
days for one participant for one 
month
T
M1+M2+M3+…Mn
n
=
Avearge perecent of sex acts in past 7 
days covered by gel with a primary 
partner for one participant over follow-
up
P
Q1+Q2+Q3+…Qn
n
=
Average percent of all sex acts in past 7 
days covered by gel for one participant 
over follow-up
N
c+d
=
Total sex acts in the past 7 days with 
gel, but no condom for one 
participant in one month
X
a+b
=
Total sex acts in the past 7 days for 
one participant in one month
S
In the past 7 days how many 
vaginal sex acts using a new 
condom, but no new study gel, with 
primary partner?
In the past 7 days how many 
vaginal sex acts using both a new 
study gel and a new condom, with 
primary partner?
In the past 7 days how many 
vaginal sex acts using both a new 
study gel and a new condom, with 
other partners?
In the past 7 days how many 
vaginal sex acts using a new 
condom, but no new study gel, with 
other partners?
n = number of women contributing
c
d
e
b
a
f
g
h
Figure 3.3.10: CS CONRAD calculation of summary adherence estimates
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The second summary adherence estimate reported in the main trial paper for CS CON-
RAD was: 78% of all sex acts with primary partners in the trial were covered by gel. Figure
3.3.10 shows how this estimate was calculated from the source data. To obtain the num-
ber of vaginal sex acts with a primary partner when gel was used in the past 7 days for an
individual participant (B), the responses from the following two questions were summed:
“In the past 7 days how many vaginal sex acts using a new study gel, but no new condom
with primary partner”? (c) and “In the past 7 days, how many vaginal sex acts using both
a new study gel and a new condom, with primary partner”? (g). To obtain the number
of sex acts with a primary partner over the past 7 days, participants at each monthly visit
were asked “In the past 7 days how many vaginal sex acts with a primary partner”? (a).
The number of sex acts covered by gel with a primary partner for one participant for one
monthly visit (B) was divided by the total number of vaginal sex acts with a primary part-
ner reported by that participant at that monthly visit (a), to calculate the percentage of sex
acts with a primary partner covered by gel at that monthly visit (M) for one participant.
Each participant’s monthly gel coverage with a primary partner was then calculated by
adding each monthly visit’s percentage of gel coverage (M1+M2+M3+...+ Mn) and divid-
ing by the number of monthly visits contributed in the numerator, to obtain an average
gel coverage with primary partner for each participant over follow up (P). Then all partic-
ipants’ averages across the trial were added (P1+P2+P3+...+ Pn) and divided by the total
number of participants contributing to the numerator, to obtain the average percentage
of vaginal sex acts covered by gel with primary partners for the trial.
The third summary adherence estimate reported in the main trial paper for CS CON-
RAD was: 45.8% of condom-free sex acts in the trial were covered by gel. Figure 3.3.10
shows how this estimate was calculated from the source data. First, the number of sex acts
with a condom in the past 7 days (T) was determined by adding responses to the follow-
ing four questions: “In the past 7 days how many vaginal sex acts using a new condom,
but no new study gel with primary partner”? (e); “In the past 7 days how many vaginal
sex acts using a new condom, but no new study gel, with other partners”? (f); “In the past
7 days how many vaginal sex acts using both a new study gel and a new condom, with
primary partner”? (g); and “In the past 7 days how many vaginal sex acts using both a
new study gel and a new condom, with other partners”? (h), to give T. Then the total
number of sex acts in the past 7 days (S) was calculated by summing responses from the
following two questions: “In the past 7 days how many vaginal sex acts with primary part-
ner”? (a) and “In the past 7 days how many vaginal sex acts with other partners”? (b). To
calculate the number of sex acts in the past 7 days with no condom (V), the number of
sex acts in the past 7 days with a condom (T) was subtracted from the total number of
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sex acts in the past 7 days (S) for that participant for that monthly visit. To calculate the
total number of sex acts in the past 7 days with gel and no condom (X), responses to the
following two questions were summed: “In the past 7 days how many vaginal sex acts
using a new study gel, but no new condom with primary partner”? (c) and “In the past
7 days how many vaginal sex acts using a new study gel, but no new condom with other
partners”? (d). The total number of sex acts in the past 7 days with gel and no condom
(X) was then divided by the total number of sex acts without a condom (V) to give one
participant’s percentage of condom-free sex acts covered by gel for one monthly visit (W).
Each participant’s percentage of condom-free, gel-covered sex acts for the trial (K) was
calculated by adding together the percentages of condom-free, gel-covered sex acts across
all monthly visits of observation (W1+W2+W3+...+ Wn) and dividing by the number of
monthly visits contributed in the numerator. Then all participants’ averages across the
trial were added together (K1+K2+K3+...+Kn) and divided by the total number of par-
ticipants contributing to the numerator to obtain the average percentage of vaginal sex
acts covered by gel and no condom for the trial.
3.3.3.5 caprisa 004
The first set of summary adherence estimates reported in the main trial paper for CAPRISA
004 were 72% (average) and 60.2% (median) of self-reported sex acts in the last 30 days
covered by two doses of gel, trial-wide. Figure 3.3.11 shows how this estimate was calcu-
lated from the source data. Each month, the number of used applicators were counted
for each trial participant (j). For each participant, the total number of used applicators
(j) was divided by 2 to obtain “half the number of returned used applicators in the last
30 days” (L). To obtain the proportion of sex acts in the last 30 days covered by 2 gels for
each participant (M), half of the number of returned used applicators for each month (L)
was then divided by the answer to the question “In the last 30 days how many times did
you have sex?” (a). For each participant, the median monthly adherence (N) was then
calculated by taking the median “proportion of sex acts in the last 30 days covered by 2
gels” across all months of observation (M). The average percent of self-reported sex acts
in the last 30 days covered by two doses of gel for the whole trial was then calculated by
taking each participant’s median monthly adherence (N) and dividing by the number of
participants who contributed a median monthly adherence value, giving a mean of medi-
ans. The median percentage of self-reported sex acts in the last 30 days covered by 2 doses
of gels for the trial was calculated by taking the median of each of the participant’s median
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monthly adherence estimates (N).
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CAPRISA 004: Flow of source variables to summary adherence estimates
Source data at 
participant level
Intermediate calculations:
source data which have been summed 
across the trial
Overall adherence in primary 
results manuscript
Percent of self reported sex acts in the last 30 days 
covered by two doses of gel, trial wide
72% (average)
=
N1 + N2 + N3 +N4 ...Nn
n
......................................................................
60.2% (median)
=
Median (N1,N2,N3,N4...Nn)
Overall median “Gel Adherence” for women who:
did NOT acquire HIV: 61.3%
Median (N1, N2, N4, N6..Nn)
....................................................................................
did acquire HIV: 59.2%
Median (N3, N5, N7, N8...Nn)
40%
Percent of women in study who had below 50% “Gel 
Adherence”
Number of participants with median gel adherence (N) of 
<50%/
Number of all participants with median gel adherence 
(N) calculated
j/2
=
Half the number of returned used 
applicators in last 30 days, for one 
participant
L
L/a
=
Proportion of sex acts in last 30 days 
covered by 2 gels
M
Median (M1, M2, M3, M4, Mn)
=
Median monthly adherence for one 
woman, across follow up
N
In last 30 days how many times did 
you have sex?
a
Number of used applicators 
j
n = number of women contributing
Figure 3.3.11: CAPRISA 004 calculation of summary adherence estimates
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The second set of summary estimates of adherence for CAPRISA 004 includes the overall
median gel adherence for women who did not acquire HIV (61.3%) and for women who
did acquire HIV (59.2%). Figure 3.3.11 shows how these numbers were calculated. The
median of each participant’s median monthly adherence (N) for participants who did not
acquire HIV was taken to obtain the 61.3% gel adherence for women who did not acquire
HIV. The median of each participant’s median monthly adherence (N) for participants
who did acquire HIV was taken to obtain the 59.2% gel adherence for women who did
acquire HIV.
The final summary estimate of adherence reported for CAPRISA 004 was 40% of women
in the study had less than 50% gel adherence. This summary estimate was calculated by
taking the number of participants with a median gel adherence (N), as described above,
who had less than 50% adherence, and dividing by the number of all participants for
whom a median gel adherence was calculated.
3.3.3.6 summary of calculations
Not all source data collected were ultimately used to summarise adherence in primary re-
sults manuscripts. Two different methods to summarise adherence results emerged: some
trials used the total number of sex acts as the denominator, with the numerator being
comprised of the total number of sex acts covered by gel in the trial; other trials used the
number of participants as the denominator, with the numerator being comprised of the
addition of each participant’s average adherences over trial follow-up. Two trials used cal-
culations based on the number of sex acts across the trial as the denominator for some
summary estimates (HPTN 035, Carraguard). Four trials used calculations based on av-
erages of participant adherence to characterise overall adherence (MDP 301, Carraguard,
CS CONRAD, CAPRISA 004).
Three trials exclusively used self-reported data to calculate overall adherence estimates
reported in primary results publications (HPTN 035, MDP 301, CS CONRAD). One
trial (CAPRISA 004) used only composite measures, including self-report and applica-
tor data, to calculate all of the overall adherence measures reported in their manuscript.
One trial (Carraguard) reported overall adherence by including one estimate using exclu-
sively self-reported data as well as one composite estimate that included a combination of
self-reported data and results from the DSA.
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3.3.4 comments and lessons learned from trialists
During the process of providing feedback through the trial team survey, trial teams were
invited to share comments or lessons learned about trial procedures for collecting adher-
ence data. Four of the five trial teams provided comments and feedback (MDP 301, Car-
raguard, CS CONRAD, CAPRISA 004). The sections below summarise some of the key
points shared by these trial teams.
3.3.4.1 choice of adherence measures
At the time that most of the included trials were being designed, last sex act was thought
to be a good proxy for all sex acts for general populations. Because the CS CONRAD trial
population included sex workers with different partner types (such as paying clients and
primary partners), the trial team thought that last sex act might not be as informative as
a recall period that included more sex acts. Due to the high frequency of sex acts for their
population, they thought that a 30-day recall period would be too long of a duration, so
a 7-day recall period was chosen to account for enough sex acts and not be too difficult
for participants to recall.
Asking about adherence over multiple days better allows the opportunity to compare self-
reported data with returned applicators and biomarkers. CAPRISA 004 chose a 30-day
recall period so applicators from the last visit could be reconciled with participant report
and because participants did not necessarily have frequent sex.
How often to ask participants about sex and gel use is another factor that must be consid-
ered. Asking adherence information at less-frequent intervals is less burdensome to trial
participants and staff, and is less costly as well. Two trial teams noted that when partici-
pants have fewer times to report about adherence, it might create an environment where
they are less comfortable admitting that they had not used the gel.
Trial teams were highly supportive of including biomarkers and new technologies in fu-
ture trials, especially as these technologies are continuing to improve. There was also sup-
port for using different measures to assess adherence, such as composite measures and tri-
angulation of results. Trial teams that included a strong social science component thought
those elements were essential and helped improve adherence and overall trial implemen-
tation. One trial team that did not include a strong social science component thought it
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should be included in future trials.
It was stressed by some trial teams that an element of self-reported adherence is essential
in any microbicide trial. Asking about adherence provides an opportunity for trial staff to
ascertain if trial participants understand the regimen and how to use the product. If staff
members discover issues with adherence during the FTFIs, they can then provide support
to participants about how to use the product correctly and manage situations where they
have had difficulty using the product. This is a critical way that trials can prospectively
improve product adherence.
3.3.4.2 reporting adherence in primary publications
All trial teams reported adherence as overall estimates that were means or medians across
the trials. Space limitation was noted by some trial teams as a reason for not providing
more information about adherence. One trial team noted that averages are not particu-
larly informative for data of a time-varying nature.
3.3.4.3 recommendations for future trials
As stated earlier, trial teams recommended more reliance on biomarkers and technologies
to help assess adherence in trial populations, as well as inclusion of a strong social science
component. Trial teams noted that future adherence questions should be phrased to ask
about non-use, with the underlying assumptions of the questionnaire being that all par-
ticipants will miss some doses and that doing so is both normal and acceptable. Creating
an environment where participants feel it is expected that they will not be able to adhere
all of the time can improve honest reporting. One trial team noted the need for improved
and innovative ways to help trial participants remember actual sex acts and gel use. An-
other team noted that the underlying problem in microbicide trials is low adherence, and
that finding ways to ensure better adherence to study products is therefore of critical im-
portance to the field of microbicide development.
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3.4 discussion
3.4.1 limitations and strengths
The main limitation of this study is that four of the five trials available to be examined in
this study represent second generation microbicide trials, rather than third generation
microbicide trials, which is currently the direction that the microbicide field is taking.
In recent years, microbicide trials have tested ARV-based products that allow biomarker
source data to be collected. Biomarkers were not available for the investigational prod-
ucts tested in HPTN 035, MDP 301, CS CONRAD, and Carraguard. Over time, micro-
bicide trial design has become more sensitive to the importance of adherence, and each
subsequent microbicide trial draws on lessons learned from previous trials. In particular,
current biomedical HIV prevention trials have focused attention on improved adherence
counselling and stronger social science components which comprehensively examine ad-
herence.90,91,92 Another limitation of this study is that CRFs were reviewed in English
and not in the local languages used at each site. It is possible that exact wordings of ques-
tions in the final local language forms were not exactly equivalent to the approved English
versions, despite procedures used for translations and back translations.
Two strengths of this study are that trial-specific documents such as actual CRFs, SAPs,
and protocols were used in the analysis and that results, before finalisation, were shared
with trial teams for corrections and clarifications. A third strength of this study is that
five post-surfactant effectiveness trials were included in the analysis, which gives a broad
sense of the ways that second generation trials were measuring, calculating, and reporting
adherence.
3.4.2 source data
The five included trials collected a variety of source data that could be used to assess adher-
ence, although not all of the source data collected were used in the primary publications
to characterise adherence.
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3.4.2.1 clarity of wording and how questions are asked
The wording of some questions was ambiguous, which created a situation where trialists
may have understood the meaning of the question in one way and different trial partic-
ipants may have understood it in other ways. One example would be when trialists are
interested in knowing about sex acts and gel use in the last 7 days, but ask participants
about the “last week.” The understandings of “week” and “last week” may vary from per-
son to person,93 whereas “day” is a term that is likely to have more similar interpretations
across different people. A trial collecting data on sex acts in the “last week” may inadver-
tently be including information about sex acts in different periods of time in their dataset
compared to trials that ask about “last 7 days,” unless each interviewer at each interview
takes time to carefully and correctly define the trial team’s definition of “last week” for the
duration of the trial. Similar problems with meanings of words or phrases have also been
identified with terms such as “sex” and “sex act,” and “anal sex.”70,19 In order to better en-
sure that terms used in study forms are clear, unambiguous, and have the same meaning
to trial staff as they do to the diversity of participants participating in the trials, it is impor-
tant for leaders of trial teams to invest appropriate resources in creating study materials.
Trial staff must understand their own limitations with regard to cultural understanding,
and work closely with study populations to pilot forms and terminology until there is
certainty that meanings are understood as intended.93,70
An interesting finding is that questions using the same recall period may be written in
significantly different ways that may be easier or more difficult for participants to answer
accurately. MDP 301 asked participants about sex acts “last week” by first asking about
the last time the participant had sex and then filling in information about gel and condom
use for that sex act. The sex act after that one was then identified; the participant was
asked about gel and condom use for that sex act; and so on. HPTN 035, by contrast,
asked participants to produce verbal statements of how many sex acts in the last week
were covered by differing combinations of gel and condom use. A question that asks
participants to mathematically calculate in their heads the number of sex acts in the last
week covered by various combinations of gel and condom, such as “How many times did
you use the study gel and not the male or female condom”? may have been challenging
for some participants to answer, and may have increased the chance for error. Asking
participants to remember the most recent sexual event, recall specifics of that event, and
then move on to the next most recent event may make it easier for participants to recall
and report more accurately.
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3.4.2.2 recall time
Choosing a recall time to collect adherence data requires considering the trial popula-
tion, the types of sexual partners they have, the frequency with which they have sex, and
what other type of adherence data might be collected that could be combined with self-
reported data to develop composite measures of adherence. Last sex act is a simple and
useful recall period, especially for general population participants. For participants who
have different types of partners, and potentially different gel and condom use patterns,
according to partner type, asking about sex acts over multiple days may be advantageous.
Asking about a recall period that includes multiple days can be helpful when combined
with other types of data, such as returned applicators.
3.4.2.3 self-reported data
Since the results of Carraguard were published, and showed a large discrepancy between
self-reported adherence and adherence results estimated from of the applicator DSA, it
has been well established that self-reported data in biomedical HIV prevention trials are
likely to overestimate adherence.26,88,94,95,96 However, there are important reasons why
self-reported adherence data will continue to be an essential element within microbicide
trials. Adherence to microbicide regimens that are used around the time of sex can only
be assessed in the context of knowing when sexual intercourse takes place. At this time,
the only way to know when participants have had sexual intercourse is to ask them. Even
in the context of non-coitally dependent microbicides, where biomarkers can be used to
measure adherence, it is important to ask participants about when their sex acts have oc-
curred, so that data on exposure to HIV can be examined along with exposure to the study
drug.
Asking about adherence in any microbicide trial is also of critical importance because do-
ing so provides a platform for staff to assess if participants understand the regimen cor-
rectly and are having any problems using the product. Many of these products, such as
gels, are new to trial participants and may be uncomfortable or seem strange at first. In
the context of asking about adherence, staff can correct misunderstandings, provide more
advice on product use, and help participants problem solve situations where adherence
might have been difficult or impossible. For example, if a participant is concerned about
her partner’s reaction to her gel use, a staff member can suggest inviting the partner to
the study clinic to learn about the gel and the trial. Engaging participants in discussions
about their adherence is one of the most important ways that adherence within a trial
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can be improved prospectively. It is important to note, however, that asking participants
about their adherence for counselling purposes can be conducted separately from the pro-
cedures for adherence data collection.
Accuracy of self-reported adherence can be facilitated in a number of ways that relate to
the study clinic environment and how questions are asked. Preceding questions with “per-
missive” statements that acknowledge that it is not always possible to use the study gel are
being included more often in trials. As noted by some trial teams in this study, another
important way to increase accuracy in self-reported data would be to create an environ-
ment where times of non-adherence are expected and considered a normal part of trial
participation. Questions around product use should begin with asking about non-use,
which helps the participant understand that using the gel all of the time is not usually
possible.
3.4.2.4 non self-reported source data
Applicator returns were used in three of the five included trials, although they were not
always included in summary adherence estimates. Returned applicator data give trial staff
an additional avenue to understand participant adherence, but as with verbal self-reports,
participants can manipulate their “answers” by controlling how many applicators they
return as “used.” The Population Council attempted to address this issue by developing
their DSA, which identifies a mucosal enzyme and therefore can differentiate between
vaginally inserted applicators and those that simply had the gel expelled, outside of the
vagina. This assay was not validated in the context of washed applicators, however (some
participants may have washed them before returning them to the clinic);66 nor can the
assay identify if the applicator contents were expelled into the correct participant’s vagina.
Distinct advantages of applicator assessments is that they can be used with both placebo
and active products and that adherence information can be fed back to participants dur-
ing trial follow-up to prospectively improve adherence.
Trial teams included in this study were enthusiastic about inclusion of biomarkers in fu-
ture trials, as they can provide additional and potentially more accurate data about prod-
uct use. Now that most microbicides being investigated are ARVs, collection of blood
and vaginal specimens is included in trial protocols. Biomarkers do have a number of chal-
lenges, however. Analyses of biological specimens for microbicides tend to only provide
information about product use proximate to sample collection, and rates of drug absorp-
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tion can vary within individuals and between individuals.85 Results of biomarker assays
do not provide information about sexual activity, and thus about exposure to HIV. Re-
sults are subject to being manipulated by participants, as participants may choose to use
the product immediately before attending study visits where samples are collected, but
not at other times. In placebo-controlled trials, results of adherence based on study drug
found in biological samples cannot be shared with participants in real time during trials
to improve adherence prospectively, as this would break the blinding. Biomarker data are
also not available for the placebo group, which eliminates the possibility of conducting
sub-analyses of efficacy by adherence on both the investigational and control products.
Finally, a current major limitation of collection of biological samples and processing for
biomarkers is the high expense.
3.4.3 overall adherence estimates
All five included trials presented summary adherence estimates for the trials as means or
medians. Overall averages can mask important information and can paint a more posi-
tive image of adherence. For example, CAPRISA 004 reported that an average of 72%
of sex acts “were covered by two doses of gel,” yet another measure indicates that 40% of
women had below 50% adherence. Reliance on averages is particularly a problem when
trials report null results.
Overall, summary estimates also do not convey important differences between members
of trial populations, such as age categories or site, which may have differences in adherence.
Importantly, overall averages may not convey enough information to assist trial teams and
other members of the field in interpreting the primary results of the trials. Participants
use microbicide products over many months or even years, but overall averages are unable
to convey how product use may vary over time and how product use may vary between
different trial participants.
There are a number of possible reasons why trials have historically reported more sim-
plistic estimates of adherence in primary results publications. One is that it has taken
time for the microbicides field to learn the central role that adherence plays in these trials,
and thus dedicate more resources to understanding adherence. Another is that, with no
biomarkers being available for first and second generation products, adherence estimates
have largely relied on participant self-report of product use. Yet another is that the objec-
tive of publications of primary results from microbicide trials is to report the main trial
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findings, and more detailed analyses of adherence typically are conducted and published
at a later time. Finally, journal space restrictions may have also played a role in limiting
the amount of information trial teams provided about adherence. One hopes that space
limitations will not continue to be a factor; journals are increasingly offering supplemen-
tal sections online to provide greater detail and clarifications for publications.
3.4.4 how calculations were made
3.4.4.1 two types of averages
Two main differences emerged in how summary estimates were calculated: some sum-
mary estimates were based on total sex acts as the denominator, whereas other summary
estimates were based on trial participants as the denominator. Both methods provide
an overall summary of adherence, but numbers produced from the different estimates
can be different and can provide different information. When the total number of sex
acts is used as the denominator, the numerator includes the total number of sex acts that
are covered by gel in the trial. In this case, the adherence estimate provides information
about what proportion of sex acts within the entire trial were covered by the investiga-
tional product. Here, all sex acts are treated equally and the estimate can more directly
be used to help interpret the effectiveness estimate of the trial. Overall estimates that use
participants as the denominator use the addition of each participant’s average adherences
over trial follow-up as the numerator. In this case, the overall estimate is influenced by
the adherence behaviour of participants. This type of estimate is helpful to provide infor-
mation about participant adherence over follow-up.
A simple mathematical example designed to demonstrate the difference is a hypothetical
trial with 10 participants. Two participants have 100 sex acts each (with no condoms) and
do not use the gel during any of the sex acts. The remaining 8 participants have 6 sex acts
each (with no condoms) and use the gel for each of those sex acts. In the method where
overall adherence is calculated by having the total number of sex acts as the denominator,
there are a total of 248 sex acts (100 + 100 + 6 + 6 + 6 + 6 + 6 + 6 + 6 + 6) over trial
follow-up. The numerator is comprised of 48 sex acts which have been covered by gel (0
+ 0 + 6 + 6 + 6 + 6 + 6 + 6 + 6 + 6). 48/248=19% adherence, meaning that 19% of sex acts
in the trial were covered by gel. In the method where overall adherence is calculated by
having the total number of participants as the denominator, there are 10 participants in
the trial. The numerator is comprised of each participant’s average adherence (0% + 0%
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+ 100% + 100% + 100% + 100% + 100%+ 100% + 100% + 100%), which is then divided
by the number of participants to yield 800%/10=80% adherence.
In this example, different methods to calculate average adherence using the same data pro-
duced very different summary estimates: 19% adherence and 80% adherence. If a trial had
a null result, and adherence was reported to be 19%, it would indicate that participant use
was low and that biological efficacy of the investigational drug was still unknown. If in
that same trial adherence was reported to be 80%, the assumption might be that adher-
ence was high; thus, a reasonable conclusion might be that the investigational drug is not
efficacious.
In reality, these two estimates do not provide the same information. The 19% estimate
provides information about how many sex acts were covered by gel, and this estimate is
helpful to interpret the result of a trial result with respect to potential biological efficacy.
The 80% estimate based on averages of participant adherence, however, is not necessar-
ily helpful in interpreting the result of the trial with respect to product efficacy. Rather,
the 80% estimate is an average of each participant’s overall adherence over follow-up and
therefore provides more direct information about participant behaviour.
3.4.4.2 assumptions in calculations
The two trials that used composite estimates to report overall adherence estimates in-
cluded important assumptions in their calculations. Carraguard was unable to test ap-
plicators in real time with the DSA, and thus results of the assays are not linked to actual
time periods of reported sexual activity during the trial. Averages for each participant
were taken of reported sex acts over 2-week periods over follow-up, and then divided by 2.
Accordingly, the trial team accurately characterised their summary composite adherence
measure in their publication as “estimated.” As noted earlier, the DSA was not validated
in the context of washing the applicators. Thus it is not known if washing applicators
may have reduced the DSA’s ability to detect if an applicator was used, potentially bias-
ing their estimate of adherence to a lower value.
CAPRISA 004, in their calculations of overall adherence, assumed that each sex act was
covered by two gels even though data for pre- and post-sex applications were not col-
lected for the 30-day recall period. In their publication, their main summary estimate
is referred to as “sex acts covered by two doses of gel in the last 30 days.” This calculation
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was achieved by taking the number of returned used applicators, dividing by 2, and then
dividing by the number of sex acts reported for that same period of time. The trial team
states in their manuscript that “adjusting for multiple sex acts within 24 hours made no
material difference” to the estimates made. This statement does not consider situations,
however, when participants may have consistently used only one applicator of gel for each
sex act. Thus, the adherence estimates reported by CAPRISA 004 may have been biased
in a higher direction.
3.4.4.3 lack of clarity of methods used to estimate adherence
in trial information
To understand how the five trial teams estimated adherence in their trials, this compara-
tive study examined primary results publications, trial protocols, CRFs, and SAPs. Inter-
estingly, reading those materials did not locate clear explanations on how all adherence
estimates were calculated. In some cases, there was a lack of clarity in the SAP or pub-
lication as to exactly how calculations were made, particularly with respect to whether
denominators were sex acts or participants. In other cases, methods may have been well
defined in the SAP, but a different definition or method was used in the primary publica-
tion or vice versa. In one case, the SAP stated that trial teams were still determining how
adherence would be calculated.
It appeared, in reviewing the SAPs, that some of the methods described for analysing
adherence data were intended for internal purposes and that there was not necessarily
clear documentation about how adherence estimates would be reported in publications.
Moreover, in communicating with trial teams, it appeared that certain definitions used
for “adherence” in some SAPs were intended for thorough analyses of adherence and were
not included in the primary results publications. In all five trials, it was necessary to ask
for clarification of the methods used to calculate adherence estimates reported in primary
results manuscripts.
Good practice in clinical trials includes pre-specifying how analyses will be conducted.44
Pre-specification helps prevent investigators from only reporting results that might be
more favourable to a particular perspective—a practice which, in turn, can result in bias.
If trial teams specify analytic methods for adherence estimation a priori, but use different
methods for the results which are actually reported, it is important for trial teams to state
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the change in analysis method and the reason for making the change.
3.4.5 going forward
This study has looked at how five completed effectiveness trials of coitally dependent mi-
crobicide gels measured adherence, calculated adherence, and reported adherence in pri-
mary trial results publications. There was considerable variety in how trials measured,
calculated, and reported adherence. Better standardisation of methods would more easily
allow comparison of results across trials. There is also a need for better rigour in designing
questions used on CRFs so that terms are unambiguous and have the same meaning to
trialists as to trial participants. Questions about adherence should begin by asking about
non-adherence as the standard. In addition, continued investment in strong social science
components of trial implementation can help improve how questions are asked and im-
prove trial conduct.74,40,97,98
Interpretation of trial results will be improved as ways to test biological samples and tech-
nologies to monitor adherence are developed and refined.99,100 Despite careful reading
of trial protocols, CRFs, SAPs, and primary results publications, it was not possible to
understand exactly how reported adherence estimates were calculated. Methods used for
calculations described in SAPs were not always the same as methods described in primary
results publications. Trial teams can invest more resources in planning how adherence
analyses will be conducted, as adherence is such a critical finding in microbicide trials.
Deviations from pre-specified analysis plans should be included in publications. More
meaningful estimates of adherence need to be utilised to report product adherence of
trial participants over time.
Finally, while it is important to continue to improve accurate ways of measuring adher-
ence, lack of adherence can be a major cause for null results in trials, and more resources
should be devoted to understanding how actual adherence to study products can be im-
proved.
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hidden heterogeneity
uncovering patterns of adherence in
microbicide trials
objective
To examine, using self-reported adherence data from four completed effectiveness
microbicide trials, if longitudinal patterns of adherence are evident, and if so, what
individual-level factors are associated with these patterns of adherence
included trials
HPTN 035
MDP 301
Carraguard
CS CONRAD
4
H I D D E N H E T E RO G E N E I T Y
4.1 introduction
Understanding participant adherence is critical to interpretation of results from clinical
trials testing vaginal microbicides to prevent sexual transmission of HIV. As vaginal mi-
crobicides are user-controlled products, women may or may not use these topically ap-
plied investigational products according to protocol instructions. Due to the vaginal mi-
crobicides being user-controlled, a trial result that does not show a reduction in HIV in
the active gel arm might be due to an investigational product not having a sufficient bi-
ological effect, or it might be due to low usage by trial participants. At the start of this
PhD research, none of the completed vaginal microbicide effectiveness trials identified
a protective effect of the investigational microbicides20,21,22,23,24,25,26,27,28,29,30 except for
CAPRISA 004.31 Low adherence among trial participants is thought to have contributed
to some of the null findings.8,16,11,32,36,38
Interestingly, while adherence is a key factor in understanding vaginal microbicide trial
results, primary results publications typically report adherence to microbicides as over-
all averages for the trial populations. Trial averages can create an impression of overall
high adherence to the study product. In reality, each woman has her own trajectory of
adherence over the life of a trial, and a longitudinal approach to adherence data analysis
may provide a better understanding of how participants use study products over follow-
up. Rather than viewing trial populations as homogeneous, it would be helpful to un-
derstand if there are typical or distinct patterns of adherence that exist among trial par-
ticipants. Thus, the first objective of this study was to determine if different patterns
of adherence using self-reported data within four completed coitally dependent microbi-
cide gel effectiveness trials could be identified, and if so, how those patterns may compare
across trials. While true patterns of adherence would better be reflected in data collected
from biomarker specimens, these data were not available at the start of this PhD research.
If a microbicide trial population is indeed composed of subpopulations with different ad-
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herence patterns, it would then be useful to understand if certain individual-level factors
are associated with different patterns of adherence. If factors are associated with different
patterns of adherence, this information can be helpful to trial teams both during trial im-
plementation and trial planning. Thus, the second objective was to explore which factors
might be associated with different adherence patterns.
4.2 methods
4.2.1 included trials
Data from four completed non-ARV based vaginal gel microbicide trials were included
in this study: HIV Prevention Trials Network (HPTN) study of PRO 2000 and Buffer-
Gel (HPTN 035),29 Microbicides Development Programme’s trial of PRO 2000 (MDP
301),30 the Population Council’s trial of Carraguard (Carraguard),26 and CONRAD’s
trial of Cellulose Sulphate (CS CONRAD).28 All four trials included in this PhD study
tested vaginal gels to be used around the time of sex. Self-reported adherence data were
collected on a monthly or quarterly basis for each participant over her follow-up period.
For this study, adherence data for three of the trials (HPTN 035, MDP 301, Carraguard)
were based on asking participants about their gel use at their last sex act. Responses were
yes or no, and adherence data were therefore categorical. For one trial (CS CONRAD),
adherence was measured as the proportion of sex acts covered by gel over the past 7 days
(all partners), with adherence being treated as a continuous variable. Two trials collected
adherence data at monthly visits (MDP 301 and CS CONRAD) and two trials collected
adherence data at quarterly visits (HPTN 035 and Carraguard). Table 4.2.1 provides
overview information of each trial including investigational product, trial population size,
locations, type and frequency of adherence data collected, and dates of trial conduct. Fig-
ure 4.2.1 provides average adherence reported for the trial, as reported in primary results
publications for the trials.
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 Organization name
 Candidate product 
“Trial name”
Average 
adherence 
overall by 
self-report
Total number of 
participants
Type of data
Frequency of 
adherence data 
collection
Trial dates Locations
Planned 
follow-up
Actual follow-up and notes
 HIV Prevention Trials  Network 
(HPTN)
BufferGel
PRO 2000
“HPTN 035”
Microbicides Development 
Programme (MDP)
 PRO 2000
 “MDP 301”
Population Council
Carraguard
 “Carraguard”
  CONRAD
Cellulose Sulphate
“CS CONRAD”
Trial closed as planned
81%
 3,101  
(This analysis: 2,282) 
Average follow-up was 20.4 
months; 
trial closed as planned
89% Monthly
October 2005 –  
September 2009 
(2%  arm dropped 
February 2008)
South Africa, 
Tanzania, 
Uganda, 
Zambia
12 months for 
primary 
analysis
For 0.5% PRO 2000 and placebo 
gel arms, follow-up was 12 
months as planned 
9,385 
(This analysis: 6,238) 
(includes 0.5% 
gel arm + placebo to 
52 weeks)
Categorical: 
Gel use at last sex act 
(yes/no)
Quarterly
February 2005 – 
September 2008
Malawi, South 
Africa, Zambia, 
Zimbabwe, US
12 – 30 
months
Benin, India, 
South Africa, 
Uganda
 12 months
 Up to 12 months, 
trial halted early
Categorical: 
Gel use at last sex act 
(yes/no)
87%
1,398 
(This analysis: 1,314)
Treated as continuous: 
Proportion of gel covered 
sex acts in past 7 days
Monthly
July 2005 –  
March 2007
96%
6,202 
(This analysis: 6,038)
Categorical: 
Gel use at last sex act 
(yes/no)
Quarterly
July 2005 – 
March 2007
South Africa
9 – 12 
months
Table 4.2.1: Trials included in latent structure analysis study
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Figure 4.2.1: Average adherence in four trials
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4.2.2 data procurement and ethical approval
Trial teams from six completed microbicide trials were contacted and asked if they would
be willing to share their data for this study. Four trial teams had data that they were able
to share. Three trials requested confidentiality agreements, which were negotiated and
signed. Annotated case report forms (CRFs) and study protocols were provided by trial
teams and used to understand detailed trial procedures as well as to identify potential
individual level variables that could be included in the analysis for each trial. Lists of re-
quested variables were shared with trial teams, which were then approved for use in this
study. Data were provided by trial teams in various formats and levels of usability. Data
were examined and requests for data in more usable or appropriate formats were made.
In all cases, trial teams were eventually able to provide the agreed data in a usable format.
Ethical review from London School of Hygiene Tropical Medicine (LSHTM) ethics com-
mittee was sought and a favourable opinion was granted for this study, using secondary
data.
4.2.3 data management
Data for each trial were extracted, and cleaned as necessary. For each trial, a denominator
population for this study was identified in consultation with trial team representatives,
based on the effectiveness populations used in the primary results analyses. Data were
managed to create files with the designated denominator populations and subsequently
with required adherence and covariate data.
4.2.4 identifying patterns of adherence: latent class and la-
tent profile analysis
Data used in this analysis are self-reported adherence to vaginal gels prior to vaginal sex
collected at monthly or quarterly visits over the course of trial follow-up. Latent class
and latent profile analysis (LCA and LPA) are data reduction techniques that can help to
simplify large amounts of data and aim to identify patterns within data. They are types
of finite mixture modelling, which is a family of modelling techniques that allow sub-
groups within a larger population to be identified.101 The goal of LCA and LPA is to take a
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seemingly homogeneous population and “un-mix” it so that the existing constituent sub-
groups are identified within the larger population. Latent class analysis was initially used
to better characterise “latent” concepts in the social sciences that are difficult to measure
directly, such as racial prejudice, religious commitment, and authoritarianism.102 These
latent groups are often typologies or composed of categories of individuals.103 The groups
or subgroups are referred to as latent because they are not directly observable and cannot
be measured directly. The latent subgroups are identified and defined by their similar re-
sponse patterns to a particular set of questions or factors. Because the answers to sets of
questions are directly observable, it is their particular combination of response patterns
that is then able to characterise the latent group or category. These directly observable
data, which are called “indicator data,” are the data that are entered into the model to
identify the patterns and subsequent latent subgroups. In the latent class model, it is the
latent variable or concept that is believed to be the cause of the observed indicator vari-
ables.102,103,104,105
The term “latent class analysis” (LCA) is used when indicator data used to observe pat-
terns are categorical, as is the case for HPTN 035, MDP 301, and Carraguard. The term
“latent profile analysis” (LPA) is used to refer to the process when indicator data are con-
tinuous, as is the case for CS CONRAD. For simplicity, in this PhD research, LCA and
LPA together will be referred to as “latent structure analysis.” LCA and LPA are types of
cross-sectional finite mixture models, as opposed to longitudinal finite mixture models
that are designed to model trajectories as a function of time, such as growth mixture mod-
els or latent transition models. In this PhD research, LCA and LPA are able to model
trajectories of microbicide adherence patterns over time because the indicator data, gel
use during sex, were collected at regular intervals over each participant’s follow-up. Using
LCA and LPA rather than a longitudinal finite mixture model allows fewer assumptions
to be imposed in the modelling process, which results in models that more accurately rep-
resent the observed adherence data in the trials.
The objective of latent structure analysis in this study was to use the adherence data col-
lected over time from four trials to determine if the trial populations were actually com-
posed of subpopulations of participants with different patterns of adherence. The iden-
tified subpopulations, using LCA and LPA, will be referred to as “latent trajectories.”
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4.2.4.1 modelling process
In latent structure analysis, it is initially not known how many latent trajectories might ex-
ist within a population and what those trajectories might look like. Indeed, learning this
information is the objective of this type of latent structure analysis. This is accomplished
by running a series of separate models, with the number of trajectories for each model
specified by the user. The series of models typically begins with one trajectory, with an
additional trajectory added for each subsequent model. Results from the various models
are then examined and compared. Last, the final model which is deemed best to describe
the data for the particular research purpose is selected. These steps are described in more
detail in the sections below.
Once the number of desired latent trajectories is specified, the model will characterise the
trajectories based on individuals’ adherence data collected over time. The latent trajecto-
ries are characterised by estimating two types of overall parameters. The first parameter
type estimates the probability of adherence at each point in time, conditional on belong-
ing to that particular latent trajectory or subgroup within the population. These proba-
bilities, known as item response probabilities, indicate the form of the particular pattern
that characterises a particular latent trajectory. The second parameter type estimated by
the model is the proportion of individuals in the population estimated to be in each latent
trajectory, which is called the latent class or latent profile prevalence.103
The model also provides estimates for each individual of their probability of belonging to
each of the latent trajectories specified in the model, based on how the individual’s actual
data pattern compares to the item response probabilities estimated by the model. The
probabilities of belonging to each trajectory for each individual, called posterior probabil-
ities, range between 0 and 1 for each trajectory and sum to 1 for each individual across all
of the possible trajectories modelled. A model that is well defined will have trajectories
which are distinct from each other and individuals will have one trajectory for which they
have a high probability of membership (with remaining trajectories having much lower
probabilities of membership).103
Latent structure software typically uses an iterative search algorithm such as the expectation-
maximisation (EM) algorithm,106 which is a maximum likelihood approach, to charac-
terise the specified number of latent trajectories. The EM algorithm is designed to iden-
tify unknown data. In this case, the “unknown” data are the simplified version of gel ad-
herence patterns or trajectories for the microbicide trial population. The EM algorithm
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estimates the model parameters through an iterative approach that randomly selects ad-
herence patterns for the specified number of trajectories and compares those patterns to
actual adherence patterns of the trial population. This iterative approach continues until
the search is close enough to a set of parameter estimates that maximises or nearly max-
imises the likelihood function, or until the maximum number of iterations is reached.103
Once the model has converged, the maximum likelihood value is reported as the log like-
lihood, which increases as the number of parameters increases.
4.2.4.2 model selection
After fitting multiple models with a range of numbers of trajectories, a representative
model can be chosen from among them. Models are typically assessed for parsimony, abso-
lute model fit, relative model fit, and classification quality, in addition to being assessed for
interpretability and usefulness in answering the research question. Output from latent
structure statistical packages provides information that can assist investigators in assessing
the models. There is no gold standard, however, for choosing a model with the optimal
number of latent trajectories. The model selection process includes examining and weigh-
ing different information, and different individuals may disagree on which model should
be deemed optimal.
Parsimony is the principle by which a simple explanation is preferred to a more complex
explanation. In the case of latent structure modelling, with all else being equal, a model
which can describe the data with fewer parameters would be preferable to a model with
more parameters.103
Absolute model fit refers to whether a particular model provides an adequate rep-
resentation of a particular set of data. It can be assessed using a goodness-of-fit test to
compare the model-produced response pattern proportions to the actual response pat-
tern proportions in the data set. Hypothesis testing may not be possible, however, if data
are sparse or if the degrees of freedom are so large that the reference distribution is un-
known.103
Relativemodelfit refers to determining which model in a series is more optimal, with
respect to balancing parsimony and adequate data representation. Relative model fit can
be assessed through a likelihood ratio difference test or by examining relative fit indices,
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described below.
Relative fit indices are a set of information, provided by latent structure
software packages, that can be used to compare models with different num-
bers of trajectories. These indices provide information that try to balance
model fit and parsimony. Typical fit indices are Akaike information crite-
rion107 (AIC), Bayesian information criterion108 (BIC), and sample-size ad-
justed Bayesian information criterion109 (ABIC). These indices are based on
the value of -2 times the log likelihood of the model, and then adjusted with
a “penalty” for the number of parameters, sample size, or other factors.103
Although the model with the smallest value for the fit indices is desired, due
to the different types of penalties used to adjust each index, fit indices often
do not agree on the optimal model. Therefore, fit indices are generally con-
sidered along with other criteria for model selection.103,110
Classificationquality refers to how well a model represents the actual data from the
population. It can be assessed using a number of methods which include looking at the
results of the model and referring to diagnostics provided by software packages. Aspects
of these concepts are described below.
Homogeneityof latent trajectories is the extent to which members of a par-
ticular latent trajectory have the same response patterns. High homogeneity
occurs when many of the members of a particular trajectory have the same
response patterns. High homogeneity indicates that the model has created a
trajectory for which the included individuals have similar patterns and would
therefore constitute a district group when compared to other members in the
population from where they came.103
Latent trajectory separation is the extent to which the latent trajec-
tories in a model are distinct from one another and truly represent different
patterns. Indicators of high latent trajectory separation are that the trajecto-
ries within the model appear as distinct patterns from each other and that
many of the posterior probabilities of members of each trajectory are closer
to 0 and 1.103
Relative entropy,111 provided by software packages, is a type of measure
of classification error based on average posterior probabilities of trajectory
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membership for the population across the model. Within a particular model,
relative entropy values closest to 1 indicate less classification error than values
closer to 0. Error around assignment to trajectories, however, can increase as
a function of increasing the number of trajectories within the model.103 Rela-
tive entropy only provides information about a particular model and cannot
be used to compare models with different numbers of subgroups.
Optimal models are those which are parsimonious, useful for answering the research ques-
tion, and have good homogeneity and class separation. While no one method exists to
select an optimal model, decisions around model selection are often guided by fit indices
provided by software, parsimony, interpretability, usefulness of the model, and knowl-
edge of the field.103,112
For this PhD study, the LCA Stata plugin113 (Lanza and Collins) was used in Stata SE
13 (StataCorp, 2013) for LCA. For LPA, Mplus version 7.31 (Muthe´n and Muthe´n) was
used. Models with 1–6 latent trajectories were fitted for each of the four included trials.
All data available—for individuals with both complete and incomplete data—were used
in the analysis to model the latent structures, as software packages use full information
maximum likelihood (FIML).103
To select a model believed to best describe adherence patterns of a particular trial, the fol-
lowing information about the latent trajectory structures was examined: character of the
trajectories, proportion of trial population belonging to each trajectory, trajectory sepa-
ration, homogeneity, relative fit indices, relative entropy, parsimony, interpretability, and
usefulness of the model. Relative fit indices provided by software were BIC, AIC, and
ABIC. Consideration was also given to evidence that AIC has been demonstrated to over-
estimate the optimal number of latent groups.112
As the objective of this latent trajectory analysis was to reduce a large volume of data, in
order to understand participant adherence patterns and then perform multinomial logis-
tic regression to test associations of different factors with the trajectories, key aspects of
model selection were parsimony and interpretability of the latent trajectory structures.
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4.2.5 identifying factors associated with adherence patterns:
multinomial logistic regression
The objective of the multinomial multivariable analysis was to identify independent fac-
tors which were associated with different latent adherence trajectories within each trial,
as well as to examine those associations across the four trials. Three types of individual-
level factors were considered in this analysis: demographic characteristics (site, age, and
education), self-reported baseline behavioural characteristics collected around enrolment
(number of sex partners, number of sex acts, condom use, anal sex, exchange of sex), and
study exit acceptability characteristics (variables reflecting self-reported views of the mi-
crobicide gel and participants’ reports of how they thought their partners viewed the gel).
Multinomial logistic regression, with latent adherence trajectory as the outcome variable,
was used for this analysis. Multinomial logistic regression was chosen because the adher-
ence trajectories are distinct entities and would not be expected to have relationships or to
be ordered. The regressions were weighted by each trial participant’s posterior probability
of belonging to each of the latent trajectories in the model. This analysis was conducted
in Stata SE 13.
For each trial, univariable multinomial logistic regression adjusted for age was conducted
with each included variable to examine the relationship between that variable and latent
adherence trajectory outcome. Each variable was assessed using the likelihood ratio chi-
square test statistic that compares the model with age and the variable of interest to the
model without the variable of interest. Variables were deemed to have evidence of an as-
sociation with latent adherence trajectory based on results of likelihood ratio chi-square
test of p=0.05 or less. Multivariable multinomial logistic regression was then conducted
by adding variables one by one to the model, starting with those that had the strongest
evidence of an association. Each variable was added into the model and assessed using the
likelihood ratio chi-square test statistic of the full model versus the model without the
variable until a final set of variables were identified which had strong evidence of an asso-
ciation with the latent adherence trajectory membership, based on results of likelihood
ratio chi-square test of p=0.05 or less.
Individuals who did not have a complete set of variables in a particular model were dropped
from the model during multinomial logistic regression in Stata.
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4.3 results
4.3.1 adherence data available for latent structure analysis
Trials included in this PhD study enrolled between 1428 and 9385 participants which
were accrued with staggered entry; therefore, it may have taken months or years to enrol
the total sample size. Table 4.2.1 provides information about the follow-up times and data
available for this study. Figure 4.3.1 shows the number of participants who contributed
data to latent trajectory modelling at each time point for each trial. While entry time for
participants is staggered during the trials, time along the x-axis represents the first follow-
up visit for each participant, not calendar time for the trial. At any given point in time, the
total number of participants not contributing adherence data is due to a number of fac-
tors. Participants might not have been contributing data because they had officially exited
the trial because they completed their follow-up period as per protocol or had formally
withdrawn from the trial, or because the trial was halted, thus shortening their follow-up
period. Participants might not have been contributing data because they were on prod-
uct hold due to pregnancy or other health reasons. Participants also might not have con-
tributed adherence information at a particular time point because their data were missing
due to circumstances such as a missed visit, loss to follow-up, moving away, or death. Data
used in this latent trajectory analysis included all adherence data available for the selected
adherence measures for each trial population.
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Figure 4.3.1: Adherence data contributed in four trials
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HPTN 035 and Carraguard protocols were designed with varying follow-up times for
different participants in the whole trial. HPTN 035 planned 12–30 months of follow-
up for phase IIb participants. The actual mean adherence time for HPTN 035 partici-
pants was 20.4 months. Study retention, meaning the proportion of those enrolled who
had a study exit visit with an HIV test, was 93.6%. A total of 6.1% of person-years com-
prised follow-up time during which study product was withheld temporarily, mostly due
to pregnancy.29 The trial closed at the planned time as per protocol.
Carraguard planned 9–24 months of follow-up for participants. A total of 14% of par-
ticipants were lost to follow-up or died, and 18% withdrew early, including because of
pregnancy, which was a requirement of the protocol due to the investigational nature of
the study drug.26 The Carraguard trial closed at the planned time as per protocol.
Both MDP 301 and CS CONRAD planned 12 months of follow-up for the primary anal-
yses (MDP 301 included an extended safety subsample of serodiscordant couples for a
total of up to 24 months). MDP 301 was a three-arm trial that tested two concentrations
of PRO 2000 gel; the 2% arm was closed for futility during the trial. MDP 301 reported
that 81% of their participants completed a week 52 visit and that 4% of women-years did
not contribute to the primary analysis due to pregnancy.30 MDP 301 data used in this
PhD research include participant data for 52 weeks of follow-up for the 0.5% PRO 2000
gel arm and the placebo gel arm.
While CS CONRAD intended to follow up each participant for 12 months, the trial
closed early due to concern about the investigational product causing increased HIV trans-
mission in the CS arm. As the last enrolment took place on 25 January 2007 and the last
follow-up visit on 31 March 2007, some women’s official follow-up time in the study was
just a few months. A total of 9.9% of participants were lost to follow-up and 1.7% discon-
tinued the trial early.28
4.3.2 model selection and patterns of adherence
4.3.2.1 hptn 035
Table 4.3.1 provides information about each of the models for HPTN 035 with 1–6 la-
tent adherence trajectories. Figure 4.3.2 shows the latent adherence trajectory chosen for
HPTN 035, which was the model with four trajectories. Table 4.3.1 shows that the 5-class
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Number of 
latent classes
Number of 
parameters 
estimated
Log likelihood AIC BIC ABIC
Relative 
entropy
1 10 -6,751 1,929 1,987 1,955 1
2 21 -6,227 905 1,025 959 0.64
3 32 -6,138 749 932 831 0.66
4 43 -6,099 693 939 803 0.64
5 54 -6,060 636 946 774 0.66
6 65 -6,050 638 1,010 804 0.59
HPTN 035 Latent models (n=2,282)
Table 4.3.1: HPTN 035 latent trajectory information
model had the lowest AIC and ABIC indices of the six models (636 and 774, respectively).
The 3-class model had the lowest BIC value of the six models (932). Thus, model selec-
tion was among models with 3, 4, or 5 latent classes. Considering the fit statistics along
with parsimony and interpretability, the model with 4 classes was selected as it provided
enough information about the population and was easily interpretable, unlike the 5-class
model.
Figure 4.3.2 shows the four adherence trajectories (n=2282) selected for HPTN 035. The
first trajectory of the 4-latent trajectory model chosen for HPTN 035 was characterised by
one larger group, estimated to be 59% of the trial population, which had a consistently
high probability of reporting that they had used gel at the last sex act at each quarterly
visit over the course of the trial (“Consistently high” group). The second trajectory was
estimated to be 20% of the trial population. This trajectory was characterised by initially
having a high probability of reporting “yes” to gel use at last sex act as well as the proba-
bility of reporting that they had used the gel diminishing considerably after the first year
(“Later decliners” group). The third trajectory was estimated to be 5% of the trial popula-
tion and was estimated to have a 62% probability of reporting at their first quarterly visit
that they had used the gel at their last sex act. However, the probability of reporting gel use
then diminished quite quickly and stayed very low for the remainder of the trial (“Early
decliners” group). The fourth latent adherence trajectory was estimated to be 17% of the
study population and the pattern of adherence reporting was somewhat variable over the
course of the trial, with a range of adherence probabilities from 87%–34% throughout
the trial (“Variable” group).
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Consistently high 59%
Later decliners 20%
Early decliners 5%
Variable 17%
Latent class membership prevalences
n=2282
Figure 4.3.2: HPTN 035 latent class model
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Number of 
latent 
classes
Number of 
parameters 
estimated
Log 
likelihood
AIC BIC ABIC
Relative 
entropy
1 13 -19,787 4,426 4,514 4,473 1
2 27 -18,627 2,134 2,316 2,231 0.7
3 41 -18,536 1,980 2,256 2,126 0.74
4 55 -18,446 1,828 2,199 2,024 0.69
5 69 -18,426 1,815 2,280 2,061 0.71
6 83 -18,407 1,806 2,366 2,102 0.56
MDP 301 Latent models (n=6,238)
Table 4.3.2: MDP 301 latent trajectory information
4.3.2.2 mdp 301
Table 4.3.2 provides information about each of the models for MDP 301 with 1–6 latent
adherence trajectories. Figure 4.3.3 shows the latent adherence trajectory chosen for MDP
301, which was the model with four trajectories. Table 4.3.2 shows that the 6-class model
had the lowest AIC value (1806) whereas the 4-class model had the lowest values for both
the BIC and ABIC (2199 and 2034, respectively). As the 4-class model also fit the criteria
for parsimony and interpretability, the 4-class model was selected.
Figure 4.3.3 shows the four latent adherence trajectories (n=6238) selected for MDP 301.
Seventy percent (70%) of the trial population was estimated to be in the class that con-
sistently had a high probability of reporting they had used the gel at their last sex act
(“Consistently high” group). Nine percent (9%) of the trial population of MDP 301 was
estimated to be in a latent adherence trajectory which initially had a high probability of
saying they had used the gel at last sex act and then by week 20, reported lower adher-
ence, which continued for the rest of the trial (“Later decliners” group). The smallest
subgroup in this model was estimated to be 3% of the trial population and was charac-
terised by initially having a high probability of reporting adherence, which then dropped
off at week 8 and stayed lower than any other trajectory for the remainder of the trial
(“Early decliners” group). Eighteen percent (18%) of the trial population was estimated
to be in a subgroup whose probability of reported adherence trajectory ranged between
72% and 87% throughout the trial (mid-high “Variable” group).
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Consistently high 70%
Later decliners 9%
Variable 18%
Early decliners 3%
Latent class membership prevalences
n=6238
Figure 4.3.3: MDP 301 latent class model
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Number of 
latent classes
Number of 
parameters 
estimated
Log likelihood AIC BIC ABIC
Relative 
entropy
1 9 -4,915 667 728 699 1
2 19 -4,681 221 349 288 0.76
3 29 -4,664 206 401 309 0.8
4 39 -4,654 207 469 345 0.74
5 49 -4,646 211 539 384 0.74
6 59 -4,641 221 617 429 0.59
Carraguard Latent models (n=6,039)
Table 4.3.3: Carraguard latent trajectory information
4.3.2.3 carraguard
Table 4.3.3 provides information about each of the models for Carraguard with 1–6 latent
adherence trajectories. Figure 4.3.4 shows the latent adherence trajectory chosen for Car-
raguard, which was the model with three trajectories. Table 4.3.3 shows the 3-class model
had the lowest AIC index (206), whereas the 2-class model had the lowest BIC and ABIC
indices (349 and 288, respectively). Thus, selection was between the 2-class and 3-class
models. As the 3-class model was easily interpretable, provided more information than
the 2-class model, and had large enough proportions of the population belonging to each
class, the 3-class model was selected.
Figure 4.3.4 shows the model with three latent adherence trajectories (n=6039) selected
for Carraguard. Ninety-one percent (91%) of the trial population was estimated to be-
long to a class whose probability of reporting “yes” to gel use at last sex act was consis-
tently high throughout trial follow-up (“Consistently high” group). Five percent (5%)
of the trial population was estimated to be in the subgroup which initially reported high
adherence and then about halfway through follow-up reported lower adherence for the
remainder of the trial (“Later decliners” group). Four percent (4%) of the trial popula-
tion was estimated to be in a subgroup characterised by a medium-to-high probability of
reporting adherence, ranging from 61% to 96% over trial follow-up (“Variable” group).
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Consistently high 91%
Variable 5%
Later decliners 4%
Latent class membership prevalences
n=6039
Figure 4.3.4: Carraguard latent class model
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Number of 
latent 
profiles
Number of 
parameters 
estimated
Log 
likelihood
AIC BIC ABIC
Relative 
entropy
1 24 -2,800 5,647 5,773 5,697           1
2 37 -1,526 3,125 3,319 3,201 0.86
3 50 -1,029 2,158 2,420 2,262 0.89
4 63 -525 1,175 1,505 1,305 0.82
5 76 -23 198 596 354 0.84
6 89 289 -400 66 -217 0.83
CS CONRAD Latent models (n=1,393)
Table 4.3.4: CS CONRAD latent trajectory information
4.3.2.4 cs conrad
Table 4.3.4 provides information about each of the models for CS CONRAD with 1–6
latent adherence trajectories. Figure 4.3.5 shows the latent adherence trajectory chosen
for CS CONRAD, which was the model with four trajectories. Table 4.3.4 shows that fit
indices for CS CONRAD did not point to a particular solution. Because the fit indices
kept decreasing as the number of trajectories increased, parsimony and interpretability
were used to select a model. The 4-trajectory model provided more information about the
population than the 3-trajectory model, and was more interpretable than the 5-trajectory
model; therefore, it was selected as the optimal model.
Figure Figure 4.3.5 shows the model with a 4-latent trajectory solution (n=1393) that was
chosen for CS CONRAD. The largest subgroup was estimated to be 65% of the trial
population and belonged to the trajectory that had a consistently high probability of re-
porting high adherence over the 12-month follow up period (“Consistently high” group).
Sixteen percent (16%) of the trial population was estimated belong to the subgroup which
initially had high probability of reporting gel use over the last 7 days but whose reported
adherence declined after month 5 (“Later decliners” group). Nine percent (9%) of the trial
population was estimated to be in a subgroup that initially had a high probability of re-
ported adherence but whose probability of reported adherence immediately declined and
stayed low for the remainder of the trial follow-up (“Early decliners” group). Ten percent
(10%) of the trial population was estimated to be in a group whose reported adherence
was somewhat variable over the trial, mostly ranging from medium to high reported ad-
herence (62–89%) except for one month where reported adherence on average dropped
to 26% (“Variable” group).
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Consistently high 65%
Early decliners 9%
Later decliners 16%
Variable 10%
Latent profile membership prevalences
n=1393
Figure 4.3.5: CS CONRAD latent profile model
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4.3.2.5 across trials
For all four trials, the largest subgroup within the trial population was the group that con-
sistently reported high adherence throughout trial follow-up (“Consistently high” group).
In all four trials, this was also the subgroup that had the least variability in its adherence
reporting. In all four trials, a subpopulation was identified whose initially high adherence
changed about midway to lower adherence reporting (“Later decliners” group). The spe-
cific shape of the declining curves varied across the trials, although there were two con-
sistencies: the drop in the reported adherence around midway, and that while reported
adherence then remained low for the rest of the trial, adherence for this subgroup never
stayed as low as adherence for those in the “Early decliners” subgroup. “Early decliners”
were identified in three of the four trials (HPTN 035, MDP 301, and CS CONRAD).
While the particular shape of the curve was different in each trial, a drop after the first
or second visits where adherence was reported was consistent in all three trials. Also con-
sistent was that the “Early decliners” trajectories were characterised by the probability of
adherence remaining lower than any other trajectory within the trials for the remainder
of follow-up. Finally, a subgroup with somewhat variable mid-high adherence (“Vari-
able” group) was identified in each trial. In two trials (MDP 301 and Carraguard) this
subgroup’s pattern was more consistent than in the two other trials (HPTN 035 and CS
CONRAD).
4.3.3 identifying factors associated with adherence patterns
Multinomial logistic regression was used to examine which demographic, baseline sexual
behavioural, and gel acceptability factors might be associated with membership of differ-
ent latent adherence trajectories for each microbicide trial. In multinomial logistic regres-
sion, relative risk ratios (RRR) for each factor were estimated by comparing these factors
or covariate data between one latent trajectory and a selected reference trajectory. For ex-
ample, for a model with four latent trajectories, RRRs were estimated for each included
variable for three of the four trajectories; the reference trajectory served as the comparison
for all other trajectories. For this analysis, the latent adherence trajectory that consistently
had a high probability of reporting adherence (“Consistently high” group) was selected
as the reference trajectory for all trials.
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4.3.3.1 hptn 035
factors included in multinomial logistic regression
Table 4.3.5 provides detailed information about the factors examined in the multinomial
logistic regression for HPTN 035 and the number of trial participants in each category.
Table 4.3.5 also provides estimates of the numbers of participants in the various categories,
by latent class. As each trial participant had a probability of belonging to each of the latent
trajectories, the estimated numbers of participants in these categories are not represented
by integers.
age adjusted univariable multinomial logistic regression
Table 4.3.6 provides results from the age-adjusted univariable multinomial logistic regres-
sion for HPTN 035. There was strong evidence that age was associated with latent ad-
herence trajectory. Of the other factors, site and partner dislike of gel had the strongest
evidence for being associated with latent adherence trajectory when adjusted only for age.
multivariable multinomial logistic regression
Table 4.3.7 provides results from the multivariable multinomial logistic regression for
HPTN 035 (n=2174). Variables at the top of the table show an association with latent
adherence trajectory at the p=0.05 level based on the likelihood ratio chi-square-ratio test
and are adjusted for each other. Variables at the bottom of the table did not meet the crite-
rion for being included in the model as having been associated with the latent adherence
trajectories, but are included so that they may be compared across the trials. Variables
in this section are adjusted for the variables which were associated with latent adherence
trajectory, but not adjusted for the other variables which did not meet the criterion of
p=0.05 for the likelihood ratio chi-square test. This approach was used for all of the trials
described in subsequent sections.
Factors found to have an association with latent adherence trajectory (Table 4.3.7) were
age, site, and reported partner dislike of gel. Women less than 30 years of age, compared
to women 30 and older, had a greater chance of being in the trajectory groups that did
not consistently report high adherence compared to the group that reported consistently
high adherence (Later decliners, RRR 1.64; Early decliners, RRR 2.31; Variable group,
RRR 1.62). Evidence was strong that age was associated with latent adherence trajectory
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Characteristic
Total number 
of 
participants
Estimated 
number
Estimated 
prevalence
Estimated 
number
Estimated 
prevalence
Estimated 
number
Estimated 
prevalence
Estimated 
number
Estimated 
prevalence
Overall total n=2282 59% 5% 17% 20%
Age
30 and over 597 393.5 65.9% 20.7 3.5% 83.7 14.0% 99.1 16.6%
Under 30 1685 942.1 55.9% 87.4 5.2% 293.2 17.4% 362.4 21.5%
Site
 Durban, South Africa 522 284.5 54.5% 27.0 5.2% 93.5 17.9% 116.9 22.4%
Philadelphia, PA, US 146 82.8 56.7% 12.8 8.8% 21.9 15.0% 28.4 19.5%
 Harare, Zimbabwe 169 117.4 69.5% 3.8 2.2% 14.4 8.5% 33.4 19.8%
 Chitungwiza, Zimbabwe 193 145.6 75.5% 3.2 1.7% 11.1 5.7% 33.0 17.1%
 Hlabisa, South Africa 256 149.4 58.4% 13.0 5.1% 48.0 18.7% 45.7 17.8%
 Blantyre, Malawi 321 200.0 62.3% 11.6 3.6% 56.0 17.4% 53.4 16.6%
Lilongwe, Malawi 439 213.2 48.6% 26.6 6.1% 99.4 22.6% 99.8 22.7%
 Lusaka, Zambia 236 142.6 60.4% 9.9 4.2% 32.7 13.8% 50.8 21.5%
Education
Secondary and above 1437 858.1 59.7% 70.3 4.9% 213.8 14.9% 294.9 20.5%
Primary and under 844 476.7 56.5% 37.8 4.5% 163.1 19.3% 166.4 19.7%
Number of sex partners at baseline
 1 male partner in last 3 months 2215 1302.2 58.8% 102.5 4.6% 364.6 16.5% 445.7 20.1%
 2 to 6 male partners in last 3 months 67 33.4 49.9% 5.6 8.3% 12.3 18.3% 15.8 23.5%
Number of sex acts at baseline
 0 to 4 sex acts in past week 1905 1102.8 57.9% 89.9 4.7% 318.1 16.7% 394.2 20.7%
5 to 21 sex acts in past week 377 232.8 61.8% 18.1 4.8% 58.8 15.6% 67.3 17.8%
Condom use at baseline
Yes used condom at last sex act 727 396.4 54.5% 37.8 5.2% 135.6 18.7% 157.2 21.6%
No did not use condom at last sex act 1555 939.2 60.4% 70.3 4.5% 241.3 15.5% 304.2 19.6%
Anal sex at baseline
 No anal sex ever 2186 1289.5 59.0% 97.7 4.5% 361.3 16.5% 437.5 20.0%
 Yes anal sex ever 96 46.1 48.0% 10.4 10.8% 15.6 16.2% 24.0 25.0%
Exchanged sex for money, gifts, items, 
housing, etc.
 No did not accept last time had sex 2239 1305.6 58.3% 107.1 4.8% 373.3 16.7% 452.9 20.2%
Yes did accept 42 29.6 70.5% 0.8 1.9% 3.4 8.2% 8.2 19.4%
What did you not like about your study 
gel? 
Other responses 2017 1194.9 59.2% 90.4 4.5% 327.6 16.2% 404.1 20.0%
The gel was messy 156 83.3 53.4% 9.8 6.3% 28.6 18.3% 34.4 22.0%
What did you not like about your study 
gel? 
Other responses 2016 1189.2 59.0% 88.4 4.4% 328.5 16.3% 409.8 20.3%
Gel was difficult to remember 157 88.9 56.6% 11.8 7.5% 27.6 17.6% 28.6 18.2%
What did you like about the gel? 
It may protect against HIV 1670 985.1 59.0% 71.3 4.3% 280.5 16.8% 333.1 19.9%
Other responses 504 293.8 58.3% 29.0 5.7% 75.6 15.0% 105.5 20.9%
The last time you used the gel, what 
were your partner's reactions? 
He liked it 842 511.2 60.7% 35.5 4.2% 135.3 16.1% 160.0 19.0%
Other responses 1332 767.8 57.6% 64.8 4.9% 220.8 16.6% 278.6 20.9%
The last time you used the gel, what 
were your partner's reactions? 
Other responses 2119 1261.9 59.6% 92.8 4.4% 339.6 16.0% 424.7 20.0%
  He did not like it 55 17.1 31.1% 7.5 13.6% 16.5 30.0% 14.0 25.4%
Ex
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Table 4.3.5: HPTN 035 factors for multinomial logistic regression
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Early decliners Variable
Later 
decliners
Age-adjusted 
RRR
Age-adjusted 
RRR
Age-adjusted 
RRR
[95% CI] [95% CI] [95% CI]
Age (crude) 1.77 1.46 1.53 p< 0.001
Under 30 vs. 30+   [1.08- 2.89] [1.12-1.92] [1.19-1.96]
Site (vs. Durban) p<0.001
2.37 1.00 1.05
[1.13-5.01] [0.59-1.73] [0.64-1.72]
0.37 0.39 0.73
[0.12-1.12] [0.22-.72] [0.47-1.14]
0.23 0.23 0.55
[0.07-0.76] [0.12-.45] [0.36-.85]
0.95 1.00 0.76
[0.48-1.90] [0.67-1.50] [0.51-1.13]
0.63 0.87 0.66
[0.31-1.28] [0.59-1.27] [0.46-0.96]
1.45 1.51 1.21
[0.82-2.56] [1.08-2.11] [.88-1.68]
0.64 0.64 0.79
[0.30-1.37] [0.41-1.00] 0.54-1.17]
Education 1.02 1.43 1.06
Primary or less  vs. secondary+ [0.68-1.55] [1.13-1.81] [0.85-1.33]
Number of sex partners at baseline 2.34 1.4 1.48
 2-6 vs. 1 in last 3 months [0.93-5.90] [0.72-2.73] [0.80-2.74]
Number of vaginal sex acts at baseline 0.97 0.88 0.82
5-21 vs. 0-4 in past week [0.57-1.64] [0.65-1.21] [0.61-1.10]
Condom use at baseline 0.766 0.74 0.8
No vs. yes to condom at last sex act [0.51-1.16] [0.58-0.94] [0.64-1.01]
Anal sex at baseline 3.56 1.35 1.74
Yes to anal sex ever vs. no [1.73-7.30] [0.74-2.43] [1.0-2.90]
Exchanged sex for money, etc. at baseline 0.29 0.38 0.74
Yes vs. no [0.03-2.79] [0.12-1.17] [0.37-1.62]
Participant thought gel was messy 1.65 1.30 1.27
Yes vs. no [0.82-3.31] [0.83-2.03] [0.84-1.93]
Participant thought the gel was difficult to 
remember
1.86 1.16 0.96
Yes vs. no [0.98-3.55] [0.74-1.81] [0.62-1.49]
Participant liked the gel because they thought it 
may protect against HIV
1.34 0.90 1.05
No vs. yes [0.86-2.11] [0.67-1.19] [0.81-1.36]
Participant reported that their partner liked the gel 
the last time they used it
1.19 1.07 1.14
Other responses vs. yes he liked it [0.78-1.83] [0.84-1.37] [0.91-1.43]
Participant reported that their partner did not like 
the gel the last time they used it
6.24 3.72 2.52
He did not like it vs. other responses [2.56-15.20] [1.87-7.41] [0.19-0.30]
p=0.356
p=0.310
p=0.451
p=0.591
p<.001
p=0.175
Blantyre 
Lilongwe 
Lusaka 
p=0.028
p=0.268
p=0.556
p=0.039
p=0.0072
Harare
Chitungwiza 
Hlabisa 
Philadelphia 
 HPTN 035 age-adjusted univariable multinomial logistic regression
Reference Class: 
Reported consistently high adherence            
n=2282
Likelihood 
ratio chi- 
square test
Table 4.3.6: HPTN 035 age-adjusted multinomial logistic regression
CHAPTER 4. hidden heterogeneity 126
Early decliners Variable
Later 
decliners
Adjusted RRR Adjusted RRR Adjusted RRR
[95% CI] [95% CI] [95% CI]
Age 2.31 1.62 1.64
Under 30 vs. 30+ [1.34-4.00] [1.21-2.17] [1.25-2.15]
Site (vs. Durban) p<0.001
2.15 0.96 1.01
[0.98-4.71] [0.55-1.68] [0.61-1.67]
0.39 0.40 0.74
[0.13-1.20] [0.22-0.74] [0.47-1.16]
0.24 0.24 0.55
[0.07-0.82] [0.12-0.47] [0.35-0.87]
0.83 0.94 0.72
[0.39-1.73] [0.62-1.42] [0.48-1.09]
0.62 0.85 0.65
[0.30-1.29] [0.58-1.26] [0.44-0.95]
1.46 1.51 1.22
[0.80-2.64] [1.06-2.14] [0.87-1.70]
0.66 0.63 0.80
[0.30-1.44] [0.39-1.00] [0.54-1.19]
Partner dislike of gel 5.53 3.37 2.57
He did not like it vs. other responses [2.23-13.75] [1.67-6.79] [1.25-5.32]
Education 0.87 1.17 0.95
Primary or less  vs. secondary+ [0.47-1.59] [0.83-1.64] [0.69-1.30]
Number of sex partners at baseline 1.68 1.51 1.47
 2-6 vs. 1 in last 3 months [0.60-4.71] [0.72-3.13] [0.75-2.87]
Number of vaginal sex acts at baseline 1.43 1.29 0.96
5-21 vs. 0-4 in past week [0.81-2.54] [0.92-1.82] [0.70-1.33]
Condom use at baseline 0.86 0.88 0.81
No vs. yes to condom at last sex act [0.55-1.34] [0.68-1.14] [0.64-1.04]
Anal sex at baseline 2.52 1.36 1.82
Yes to anal sex ever vs. no [1.02-6.21] [0.67-2.73] [0.99-3.34]
Exchanged sex for money, etc. at baseline 0.31 0.44 0.73
Yes vs. no [0.03-3.04] [0.14-1.38] [0.32-1.66]
Participant thought gel was messy 1.07 1.17 1.19
Yes vs. other responses [0.50-2.32] [0.72-1.89] [0.76-1.85]
Participant thought the gel was difficult to 
remember
1.26 0.90 0.83
Yes vs. other responses [0.64-2.49] [0.57-1.42] [0.53-1.30]
Participant liked the gel because they thought it 
may protect against HIV
1.32 0.96 1.05
No vs. yes [0.82-2.14] [0.71-1.30] [0.80-1.37]
Participant reported that their partner liked the gel 
the last time they used it
1.10 1.14 1.18
Other responses vs. yes he liked it [0.68-1.79] [0.87-1.50] [0.92-1.51]
Philadelphia 
HPTN 035 multivariable multinomial logistic regression
Reference Class: 
Reported consistently high adherence            
n=2282
Likelihood 
ratio chi-
quare test
p<0.001
Harare
Chitungwiza 
Hlabisa 
Blantyre 
Lilongwe 
Lusaka 
p=0.555
p<0.001
p=0.711
p=0.503
p=0.308
p=0.361
p=0.103
p=0.305
p=0.857
p=0.694
p=0.672
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(likelihood ratio chi-square test p<0.001).
For the overall model, site was also found to be associated with belonging to latent adher-
ence trajectory (likelihood ratio chi-square test p<0.001). Durban served as the reference
category for site; whether there was an increased or decreased chance of being in the high-
adhering group versus another trajectory depended on which site was being compared
to Durban. At the individual site level, not all sites compared to Durban were found to
have an association with latent adherence trajectory and the effect sizes for some sites were
small.
If a participant reported that her partner did not like the gel, her chance of being in one
of the latent adherence trajectories that did not report consistently high adherence was
greatly increased (RRR 2.57 of being in the Later decliners group compared to the Con-
sistently high group, RRR 5.53 of being in the Early decliners group compared to Consis-
tently high group, and RRR 3.37 of being in the Variable group compared to the Consis-
tently high group; likelihood ratio chi-square test p<0.001). Evidence for this association
was strong and the effect size was large.
Factors that were not found to be associated with latent adherence trajectory for HPTN
035 in the multivariable model were education, number of sex partners at baseline, num-
ber of sex acts at baseline, condom use at baseline, anal sex at baseline, exchange of sex,
participant thinking the gel was messy, participant thinking the gel was difficult to re-
member, participant liking the gel because she thought it may protect against HIV, and
participant reporting that her partner liked the gel.
4.3.3.2 mdp 301
factors included in multinomial logistic regression
Table 4.3.8 provides detailed information about the factors examined in the multinomial
logistic regression for MDP 301 and the number of trial participants in each category. Ta-
ble 4.3.8 also provides estimates of the number of women in the various categories, by la-
tent class. As each trial participant has a probability of membership for each of the latent
trajectories, the estimated number of participants in these categories are not represented
by integers.
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Characteristic
Total number 
of participants
Estimated 
number
Estimated 
prevalence
Estimated 
number
Estimated 
prevalence
Estimated 
number
Estimated 
prevalence
Estimated 
number
Estimated 
prevalence
Overall total n=6238 70% 3% 18% 9%
Age
30 and over 2761 2101.9 76.1% 49.2 1.8% 416.2 15.1% 193.7 7.0%
Under 30 3477 2280.3 65.6% 130.0 3.7% 694.4 20.0% 372.3 10.7%
Site
Durban 1700 1213.7 71.4% 44.2 2.6% 279.3 16.4% 162.7 9.6%
Johannesburg 1643 950.1 57.8% 89.9 5.5% 426.2 25.9% 176.8 10.8%
Masaka 572 446.3 78.0% 6.3 1.1% 90.1 15.7% 29.3 5.1%
Mwanza 730 546.5 74.9% 15.1 2.1% 105.0 14.4% 63.3 8.7%
Africa Centre 779 617.3 79.2% 12.9 1.7% 90.8 11.7% 58.0 7.4%
Mazabuka 814 608.3 74.7% 10.7 1.3% 119.1 14.6% 75.9 9.3%
Education
Secondary and above 1508 914.2 60.6% 67.4 4.5% 354.6 23.5% 171.8 11.4%
Primary and under 4730 3468.0 73.3% 111.8 2.4% 756.0 16.0% 394.3 8.3%
 How many different people have you had sex with in 
the last week?
 1 person in the last week 5044 3491.9 69.2% 155.7 3.1% 927.2 18.4% 469.3 9.3%
More than one partner in the last week 38 23.4 61.5% 1.8 4.7% 7.4 19.6% 5.4 14.2%
 How many times have you had sex in the past week?
 1 to 3 sex acts past week 3599 2561.8 71.2% 100.7 2.8% 613.5 17.0% 322.9 9.0%
 4 to 77 sex acts in past week 1484 954.3 64.3% 56.7 3.8% 321.2 21.6% 151.8 10.2%
 Did you use a condom the last time you had sex?
 No did not use condom 3261 2348.0 72.0% 82.3 2.5% 557.2 17.1% 273.5 8.4%
 Yes used condom at last sex act 2926 1999.1 68.3% 96.4 3.3% 542.5 18.5% 288.1 9.8%
Have you had anal sex in the last 4 weeks?
 No anal sex in the last 4 weeks 6166 4339.1 70.4% 174.7 2.8% 1092.9 17.7% 559.4 9.1%
 Yes anal sex in the last 4 weeks  69 41.4 60.1% 4.5 6.6% 17.5 25.3% 5.6 8.1%
Would you encourage or discourage your friends to use 
the gel if we showed this microbicide halves women's 
risk  of getting HIV?
Encourage 4426 3171.2 71.6% 108.5 2.5% 768.7 17.4% 377.6 8.5%
Discourage 140 99.3 71.0% 3.2 2.3% 22.8 16.3% 14.7 10.5%
Was it easy to predict when you may need to insert the 
gel?
Yes 560 380.1 67.9% 22.7 4.1% 103.2 18.4% 53.9 9.6%
No 4095 2948.3 72.0% 90.8 2.2% 706.3 17.2% 349.6 8.5%
How likely do you think it is that you might get infected 
with HIV?
Very likely 1536 1118.4 72.8% 38.8 2.5% 258.7 16.8% 120.2 7.8%
Not very likely 2249 1604.7 71.3% 53.0 2.4% 390.4 17.4% 201.0 8.9%
Impossible 724 506.3 69.9% 18.4 2.5% 132.8 18.3% 66.4 9.2%
What did your partner think of the gel?
Other responses 4503 3236.4 71.9% 106.0 2.4% 771.2 17.1% 389.5 8.6%
Disliked it 153 94.1 61.5% 7.5 4.9% 37.7 24.6% 13.6 8.9%
Did the gel affect how much your partner enjoyed sex?
Other responses 4436 3169.6 71.5% 108.7 2.4% 771.9 17.4% 385.9 8.7%
Made sex less enjoyable 225 163.6 72.7% 4.9 2.2% 39.2 17.4% 17.3 7.7%
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age adjusted univariable multinomial logistic regression
Table 4.3.9 provides results from the age-adjusted univariable multinomial logistic regres-
sion for MPD 301. There was strong evidence that age was associated with latent adher-
ence trajectory. Site, education, number of sex acts at baseline, and partner dislike of gel
had the strongest evidence for being associated with latent adherence trajectory when ad-
justed only for age.
multivariable multinomial logistic regression
Table 4.3.10 provides results from the multivariable multinomial logistic regression for
MDP 301. Factors found to be associated with latent adherence trajectory were age, site,
number of sex acts at baseline, and education. Women who were less than 30 years old
versus 30 or older had an increased chance of being in the three latent adherence trajec-
tories that did not consistently report high adherence (Later decliners, RRR 1.53; Early
decliners, RRR 1.80; Variable mid-high adherers, RRR 1.21). There was strong evidence
of the association between age and latent adherence trajectory (likelihood ratio chi-square
test p<0.001).
There was strong evidence that site was also associated with latent adherence trajectory
(likelihood ratio chi-square p<0.001). Durban was used as the reference category, and
the direction of the estimate depended on which site was being compared to Durban. At
the individual site level, not all sites compared to Durban were found to have an associa-
tion with latent adherence trajectory and the effect sizes for some sites were small.
Participants with primary education or lower versus participants with secondary or higher
education had a lower chance of being in latent adherence trajectories which did not con-
sistently report high adherence (Later decliners, RRR 0.79; Early decliners, RRR 0.79;
Mid-high variable adherence reporters, RRR 0.76). There was strong evidence that ed-
ucation was associated with latent adherence trajectory in the multivariable multinomial
logistic regression for MDP 301 (likelihood ratio chi-square test p=0.009).
There was also strong evidence that number of sex acts at baseline was associated with
belonging to latent adherence trajectories (likelihood ratio chi-square test p=0.017). Four
or more sex acts in the last week prior to enrolment versus 3 or fewer sex acts reported at
baseline was associated with an increased chance of being in one of the trajectories which
did not consistently report high adherence (Later decliners, RRR 1.16; Early decliners,
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Early decliners Variable Later decliners
Adjusted RRR Adjusted RRR Adjusted RRR
[95% CI] [95% CI] [95% CI]
Age  (crude)                                         2.44                       1.54                      1.77                 p<0.001
under 30 vs. 30+ [1.75-3.40] [1.34-1.76] [1.47-2.13]
Site vs. Durban p<0.001
2.43 1.89 1.32
[1.68-3.52] [1.59-2.25] [1.05-1.66]
0.44 0.93 0.53
[0.19-1.02] [0.71-1.20] [0.35-0.80]
0.79 0.85 0.89
[0.44-1.43] [0.66-1.09] [0.65-1.21]
0.65 0.68 0.76
[0.35-1.22] [0.52-0.87] [0.56-1.05]
0.48 0.85 0.93
[0.24-.94] [0.67-1.07] [0.69-1.23]
Education 2.11 0.61 0.69 p<.001
Primary or less vs. secondary + [1.50] [0.53-0.71] [0.57-0.84]
Number of sex partners at baseline 1.65 1.17 1.67 p=0.730
>1 partner in last week vs. 1 [0.36-7.61] [0.51-2.69] [0.65-4.29]
Number of sex acts at baseline 1.47 1.39 1.24 p<0.001
4+ or more last week vs. 3 or less [1.05-2.06] [1.19-1.62] [1.01-1.52]
Condom use at baseline 1.24 1.09 1.16 p=0.176
Yes vs. no condom at last sex [0.92-1.68] [0.95-1.24] [0.97-1.38]
Anal sex at baseline 2.66 1.66 1.03 p=0.151
Yes anal sex in last 4 weeks vs. no [0.99-7.14] [0.94-2.91] [0.42-2.51]
Recommend gel to friends if halves women's 
risk of HIV?
0.92 0.94 1.23 p=0.881
Discourage vs. encourage [0.29-2.87] [0.59-1.50] [0.70-2.15]
Was it easy to predict when you needed to use 
the gel?
0.52 0.89 0.85 p=0.059
No vs. yes [0.33-0.84] [0.71-1.12] [0.62-1.15]
How likely do you think it is that you might get 
infected with HIV?
p=0.908
Not very likely vs. very likely 0.91 1.03 1.13
[0.59-1.38] [0.86-1.22] [0.89-1.43]
Impossible vs. very likely 0.99 1.10 1.18
[0.56-1.74] [0.87-1.39] [0.85-1.62]
Partner dislike of gel 2.31 1.63 1.16
Disliked it vs. other responses [1.07-4.98] [1.11-2.40] [0.65-2.07]
Effect of gel on partner's enjoyment of sex? 0.86 0.98 0.86
Less enjoyable vs. other responses [.344-2.17] [0.68-1.40] [0.52-1.43]
Africa Centre
Mazabuka 
p=0.036
p=0.934
Joburg
Masaka 
Mwanza
MDP 301 age-adjusted multinomial logistic regression
Reference Class: 
Reported consistently high adherence            
n=5083 
Likelihood ratio 
chi-square test
Table 4.3.9: MDP 301 age-adjusted multinomial logistic regression
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Early decliners Variable Later decliners
Adjusted RRR Adjusted RRR Adjusted RRR
[95% CI] [95% CI] [95% CI]
Age 1.80 1.21 1.53
Under 30 vs.30+ [1.25-2.60 ] [1.04-1.42] [1.24-1.88]
Site vs. Durban p<0.001
2.24 1.77 1.25
[1.50-3.33] [1.47-2.14] [0.98-1.60]
0.49 1.05 0.62
[0.19-1.28] [0.77-1.43] [0.39-0.99]
1.00 0.92 0.96
[0.52-1.91] [0.69-1.23] [0.67-1.37]
0.77 0.72 0.79
[0.38-1.57] [0.53-0.97] [0.54-1.15]
0.46 0.88 0.91
[0.22-0.95] [0.68-1.13] [0.66-1.25]
Number of sex acts at baseline 1.28 1.27 1.16 p=0.017
4+ or more last week vs. 3 or less [0.91-1.81] [1.08-1.48] [0.94-1.44]
Education 0.79 0.76 0.79
Primary or less vs. secondary + [0.55-1.14] [0.64-0.91] [0.63-1.00]
Number of sex partners at baseline 1.67 1.19 1.62
>1 partner in last week vs. 1 [0.35-7.98] [0.51-2.78] 0.62-4.25]
Condom use at baseline 0.92 0.88 1.05
Yes vs. no condom at last sex [0.66-1.30] [0.75-1.02] [0.85-1.29]
Anal sex at baseline 2.21 1.33 0.81
Yes anal sex in last 4 weeks vs. no [0.81-6.04] [0.72-2.45] [0.30-2.17]
Recommend gel to friends if halves women's 
risk of HIV?
0.90 0.86 1.14
Discourage vs. encourage [0.27-3.01] [0.51-1.46] [0.62-2.10]
Was it easy to predict when you needed to use 
the gel?
0.57 0.89 0.84
No vs. yes [0.34-0.96] [0.69-1.16] [0.59-1.18]
How likely do you think it is that you might get 
infected with HIV?
Not very likely vs. very likely 0.63 1.00 0.94
[0.39-1.02] [0.80-1.25] [0.71-1.27]
0.63 0.95 1.04
Impossible vs. very likely [0.33-1.19] [0.72-1.24] [0.72-1.48]
Effect of gel on partner's enjoyment of sex? 1.08 1.00 0.92 p=0.990  
Less enjoyable vs. other responses [0.42-2.78] [0.67-1.48] [0.53-1.60]
Partner dislike of gel 2.01 1.50 1.26
Disliked it vs. other responses [0.87-4.64] [0.98-2.29] [0.68-2.33]
p=0.165
p=0.757
p=0.329
p=0.397
p=0.900
p=0.167
p=0.620 
Joburg
Masaka 
Mwanza
Africa Centre
Mazabuka 
p=0.009
p<0.001
MDP 301 multivariable multinomial logistic regression
Reference Class: 
Reported consistently high adherence            
n=5083 
Likelihood ratio 
chi-square test
Table 4.3.10: MDP 301 multivariable multinomial logistic regression
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RRR 1.28; Mid-high variable adherence reporters, RRR 1.27). However, the effect sizes
were not very large.
Factors that were not associated with latent adherence trajectory for MDP 301 in the mul-
tivariable model were number of sex partners at baseline, condom use at baseline, anal sex
at baseline, whether the participant would recommend the gel to another person, whether
the participant could predict needing the gel, whether the participant thought she might
be infected by HIV, whether the participant reported the gel affected sex, and whether
the participant reported that her partner did not like the gel.
4.3.3.3 carraguard
factors included in multinomial logistic regression
Table 4.3.11 provides detailed information about the factors examined in the multinomial
logistic regression for Carraguard and the number of trial participants in each category. Ta-
ble 4.3.11 also provides estimates of the number of participants in the various categories,
by latent class. As each trial participant has a probability of membership for each of the
latent trajectories, the estimated numbers of participants in these categories are not repre-
sented by integers.
age-adjusted univariable multinomial logistic regression
Table 4.3.12 provides results from the age-adjusted univariable multinomial logistic re-
gression for Carraguard. There was strong evidence that age was associated with latent
adherence trajectory. Site and partner refusal of gel had the strongest evidence for being
associated with latent adherence trajectory when adjusted only for age.
multivariable multinomial logistic regression
Table 4.3.13 provides results from the multivariable multinomial logistic regression for
Carraguard. Factors found to be associated with latent adherence trajectory were age, site,
number of sex partners at baseline, and partner refuse of gel use (data only available for
a subsample of 1191). Participants who were less than 35 years of age versus over 35 had
an increased chance of being in a latent adherence trajectory that did not consistently re-
port high adherence (Later decliners, RRR 1.63; Variable adherence reporters, RRR 1.40).
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Characteristic
Total number 
of participants
Estimated 
number
Estimated 
prevalence
Estimated 
number
Estimated 
prevalence
Estimated 
number
Estimated 
prevalence
Overall total n=6039 91% 4% 5%
Age
35 and over 2180 2018.5 92.6% 85.9 3.9% 75.5 3.5%
Under 35 3859 3463.4 89.7% 229.4 5.9% 166.2 4.3%
Site
UTC 2245 2030.7 90.5% 109.1 4.9% 105.1 4.7%
Medunsa 2329 2211.0 94.9% 66.5 2.9% 51.5 2.2%
MRC 1465 1240.2 84.7% 139.7 9.5% 85.1 5.8%
Education
Secondary and above 1142 1032.9 90.4% 63.7 5.6% 45.4 4.0%
Primary and under 455 421.2 92.6% 19.1 4.2% 14.7 3.2%
Number of sex partners at baseline in past 3 months
1 partner 5518 5020.5 91.0% 282.3 5.1% 215.2 3.9%
2 or more partners 521 461.4 88.6% 33.0 6.3% 26.5 5.1%
Number of vaginal sex acts in past two weeks
0 to 4 sex acts 4257 3859.8 90.7% 228.5 5.4% 168.7 4.0%
5 to 56 sex acts 1781 1621.2 91.0% 86.8 4.9% 73.0 4.1%
Condom use at last sex with steady partner? 
No 3557 3228.7 90.8% 183.7 5.2% 144.7 4.1%
Yes 1073 978.2 91.2% 54.0 5.0% 40.8 3.8%
In the past 3 months have you had unprotected anal 
sex?
No 5908 5367.9 90.9% 306.2 5.2% 233.9 4.0%
Yes 130 113.0 86.9% 9.2 7.1% 7.8 6.0%
Have you ever had sex in exchange for money?
No 5872 5328.3 90.7% 306.7 5.2% 237.0 4.0%
Yes 167 153.6 92.0% 8.7 5.2% 4.7 2.8%
What effect did the study gel have on your sexual 
pleasure?
More pleasure 623 574.7 92.3% 28.5 4.6% 19.7 3.2%
Less Pleasure 40 34.4 86.1% 4.9 12.2% 0.7 1.8%
No effect 938 848.9 90.5% 49.5 5.3% 39.6 4.2%
What effect did the gel have on your most recent 
partner's sexual pleasure?
Other responses 1431 1315.2 91.9% 66.3 4.6% 49.5 3.5%
Made sex less pleasurable 60 54.2 90.3% 3.7 6.2% 2.1 3.5%
What was your most recent parner's reaction to you 
using the study gel?
Other responses 1568 1435.4 91.5% 76.7 4.9% 55.9 3.6%
He refused to allow me to use the gel 31 21.1 68.0% 5.7 18.5% 4.2 13.5%
*Subsample of 1191 participants
        Reference group: 
consistently high 
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Later decliners Variable
Adjusted RRR Adjusted RRR
[95% CI] [95% CI]
Age (crude) p<0.001
Under 35 vs. 35+
Site vs. UTC p<.0001
0.51 0.42
[0.37-0.070] [0.30-0.059]
1.97 1.27
[1.52-2.57] [0.94-1.71]
Education* 0.92 0.95 p=0.952
Primary or less vs. secondary + [0.52-1.65] [0.49-1.84]
Number of sex partners at baseline 1.23 1.32 p=0.276
2 or more in past 3 months vs. 1 [0.85-1.79] [0.87-1.99]
Number of sex acts baseline 0.91 1.03 p=0.723
5 or more sex acts in  past 2 weeks vs. 4 or less [0.70-1.17] [0.78-1.37]
Condom use at baseline 1.08 1.12 p=0.742
No condom used at last sex act with steady partner vs. yes condom [0.79-1.48] [0.78-1.59]
Anal sex at baseline 1.38 1.55 p=0.387
Yes unprotected anal sex in the past 3 months vs. no [0.70-2.73] [0.74-3.25]
Have you ever had sex in exchange for money? 1.00 0.70 p=0.722
Yes vs. no [0.50-2.00] [0.28-1.76]
What effect did the study gel have on your sexual pleasure?* p=0.318
Less pleasure vs. more pleasure 2.73 0.58
[0.98-7.61] [0.05-6.37]
No effect vs. more pleasure 1.15 1.34
[0.72-1.85] [0.77-2.32]
What effect did the gel have on your most recent partner's sexual 
pleasure?*
1.36 1.02 p=0.866
Less pleasure vs. other responses [0.46-3.99] [0.25-4.18]
What was your most recent partner's reaction to you using the study gel?*
4.93 4.96 p=0.002
Refused me to use gel vs. other responses [1.90-12.80] [1.68-14.69]
*Subsample of 1191 participants
1.56                     
[1.21-2.01]
1.28                              
[0.97-1.69]
Carraguard age-adjusted univariable multinomial logistic regression
Reference Class: 
Reported consistently high 
n=6039
Likelihood ratio 
chi-square test
Medunsa 
MRC 
Table 4.3.12: Carraguard age-adjusted multinomial logistic regression
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Later decliners Variable
Adjusted RRR Adjusted RRR
[95% CI] [95% CI]
Age 1.63 1.40
Under 35 vs. 35+ [1.26-2.11] [1.06-1.86]
Site p<.001
0.48 0.39
[0.34-0.66] [0.27-0.55]
1.94 1.24
 [1.49-2.52] [0.92-1.66]
Number of sex partners at baseline 1.56 1.74
2 or more vs. 1 [1.06-2.29] [1.13-2.67]
What was your most recent partner's reaction to you using the study gel?* 
3.26 3.98
Refused me to use gel vs. other responses [1.22-8.69] [1.30-12.17]
Education* 0.79 0.82
Primary or less vs. secondary + [0.44-1.40] [0.42-1.60]
Number of sex acts baseline 1.08 1.11
5 or more sex acts in  past 2 weeks vs. 4 or less [0.83-1.41] [0.83-1.48]
Condom use at baseline 0.99 0.91
No condom used at last sex act with steady partner vs. yes condom [0.71-1.39] [0.62-1.33]
Anal sex at baseline 0.94 1.24
Yes unprotected anal sex in the past 3 months vs. no [0.47-1.89] [0.58-2.62]
Have you ever had sex in exchange for money? 0.99 0.72
yes vs no [0.48-2.06] [0.27-1.86]
What effect did the study gel have on your sexual pleasure?* p=0.531
Less pleasure vs. more pleasure 2.20 0.44
[0.77-6.29] [0.04-4.91]
No effect vs. more pleasure 1.09 1.18
0.67-1.79 [0.67-2.09]
What effect did the gel have on your most recent partner's sexual 
pleasure?*
1.38 0.99
Less pleasure vs. other responses [0.46-4.10] [0.24-4.09]
*Subsample of 1191 participants
p=0.677
p=0.882
p=0.844
p=0.773
p=0.859
p=0.621
n=6039
Likelihood ratio 
chi-square test
p<.001
Medunsa (vs. UTC)
MRC (vs. UTC)
p=0.008
p=0.016
Reference Class: 
Reported consistently high 
Carraguard multivariable multinomial logistic regression
Table 4.3.13: Carraguard multivariable multinomial logistic regression
There was strong evidence that age in the Carraguard study was associated with latent tra-
jectory membership (likelihood ratio chi-square test p<0.001).
Site was also found to be associated with latent adherence trajectory (likelihood ratio chi-
square p<0.001). Participants from Medunsa versus UTC had a decreased risk of being
in either the Later decliners group (RRR 0.48) or the Variable trajectories group (RRR
0.39) compared to the reference group, Consistently high adherence group. Participants
from MRC had a greater chance of being in the Later decliners (RRR 1.94) or Variable
(RRR 1.24) groups compared to the reference High adherence-reporting group.
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There was strong evidence in this analysis that number of sex partners at baseline was as-
sociated with membership of the latent adherence trajectories (likelihood ratio chi-square
test p=0.008). Participants who reported two or more sex partners at baseline versus par-
ticipants who reported one sex partner were more likely to be in one of the adherence
trajectories that did not consistently report high adherence (Later decliners, RRR 1.56;
Variable adherence reporters, RRR 1.74).
Study exit data completed with a subsample of Carraguard trial participants allowed ex-
ploration of latent adherence trajectory membership with several additional factors that
were not available for the whole trial population. In a subsample of 1191 trial participants,
those who reported their partner refused their use of the gel had a greater chance of being
in the latent adherence trajectories that did not consistently report high adherence. There
was strong evidence of the association of partner refusal and latent class membership (like-
lihood ratio chi-square test p=0.016), and effect of partner refusal was large (Later declin-
ers, RRR 3.26; Variable adherence reporters, RRR 3.98).
Factors that were not associated with latent adherence trajectory for Carraguard in the
multivariable model were education (subsample) number of baseline sex acts, condom
use at baseline, anal sex at baseline, exchanging money for sex, whether the participant
reported that gel affected her pleasure during sex, and whether the participant reported
that the gel affected her partner’s pleasure.
4.3.3.4 cs conrad
factors included in multinomial logistic regression
Table 4.3.14 provides detailed information about the factors examined in the multino-
mial logistic regression for CS CONRAD and the number of trial participants in each
category. Table 4.3.14 also provides estimates of the number of women in the various cat-
egories, by latent class. As each trial participant has a probability of membership for each
of the latent trajectories, the estimated numbers of participants in these categories are not
represented by integers.
age-adjusted univariable multinomial logistic regression
Table 4.3.15 provides results from the age-adjusted univariable multinomial logistic re-
gression for CS CONRAD. There was strong evidence that age was associated with latent
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Characteristic
Total number 
of 
participants
Estimated 
number
Estimated 
prevalence
Estimated 
number
Estimated 
prevalence
Estimated 
number
Estimated 
prevalence
Estimated 
number
Estimated 
prevalence
Overall total n=1393 65% 9% 16% 10%
Age
30 and over 668 453.9 67.9% 45.1 6.8% 100.7 15.1% 68.3 10.2%
Under 30 725 454.5 62.7% 84.6 11.7% 120.8 16.7% 65.2 9.0%
Site
South Africa 589 385.0 65.4% 68.8 11.7% 93.9 15.9% 41.4 7.0%
Bangalore 22 13.4 60.8% 3.8 17.2% 2.6 11.9% 2.2 10.2%
Benin 227 158.6 69.9% 15.9 7.0% 39.2 17.3% 13.3 5.9%
Chennai 252 145.9 57.9% 11.9 4.7% 49.2 19.5% 45.0 17.9%
Uganda 303 205.4 67.8% 29.4 9.7% 36.6 12.1% 31.6 10.4%
Education
Secondary and above 633 403.1 63.7% 77.1 12.2% 96.5 15.2% 56.3 8.9%
Primary and under 673 453.6 67.4% 47.4 7.0% 110.0 16.3% 62.0 9.2%
In the last 30 days, with how many 
different men have you had vaginal 
sex?
0-4 640 422.3 66.0% 69.8 10.9% 96.9 15.1% 51.0 8.0%
5 or more 753 486.0 64.5% 59.9 8.0% 124.5 16.5% 82.5 11.0%
How many times did you have 
vaginal sex in the last 7 days? 
8 or less 1001 644.1 64.4% 92.9 9.3% 165.1 16.5% 98.9 9.9%
9 or more 392 264.2 67.4% 36.9 9.4% 56.4 14.4% 34.6 8.8%
The last time you had vaginal sex, 
did you use a condom?
Yes 850 561.1 66.0% 72.3 8.5% 133.8 15.7% 82.8 9.7%
No 543 347.2 64.0% 57.4 10.6% 87.6 16.1% 50.7 9.3%
Have you had anal sex in the past 30 
days?
No 1341 873.0 65.1% 123.9 9.2% 212.5 15.8% 131.6 9.8%
Yes 52 35.3 67.9% 5.8 11.2% 8.9 17.2% 2.0 3.8%
What effect does the gel have on 
sexual intercourse? 
I enjoy sex more
Other responses 425 260.6 61.3% 51.2 12.1% 68.5 16.1% 44.7 10.5%
Yes 945 638.8 67.6% 73.5 7.8% 148.9 15.8% 83.8 8.9%
I enjoy sex less
Other responses 1351 888.8 65.8% 121.0 9.0% 214.8 15.9% 126.3 9.4%
Yes 19 10.6 55.9% 3.7 19.6% 2.5 13.3% 2.1 11.3%
Partner enjoys sex more
Other responses 729 450.4 61.8% 73.3 10.1% 131.0 18.0% 74.3 10.2%
Yes 641 449.1 70.1% 51.4 8.0% 86.4 13.5% 54.2 8.4%
Partner enjoys sex less
Other responses 1351 890.6 65.9% 122.7 9.1% 123.2 9.1% 214.5 15.9%
Yes 19 8.9 46.6% 2.1 11.0% 5.2 27.6% 2.8 14.8%
Ex
it 
ac
ce
pt
ab
ili
ty
Reference group: 
consistently high 
adherence  
Early decliners   Later decliners  Variable
D
em
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s
Ba
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lin
e 
be
ha
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ou
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l
Table 4.3.14: CS CONRAD factors for multinomial logistic regression
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Early decliners Later decliners Variable
Adjusted RRR Adjusted RRR Adjusted RRR
[95% CI] [95% CI] [95% CI]
Age
Under 30 vs.30+
Site vs. South Africa p<0.001
1.56 0.80 1.55
[0.48-5.09] [0.21-3.07] [0.36-6.64]
0.52 0.97 0.77
[0.29-0.93] [0.64-1.47] [0.40-1.46]
0.54 1.51 3.00
[0.28-1.03] [1.01-2.26] [1.86-4.80]
0.66 0.65 1.36
[0.41-1.06] [0.42-1.00] [0.81-2.26]
Education 0.60 1.05 0.98
Primary or less vs. Secondary + [0.40-.88] [0.77-1.43] [0.67-1.45]
Number of sex partners at baseline 0.71 1.10 1.41
5 or more in the past 30 days vs. 
3 or under
[0.49-1.04] [0.82-1.48] 0.97-2.05]
Number of sex acts at baseline 0.87 0.80 0.86
9 or more in last 7 days vs. 8 or less [0.57-1.31] [0.57-1.13] [0.56-1.30]
Condom use at baseline 1.32 1.07 0.99
No condom at last sex vs. yes [0.91-1.92] [0.79-1.44] [0.68-1.44]
Anal sex at baseline 1.19 1.05 0.37
Yes anal sex in last 30 days vs. no [0.48-2.9] [0.50-2.02] [0.09-1.56]
I enjoy sex more 0.59 0.89 0.76
Yes vs. other responses [0.40-.88] [0.65-1.23] [0.52-1.13]
I enjoy sex less 2.59 0.98 1.42
Yes vs. other responses [0.78-8.62] [0.25-3.92] 0.32-6.24
Partner enjoys sex more 0.66 0.65 0.73
Yes vs. other responses [0.45-0.97] [0.48-0.88] [0.50-1.07]
Partner enjoys sex less 1.88 1.36 4.25
Yes vs. other responses [0.41-8.68] [0.35-5.24] [1.42-12.73]
Uganda 
p=0.058
p=0.049
p=0.546
p=0.532
p=0.414
p=0.050
p=0.531
p=0.008
p=0.123
Chennai 
CS CONRAD age-adjusted univariable multinomial logistic regression
Reference Class: 
Reported consistently high adherence            
n=1393
Likelihood ratio chi-
square test
1.87                  
[1.27-2.75]
1.20                   
[0.89-1.61]
0.95                  
[0.66-1.37]
p = 0.008
Bangalore 
Benin 
Table 4.3.15: CS CONRAD age-adjusted multinomial logistic regression
adherence trajectory. Site, number of partners at baseline, participant enjoying sex more,
and partner enjoying sex more had the strongest evidence for being associated with latent
adherence trajectory when adjusted only for age.
multivariable multinomial logistic regression
Table 4.3.16 provides results from the multivariable multinomial logistic regression for CS
CONRAD. Age and site were the only factors which were found to be associated with
latent adherence trajectory for CS CONRAD. Women who were less than 30 years of age
versus 30 and over had a greater chance of being in one of the latent adherence trajectories
which did not consistently report high adherence (Later decliners, RRR 1.44; Early de-
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cliners, RRR 1.92; Variable adherence reporters, RRR 1.44). There was strong evidence
for the association between age and belonging to latent adherence trajectory (likelihood
ratio chi-square test p<0.001). Similarly, there was strong evidence of an association be-
tween site and belonging to a latent adherence trajectory (likelihood ratio chi-square test
p<0.001). Sites were compared to South Africa; the direction of effect varied depending
on which site was being compared to South Africa. At the individual site level, not all
sites compared to South Africa were found to have an association with latent adherence
trajectory and the effect sizes for some sites were small.
Factors not associated with latent adherence trajectory for CS CONRAD in the multivari-
able model were education, number of sex partners at baseline, condom use at baseline,
anal sex at baseline, participant reporting she enjoys sex more with the gel, participant
reporting she enjoys sex less when using the gel, participant reporting her partner enjoys
sex more, and participant reporting her partner enjoys sex less.
4.3.3.5 across trials
Results from the multinomial logistic regression analyses across all four trials are sum-
marised in Table 4.3.17. Factors are divided by tier. Tier 1 indicates factors that had con-
sistent results across all four trials and where there was strong evidence for an association
between the factor and latent trajectory membership. Tier 2 includes factors for which
there was strong evidence of an association between the factor and latent trajectory mem-
bership in two out of the four trials. Tier 3 shows factors for which there was strong
evidence of an association between the factor and latent trajectory membership in one of
the four trials.
age
Across all four trials (Table 4.3.17; Tables 4.3.7, 4.3.10, 4.3.13, 4.3.16), older age was asso-
ciated with belonging to the latent adherence trajectory which consistently reported high
adherence. In all trials included in this study, younger women had a greater chance than
older women of belonging to adherence trajectories whose adherence diminished later,
whose adherence diminished earlier, or whose adherence was somewhat variable, com-
pared to the consistently high adherence-reporting group. There was strong evidence for
this association across all trials (likelihood ratio chi-square testing p<0.001).
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Early decliners Later decliners Variable
Adjusted RRR Adjusted RRR Adjusted RRR
n=1393 [95% CI] [95% CI] [95% CI]
Age 1.92 1.44 1.19
Under 30 vs.30+ [1.28-2.88] [1.05-1.97] [0.79-1.78]
Site vs. South Africa p<0.001
1.56 0.80 1.55
[0.48-5.09] [0.21-3.07] [0.36-6.64]
0.52 0.97 0.77
[0.29-0.93] [0.64-1.47] [0.40-1.46]
0.53 1.51 2.99
[0.28-1.03] [1.00-2.26] [1.86-4.80]
0.66 0.65 1.36
[0.41-1.06] [0.42-1.00] [0.81-2.26]
Education 0.67 1.11 0.81
Primary or less vs. secondary + [.43-1.05] [0.78-1.57] [0.53-1.25]
Number of sex partners at baseline 2.03 2.02 0.75
5 or more in the past 30 days vs. 3 or less [0.76-5.4] [0.95-4.28] [0.36-1.54]
Number of sex acts at baseline 1.33 0.97 0.87
9 or more in last 7 days vs. 8 or less [0.76-2.31] [0.63-1.48] [0.52-1.46]
Condom use at baseline 1.13 1.03 1.26
No condom at last sex vs. yes [0.75-1.70] [0.74-1.43] [0.83-1.91]
Anal sex at baseline 1.05 0.95 0.32
Yes anal sex in last 30 days vs. no [0.42-2.62] [0.44-2.01] [0.08-1.40]
I enjoy sex more 0.65 0.96 0.67
Yes vs. other responses [0.43-0.99] [0.68-1.36] [0.44-1.02]
I enjoy sex less 2.36 0.93 1.39
Yes vs. other responses [0.70-7.97] [0.23-3.73] [0.31-6.23]
Partner enjoys sex more 0.70 0.72 0.69
Yes vs. other responses [0.44-1.12] [0.50-1.03] [0.44-1.10]
Partner enjoys sex less 2.14 1.10 2.91
Yes vs. other responses [0.45-10.22] [0.28-4.30] [0.94-9.03]
p=.084
p=0.600
p=0.102
p=0.310
p=0.209
p=0.086
p=0.693
p=0.718
p=0.358
Benin 
Chennai 
Uganda 
Reference Class: 
Reported consistently high adherence            
Likelihood ratio 
chi-square test 
p<0.001
Bangalore 
CS CONRAD multivariable multinomial logistic regression
Table 4.3.16: CS CONRAD multivariable multinomial logistic regression
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Tier    Factor HPTN 035 MDP 301 Carraguard
CS 
CONRAD
Site 2 2 2 2
Older participants compared 
to younger participants    
2: Strong evidence of 
association of factor 
and latent trajectory 
membership in 2 trials
Participant reported partner 
dislike or refusal of gel  
Higher number of sex 
partners  reported at baseline                  
Higher number of sex acts 
reported at baseline 
Lower education           
= Decreased probability of membership of consistently high adherence reporting latent trajectory
 Trial
1: Strong evidence of 
association of factor 
and latent trajectory 
membership in all 4 
trials
3: Strong evidence of 
association of factor 
and latent trajectory 
membership in 1 trial
= Increased probability of membership of consistently high adherence reporting latent trajectory
2 = Increased or decreased probability of membership of consistently high adherence reporting latent trajectory, 
dependent on which sites are compared
Table 4.3.17: Summary of effects of selected factors on reported adherence across four trials
site
In all trials (Table 4.3.17; Tables 4.3.7, 4.3.10, 4.3.13, 4.3.16), site was found to be asso-
ciated with latent adherence trajectory membership. The direction of the association de-
pended on which site was being compared to the reference site. In this study, model results
consistently showed strong evidence across all trials that site was associated with latent ad-
herence trajectory (p<0.001).
reported negative reaction of partner to gel
There was strong evidence that reported partner dislike or refusal of gel was associated
with an increased risk of being in a latent adherence trajectory that did not consistently
report high adherence in two of the four trials (HPTN 035, Table 4.3.7; and Carraguard,
Table 4.3.13) included in this study. Results from the age-adjusted univariable multino-
mial logistic regressions of reported partner dislike of gel in MDP 301 (Table 4.3.9) and
CS CONRAD (Table 4.3.15), showed a similar pattern where partner dislike of gel was
associated with belonging to trajectories that reported lower adherence, although this as-
sociation did not reach statistical significance in the overall adjusted model at the p=0.05
level in these particular analyses.
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number of sex partners at baseline
Results from the Carraguard analysis showed (Table 4.3.13) there was strong evidence
that higher number of sex partners at baseline was associated with belonging to latent
trajectories that did not consistently report high adherence. While the association of a
high number of sex partners and latent trajectory did not reach statistical significance for
the overall models in the other three trials, age-adjusted and fully-adjusted analyses in the
other trials (Tables 4.3.6, 4.3.7, 4.3.9, 4.3.10, 4.3.15, 4.3.16) showed a similar trend with
all estimates except one showing an increased risk of belonging to latent trajectories that
did not consistently report high adherence for participants reporting higher numbers of
sex partners at baseline.
number of sex acts at baseline
A higher number of sex acts reported before enrolment was associated with a decreased
risk of being in the latent adherence trajectories that consistently reported high adher-
ence in the MDP 301 trial (Table 4.3.10). Number of sex acts at baseline in relation to
latent trajectory membership in the fully-adjusted models for HPTN 035, Carraguard,
and CS CONRAD did not reach statistical significance. While there was a trend for a
higher number of sex acts to be associated with a decreased risk of being in latent adher-
ence trajectories which consistently reported high adherence, this was not observed in all
cases and the effect sizes were small (Table 4.3.7, Table 4.3.13, Table 4.3.16).
education
There was strong evidence in MDP 301 that lower education level was associated with an
increased chance of being in the group that consistently reported high adherence (Table
4.3.10). Education in relation to latent trajectory membership in the fully adjusted mod-
els for HPTN 035, Carraguard, and CS CONRAD did not reach statistical significance.
While there was a trend that lower education level was associated with belonging to the
high adherence-reporting trajectories, this was not observed in all cases and the effect sizes
were small (Table 4.3.7, Table 4.3.13, Table 4.3.16).
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4.4 discussion
Microbicide trial teams typically report adherence in primary results manuscripts as over-
all averages8 which give an impression that trial participants have one type of adherence.
This study sought to investigate if self-reported data from previously completed pre-ARV
microbicide gel trials could be used to provide more information about how trial partic-
ipants used study products over follow-up. This study used latent class and latent pro-
file analysis to identify latent adherence trajectories. This study also explored, through
multinomial logistic regression, if individual-level factors were associated with belonging
to different latent adherence trajectories and how associations of individual-level factors
and belonging to latent adherence trajectories might be similar or different across the tri-
als.
4.4.1 limitations
There are a number of limitations to this study. All of the adherence and behavioural data
are self-reported. Self-reported adherence may be higher than actual adherence as partic-
ipants may have been motivated to please staff members or may have worried if they re-
ported their actual adherence they might have been removed from the trial.95,114,115,116,117,118
Participants may not have answered all of the sexual behaviour questions honestly for fear
of how staff might perceive them. For example, they may have feared being judged by trial
staff and under-reported information such as number of sex acts, number of sex partners,
and stigmatised behaviours such as anal sex or exchanging sex for money. Behaviours seen
as positive for HIV prevention and promoted by trial staff, such as condom use, may have
been inflated.18,71 Thus associations identified, or not identified, may be biased by how
participants reported their information.
Another limitation of this study is that it only includes microbicide trials that ended most
recently in 2009. Current microbicide trials focus on ARV-based products, and trials have
developed new strategies for adherence counselling based on experience gained over years
of conducting microbicide trials.90,91,92 Thus, results presented in this analysis may rep-
resent reported adherence patterns resulting from earlier approaches to microbicide trial
conduct. Moreover, ARV-based trials are also able to examine data about participant ad-
herence via biological samples rather than just verbal self-report. Last, biomarker-based
methods were unavailable with the earlier types of microbicides included in this study
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and the DSA, used in Carraguard, was completed on batched applicators at the end of
the trial.
There are less data available to inform the modelling process at the later stages of trial
follow-up. Latent adherence trajectories were modelled using all of the data available
from each of the trials for the selected adherence variables. There are varying levels of
data that were available for any given point in time. For example, HPTN 035 followed
participants for 12–30 months; Carraguard followed participants for 9–24 months; and
all trials had participants who were lost to follow-up. Therefore, more data were available
to model patterns from the beginning to the middle of the total trial period, compared
to amount of data available for the later stages of the overall trial.
As noted in the results section, in the datasets available for this PhD research, time points
for when there are no adherence measures for participants are due to a number of factors,
such as the product being withheld or the participant having officially exited the study;
in some cases, the adherence data were actually missing. The trials included in this study
attempted to keep loss to follow-up to a minimum and had good retention overall. Ac-
cording to trial-specific definitions, HPTN 035 had 93.6% retention; MDP 301 had 81%
retention; Carraguard had 14% loss to follow-up; and CS CONRAD had 9.9% loss to
follow-up.29,30,26,28
For data which are truly missing (which are not identifiable as such in the particular datasets
available for this PhD research), it is impossible to know whether sex acts at those time
points were covered by gel. It is likely, however, that a larger proportion of missing data
would correspond to non-use of gel than to use of gel. Participants who were lost to
follow-up for multiple remaining months would not likely have an adequate gel supply
to use during all sex acts. For participants who did complete their follow-up per protocol
but missed some follow-up visits, it is possible that those missing data would also be as-
sociated with non-use of the gel because they also might not have an adequate supply of
gel, although it is also possible that they did not use all of the gel issued from the previous
visit and that lack of gel might not be a reason for non-use.
It may be that missing adherence data could be associated with gel non-use because a par-
ticipant who misses a clinic visit might experience barriers or factors beyond her control to
both using the gel and attending clinic visits. It is also possible that participants who miss
visits may represent those who are less interested in using the gel or fully participating in
the trial. If missing data are likely to correspond to non-use of gel, the latent adherence
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trajectories may be biased in the direction of showing overall higher adherence than in
reality, as in that case those who did not use the gel would not be contributing data.
Latent structure software uses full information maximum likelihood (FIML) to estimate
the trajectories and uses all available data. Full information maximum likelihood assumes
that data are missing completely at random or missing at random. In this PhD research,
it is not possible with the available datasets to assess accurately how truly missing data are
distributed across the adherence trajectories. Given the type of data (use or non-use of gel)
and the outcome (latent trajectories of gel-use patterns), it would not be surprising, how-
ever, if the early declining or later declining trajectories were associated with truly missing
data.
While modelling latent adherence trajectories is helpful in understanding longitudinal
adherence reporting patterns in trials, it is also important to remember that the model
is not representing “the truth.” For the purposes of this PhD research, LCA and LPA
are modelling strategies that provide useful simplifications of large amounts of data that
can aid in interpreting results. The number of latent trajectories chosen is arbitrary and
the model will mathematically separate the population based on the number of trajecto-
ries specified by the user. The fact that the model then separates the population into the
specified number of categories does not prove the existence of those latent structures. In
reality, each participant has a particular pattern of adherence and the model uses that pat-
tern to estimate her probability of belonging to each of the imposed estimated subgroups.
4.4.2 patterns of adherence
Latent class and latent profile analysis were able to identify subpopulations of partici-
pants with different adherence patterns in all four trials included in this study. Given that
the average adherence for all four trials was high, it is unsurprising that results included a
substantial subpopulation for each trial that reported consistently high adherence (59%
of the HPTN 035 population, 70% of the MDP 301 population, 91% of the Carraguard
population, and 65% of the CS CONRAD population). Despite the high overall adher-
ence averages reported by trial teams in primary results publications, LCA and LPA were
also able to identify additional latent adherence trajectories in each of the trials.
The most surprising result of this study was that latent adherence trajectories identified
across the trials were quite similar. In addition to each trial having a subgroup of partic-
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ipants that consistently reported high adherence, three other adherence trajectories were
identified. Subgroups characterised by “later decliners” and mid-to-high “variable” adher-
ers were identified in all four trials as well. A subgroup characterised by “early decliners”
was identified in three of the four trials in the models selected.
Identifying different adherence patterns in microbicide trials is a useful starting place for
understanding adherence and adherence reporting, what might be affecting how women
use these topically applied products, and how they report their use. While the models
identified different types of decliners (early and later), there is likely to be a difference be-
tween the types of “decliners”. Early decliners may represent a proportion of women who
joined the trial without the intention of using the study gel. Alternatively, they may have
found using the gel initially difficult. Later decliners are likely to be composed of partici-
pants who stop using the gel for a number of different reasons. Some may decline because
of fatigue with using the gel, while others may still desire to use the gel but might be expe-
riencing real-life barriers that make gel use around the time of sex difficult to implement.
By identifying trajectories, trial teams can attempt to understand the causes of reporting
patterns of gel use by following up with participants either prospectively during the trial
or retrospectively once the trial is complete. Information learned through follow-up, par-
ticularly in the form of qualitative research, can then be integrated into trial procedures
during trial implementation or for future studies in order to better support adherence
and adherence reporting.
4.4.3 factors associated with adherence patterns
4.4.3.1 site
There was strong evidence that site was associated with latent adherence trajectory mem-
bership in all four of the trials included in this study. It is important to note, however,
that as the sample sizes are large for each trial, small p-values may not necessarily indicate
large effect sizes. The magnitude and direction of the effect depended on which two sites
were being compared. Site being associated with adherence has been observed in results
of other studies using data from the included trials119,120,121 as well as other HIV preven-
tion trials such as MIRA,122 which looked at diaphragm with gel (non-microbicidal); and
FEM-PrEP,94 which involved using oral PrEP. This finding indicates that local culture
and site staff factors may have played a role in how participants reported their adherence
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or may have influenced participants’ actual adherence. It is likely that in some locations,
underlying culture may influence participants to report higher adherence so as to “please”
site staff, or participants may report gel use in order to avoid being reprimanded, removed
from the trial, or showing vulnerability to site staff.95,114,115,116,117,118
Staff conduct is a critical factor in ensuring valid clinical trial results; it is particularly im-
portant in a trial where the investigational product is user controlled and adherence is
assessed through participant self-report or means which can be manipulated by partici-
pants, such as using the product just prior to a follow-up study visit. If staff members do
not adequately explain trial procedures and help participants understand why adherence
is important as well as how to manage difficulties around using the gel, adherence might
be lower than optimal in a specific location. It is important to note that if staff members
do not build good rapport with participants, participants may be reluctant to answer be-
havioural questions honestly.
Together with multinomial logistic regression, LCA and LPA can be used to understand
how participants are reporting adherence in comparison to various other latent adherence
trajectories. During trial conduct, this method can be used to examine differences in re-
ported adherence across trial sites within one trial. Trial sites might be identified which
have consistently high reported adherence, and other trial sites might be identified as hav-
ing consistently lower reported adherence. Research teams can then investigate why those
data might be observed in the different trial sites and take corrective action if necessary.
If a site is identified as having consistently high adherence compared to other sites, this
may be due to participants actually consistently using the study gel. That consistency of
use may be due to particular circumstances of the trial populations or it might be affected
by particularly effective strategies that trial staff members use to engage and support trial
participants. In such cases, the effective strategies could be shared with other trial sites
across the trial. Consistently high reported adherence might suggest a different situation:
perhaps trial participants at that site are not comfortable reporting their adherence truth-
fully. Such reluctance might be due to less-than-optimal relationships between partici-
pants and certain staff members. Trial teams may want to investigate that and retrain
staff to improve rapport-building techniques, or reassign certain staff members to other
roles within the trial.
If low reported adherence is consistently identified at a particular site, trial teams could
also investigate reasons behind those observed data. Low reported adherence could be
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due to the unique challenges or culture of the particular population at that site. It might
also be due to factors related to the relationship between participants and staff members.
Perhaps staff members could be better trained to help support participants with the bar-
riers they are facing. Perhaps relationships between staff and participants are not optimal
and participants therefore are not as interested in using the study gel. Again, staff can be
retrained or reassigned to improve the situation. From another perspective, low reported
adherence—although not ideal for the clinical trial—could indicate that participants at
a particular site are giving candid answers to staff members. In that case, both staff and
participants at that site might be able to provide honest suggestions on how to improve
adherence, if asked.
4.4.3.2 age
Older age, in all four trials, was found to be associated with the subpopulations of partic-
ipants that consistently reported high adherence; this finding has been observed in other
studies.120,121,122,123 There are a number of reasons why older women may report higher
adherence or may actually have higher adherence. Older women may be more aware of
their risk of HIV because, for example, they may recognise that their partners are not faith-
ful to them. As mothers, they may be more interested in protecting themselves and their
children from HIV. They may also be living in more stable households where logistically
they can better manage gel use, compared to younger participants who may be having
sex outside of locations where they reside.124 Older participants, compared to younger
participants, may have more self-efficacy and be better prepared to negotiate gel use with
their partners or decide to use it even without partner approval. Younger women may
be less likely to be in stable relationships, have more partners, and be less able to plan sex
and therefore use of the gel. Biomarker data from the most recent research results have
indicated that women 21 years and younger have significantly lower adherence than older
participants.125,126 If this analysis were repeated, it would be interesting to examine the
results with separate age categories for to those 21 and younger, and those 22 and older.
4.4.3.3 partner dislike of gel
It is not surprising that if a participant reports her partner did not like the gel or refused
her use of the gel, her adherence to the gel would be negatively affected. In this study, the
factor that had the strongest effect on membership of latent adherence trajectories was a re-
ported negative reaction of the partner to gel (RRR 1.20–5.53); however, the association
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between reported partner negative reaction to gel and decreased risk of being in the high
adherence-reporting group did not reach statistical significance in two of the four trials in
the fully adjusted models. A body of evidence is growing that shows partner dynamics is
a critical factor that affects participants’ adherence and participation in biomedical HIV
prevention trials. Important factors which participants have reported as affecting their
adherence and study participation are what their partners think about them participat-
ing in the trial, what their partners think of the study product, how participants think
their partners will react to study participation or study products, and history of intimate
partner violence.95,116,121,127,128,127,129,130
It is ironic that the need for vaginal microbicides came from the reality that many male
partners refuse to use condoms and women need an HIV prevention strategy they can
control, and yet this same dynamic continues to be a barrier for female participants to
use the very product being tested to free themselves from that constraint. This speaks
strongly to the real and ongoing challenges that women face in relationships with men.
While the impetus of vaginal microbicides came from the important need for women to
have a way to protect themselves without necessarily having their partner’s knowledge or
consent, and while this criterion is still critical for implementation of a licenced product,
seeing that partner dislike of the gel can strongly affect participant adherence to the gel
indicates the importance of integrating this critical reality into future trials. To improve
adherence, trial teams can include more systematic opportunities, with the consent of
female participants, to engage male partners at the beginning of trials and throughout
follow-up.121,127,131
From a critical perspective, it is important to note that questions about partner dislike of
gel in this study were asked at the end of each trial, after each participant had already
reported her adherence, and that information on partner dislike of the gel is also self-
reported data. It is possible that some participants were aware that their reported adher-
ence was low and may have been motivated to provide an explanation for that, whether
or not it was the true cause.
4.4.3.4 higher number of sex partners and higher number of sex
acts
Results from multivariable multinomial logistic regression showed that a higher num-
ber of sex acts reported at baseline in MDP 301 and a higher number of sex partners re-
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ported at baseline in Carraguard were associated with membership of the latent trajecto-
ries that did not consistently report high adherence. These results are in agreement with
trial teams’ own findings in other studies.119,120 Participants who reported more sex acts
or more sex partners at baseline might be in less economically stable situations than par-
ticipants who report fewer sex partners or sex acts. Those who report more sex and sex
partners might be exchanging sex, living or working in less stable environments, and be
more mobile, all of which may make it challenging to use the gel at each sex act. Partic-
ipants with fewer sex partners and sex acts at baseline might represent a population of
women who are in more stable relationships and might have home situations that are
more established. If the latter is the case, they may be able to store the study gel in their
home and also be more likely to be having sex in their own home, where the study gel is
available.
By contrast, it might be expected that participants who have more sex partners or more
sex and are likely exchanging sex might see themselves at greater risk of HIV and might be
inclined to use the gel more frequently than other participants. This expectation, how-
ever, seems to be at odds with the observed results in MDP 301 and Carraguard. If it were
true, the observed results might be better understood in the context of additional results
in trials that compared self-reported adherence and drug levels through biomarker data.
In some biomedical HIV prevention trials, it was found or suspected that participants
who reported perfect or near-perfect adherence may have been less adherent than partic-
ipants who reported imperfect use or slightly lower adherence.132,133,134 In reality, it may
be that the observed results are a mixture of a number of possible realities.
4.4.3.5 education
Results from the multivariable multinomial logistic regression for MDP 301 indicated
there was strong evidence that lower education level was associated with membership of
the trajectory that consistently reported high adherence. Lower education being associ-
ated with better adherence was in agreement with MDP 301’s own findings when looking
at predictors of consistent adherence in the trial120 in separate analyses. Results from the
other trials included in this study, however, were variable. In this study, there is not clear
evidence on how education may be related to latent adherence trajectories. It is possible
that women with lower education levels have less economic stability and thus might be
more inclined to report “good” adherence for fear of being removed from the trial and
losing reimbursements. It is also possible that participants with lower education levels
are more inclined to follow directions from clinic staff or report that they are following
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those directions than women with more education. Women who are more highly edu-
cated could have more economic stability and might not fear reporting lower adherence
because the risk of losing reimbursements might not be as severe for them.
4.4.4 latent class and latent profile analysis as a method for
understanding adherence in microbicide trials
Latent class analysis and latent profile analysis are methods that allow microbicide ad-
herence data to be examined in a longitudinal fashion. A longitudinal approach provides
more information than overall averages for trial populations. In this study, the use of LCA
and LPA was effective at identifying subpopulations of microbicide trial participants that
had not been identified previously in published analyses conducted with these datasets.
Trajectory analysis, using a similar method to latent structure analysis, was used to iden-
tify patterns of adherence in the MIRA trial and to compare the utility of monthly versus
quarterly adherence data collection in CS CONRAD.122,132 This method showed that the
seemingly homogeneous populations of trial participants with high adherence were actu-
ally composed of participants with different patterns of adherence. This information was
obtained with the least resource-intensive form of data possible: self-reported adherence
collected at routine follow-up visits. While there is much interest in using biomarker data
to assess adherence in current and future microbicide trials, biomarker data are expensive
to procure and results can be biased as participants can adjust their product adherence
to precede follow-up visits when specimens will be collected. If reliable biomarker data
are available at repeated time points, those data can also be used with a latent structure
analysis approach to examine adherence trajectories within a population of microbicide
trial participants. Latent structure analysis together with logistic regression could also be
used to examine the association between adherence latent trajectory and HIV endpoint
status.
A critical benefit of an adherence analysis strategy that relies on self-reported data is that
the method does not break blinding, which is required in randomised controlled clini-
cal trials. Thus adherence data can be collected, analysed, and fed back to participants
prospectively during trial follow-up to improve adherence and adherence reporting. Re-
sults that reveal adherence patterns and factors associated with different adherence trajec-
tories are an excellent starting place for trial teams to conduct qualitative research with
different types of adherers to improve understanding of product use behaviour. The
knowledge gained can then be integrated into future recruitment efforts, adherence coun-
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selling, and overall trial conduct, with the aim of increasing the chance of identifying an
efficacious product and correctly interpreting trial results through improved adherence
and adherence reporting.
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5 
design your ownmicrobicide trial
opinions of former microbicide trial participants
on how to improve adherence and adherence
reporting in future microbicide trials
objective
To use the expertise of former microbicide trial participants to understand barriers to
adherence and accurate adherence reporting, and to seek their opinions about how to
improve adherence and adherence reporting in future microbicide trials
included trials
MDP 301
VOICE
note
This chapter is written in first person to clarify the role played by the PhD candidate in
data collection.
5
D E S I G N Y O U R O W N M I C RO B I C I D E T R I A L
5.1 introduction
Condoms are currently the only coitally dependent method women can use to protect
themselves from sexual transmission of HIV. Condoms, however, require the coopera-
tion of male partners. Cultural and gender norms in some locations may make it difficult
for women to suggest their use and even put women at risk for doing so.1,135 There is a
need for women to have a coitally dependent method of protecting themselves from sex-
ual transmission of HIV which they can control and does not require the cooperation of
male partners. In the 1990s, the field of vaginal microbicides was initiated to develop vagi-
nally inserted products such as gels so that women could protect themselves from HIV
infection.7
Products being tested in clinical trials of vaginal microbicides are user-controlled. Thus,
each enrolled participant is able to use the gel in accordance with the protocol, or not. In
trials of coitally-dependent products, adherence is estimated in the context of the num-
ber of sex acts covered by gel in a given time period. Most microbicide trials rely on par-
ticipants to provide information about both product use and sex acts. This reality has
created major challenges in the field of microbicides because low product adherence and
inaccurate adherence reporting has inhibited the ability of trials to accurately assess the
biological efficacy of candidate products.11,12,8,26,136,124
As adherence has continued to be a challenge despite many years of conducting micro-
bicide trials, it is important to consider effective ways to adjust microbicide trial design
to increase the chance of improving adherence and adherence reporting. Two key guid-
ance documents which provide direction for ethical conduct of microbicide trials,Ethical
Considerations in Biomedical HIV Prevention Trials49 and Good Participatory Practice
Guidelines for Biomedical HIV Prevention Trials,40 state the importance of stakeholder
involvement in trial design to ensure ethical and scientific quality and successful imple-
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mentation.
As tens of thousands of women have participated in microbicide trials to date, they can
serve as a rich source of expertise about difficulties with adherence and adherence report-
ing and also provide insights on how to address these issues in future microbicide trials.
The purpose of this qualitative study was to engage former microbicide gel trial partici-
pants in focus group discussion workshops (FGDWs) to understand barriers to adherence
and accurate adherence reporting and to seek their opinions on how to improve gel ad-
herence and gel adherence reporting in future microbicide trials.
5.2 methods
5.2.1 format of study and included trials
This qualitative study engaged former gel trial participants from two completed effec-
tiveness trials of microbicide gels in focus group discussion workshops (FGDWs) that in-
cluded a combination of discussion and participatory activities to explore issues around
trial participation, gel adherence, and reporting of gel adherence. This study was con-
ducted in the fourth quarter of 2014 at two locations: Tongaat, Durban, South Africa;
and Mwanza, Tanzania.
Participants included in this study were former clinical trial participants of the Microbi-
cides Development Programme 301 (MDP 301) and the Vaginal and Oral Interventions to
Control the Epidemic (VOICE) clinical trials (Table 5.2.1). MDP 301 was a randomised,
double-blind, placebo-controlled phase III clinical trial of PRO 2000 vaginal gel to re-
duce HIV-1 transmission. MDP 301, which tested a coitally dependent regimen of PRO
2000, was conducted in South Africa, Tanzania, Uganda, and Zambia between 2006 and
2009.30 In Tanzania, the MDP 301 study was not conducted at a single stable clinic loca-
tion. Rather, guesthouses in Mwanza were rented on certain days to conduct trial pro-
cedures with participants in a particular area. VOICE was a randomised, double-blind,
placebo-controlled phase IIb trial of 1% tenofovir gel (as well as oral tenofovir and oral
tenofovir + emtricitabine) to reduce HIV-1 transmission. VOICE tested a daily use reg-
imen of 1% tenofovir gel and was conducted in South Africa, Uganda, and Zimbabwe
between 2009 and 2012.136
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Trial Product
Number of 
participants
Locations Years conducted
MDP 301
 0.5% PRO 2000,                                              
2% PRO 2000
9,385
South Africa, Tanzania, Uganda, 
Zambia
October 2005-September 
2009 (2% dropped February 
2008)
VOICE
1% tenofovir gel                                             
(plus oral tenofovir disoproxil 
fumarate, oral 
tenofovir–emtricitabine )
5,029 (all regimens) South Africa, Uganda, Zimbabwe 
September 2009-August 
2012
Table 5.2.1: Trials included in qualitative study
5.2.2 site selection
The objective of site selection was to include as much diversity as possible for this small
qualitative study. As multiple effectiveness microbicide trials have been conducted in Dur-
ban, South Africa, this location had the greatest potential to recruit former participants
from a range of completed trials. A collaboration with the HIV Prevention Unit of the
South African Medical Research Council Durban was initiated. Due to the small size of
this qualitative study, one clinic, in the vicinity of Durban, was chosen to conduct the
FGDWs. Tongaat was chosen as the study location because it enabled recruitment of par-
ticipants from two completed microbicide trials: MDP 301 and VOICE.
Mwanza, Tanzania was chosen as the second location because culturally it is extremely
different from South Africa and because my fluency in Swahili allowed me to play a lead-
ing role in conducting the FGDWs. A collaboration with the Mwanza Intervention Trials
Unit (MITU) was initiated for this study.
5.2.3 staff training
5.2.3.1 tongaat
Three staff members experienced in conducting qualitative research at the HIV Preven-
tion Research Unit were seconded to assist with the conduct of the FGDWs. One staff
member was designated to take notes. Two staff members were trained to alternate be-
tween implementing the discussion and participatory activities, and providing simulta-
neous written translation from Zulu to English for me. Formal data processing was then
carried out by individuals not involved in the FGDW implementation. Additional staff
members were responsible for transcribing the audio recordings upon completion of the
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FGDWs, and a translator experienced in the conduct of microbicide trials was hired to
formally translate transcripts from Zulu to English.
Training of staff on objectives of the research and how to conduct research activities re-
lated to implementation of FGDWs, transcription, and translation was led by me. Train-
ing for FGDW implementation included detailed discussions of the objectives of the re-
search, qualitative methods for conducting focus group discussions and participatory ac-
tivities, objectives for each segment of the workshop, and extensive role-plays and prac-
tice as a team; the latter included detailed review of role-plays and practice sessions. Fi-
nal determinations of roles and responsibilities were made based on the staff members’
demonstrated competency in the above elements. As the team demonstrated a high level
of skill in understanding the nuanced nature of the discussions and activities, I decided
they would facilitate the FGDWs in Zulu while I received simultaneous written transla-
tions. This use of simultaneous written translation allowed me to follow the content in
real time during the FGDWs, ensure quality of the conduct of the FGDWs, and intervene
in case opportunities for probing or collecting important data were initially missed.
5.2.3.2 mwanza
In Mwanza, one research assistant (RA) was hired to assist with recruitment of partici-
pants and conduct of the FGDWs; a separate individual was hired to transcribe the audio
recordings; and a third individual was hired to translate the transcripts from Swahili to
English. Training proceeded as had been done in Durban. The RA was responsible for
physically tracing the former participants and liaising with them about FGDW schedul-
ing. During the discussion segments of the FGDWs, I was responsible for leading discus-
sions, conducted in Swahili, while the RA acted as note-taker. The RA was responsible
for leading the participatory activities, assisted by me.
5.2.4 recruitment
The recruitment process began by acquiring official lists of all participants enrolled in
MDP 301 and VOICE who were assigned to use a study gel in Tongaat and Mwanza.
These lists were composed of participant identification numbers (PTIDs) and were then
put in a random order using Stata SE 13. Participants would be contacted, starting at the
top of each list of randomised PTIDs, until enough participants had been contacted to
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participate in the FGDWs. The recruitment process was intended to provide all former
gel trial participants with an equal chance of being contacted and invited to participate in
the qualitative study.
5.2.4.1 tongaat
The lists of PTIDS placed in random order were linked to trial participant names using
the trials’ link logs. Name files containing participant contact information were retrieved
and mobile phone numbers were accessed. Using the lists of PTIDs in random order,
former MDP 301 and VOICE trial participants were called and informed about the qual-
itative study, according to a recruitment script, and asked if they might be interested in
participating. Two FGDWs were scheduled for former MDP 301 trial participants and
two FGDWs were scheduled for former VOICE participants. Those who were interested
were booked for one of the FGDW dates and told they would be given a reminder call
with final logistical details a day or two before the scheduled FGDW. The day before each
workshop, all former participants booked were called. Not all were reachable.
5.2.4.2 mwanza
MDP 301 locator forms were accessed from the data archives room at MITU for match-
ing with the list of randomised PTIDs. The archived locator forms available were actual
carbon copies of the original forms; some were difficult to read due to faint ink transfer.
Examination of the locator forms revealed that no phone numbers were available for any
former MDP 301 participants and that they were organised by geographic location. Key
information available included the name of the participant, the name of the ward she
lived in or worked in, and a written description of how to find her home or workplace.
These descriptions included information about the type of building, any identifying fea-
tures of the building, and nearby landmarks such as trees, shops, or schools. Addresses,
streets, and building numbers do not exist in this setting.
Due to all former participants needing to be traced by car and then on foot over a large
geographical area, for practical reasons it was not possible to recruit them based on the
order of the list of randomised PTIDs. A new recruitment strategy was therefore devised
to contact former participants in a manner intended to recruit a representative sample for
the qualitative study. A list of all of the geographical locations was developed and a plan
was made to visit a different geographical area for each day of recruitment, alternating be-
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tween urban and peri-urban locations.
Each day, locator files for a particular area were reviewed and a batch of about 10–15 loca-
tor forms was selected, based on the ink transfer of the form being legible, the description
of the location being understandable, and that the form itself could be photocopied suc-
cessfully. The RA went to each area by car and traced each former MDP 301 participant
by foot. If the former participant was found, she was informed about the new qualita-
tive study, using the recruitment script, and asked if she would like to hear more about it.
If she did, the RA explained the study in full and if the participant wanted to be called
once the study was underway, the RA took her phone number and other details. In some
cases, the RA came across former participants who were not in the batch of locator forms
in hand. If they expressed interest in joining the study, they were told about it as well, and
details were taken for contacting them again once the FGDWs were to be booked.
Prospective participants who expressed interest in joining the qualitative study were placed
into four groups, by rough age categories. Several days before FGDWs were to take place,
prospective participants were called and booked in for one of the four dates. The women
were given another reminder call the day before their appointed FGDWs.
5.2.5 fgdw implementation
5.2.5.1 implementation with participants
Eight FGDWs, four in each location, were designed to take the better part of a day, with
tea breaks and lunch provided to break up blocks of data collection sessions. In the morn-
ings, while waiting for those booked to arrive, refreshments and copies of the informed
consent (IC) forms for review were provided. Once an adequate number of prospective
participants arrived, or enough time had passed, the written IC form was read aloud verba-
tim and explained to the group. If individuals were interested in staying and participating,
they sat with a staff member one-on-one to review any questions they might have about
participation; if interested in participating, they signed the IC forms. Illiterate women
signed with a thumbprint in front of a witness, who also signed. After each IC form had
been fully signed, staff members completed a demographics form with each participant.
Each participant was provided with a numbered sticker, acting as a pseudonym, to wear
for the FGDW in order to protect her identity among her peers and on the audio record-
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Session name Method Objective
 Welcome and Introduction Welcome participants, describe logistics for the day
1 Remembering the trial Discussion Help participants remember the clinical trial
2
Microbicide trial presentation with 
participation
Presentation with 
participation
Provide education about how trials answer their research questions so 
participants can understand why adherence is critical in microbicide trials, and 
will be better able to make helpful and honest suggestions during the workshop
3
Reasons for joining the trial and gel 
use
Discussion
What are the real reasons women join trials? How do those reasons affect 
adherence?
4
Feelings and Needs/Clinic 
atmosphere
Discussion + group 
activity
What really matters to participants? How do they feel? What are their needs, what 
is important to them?
5 Research staff and participants Role-play activity
Understand participant views of research teams and how they believe research 
teams view participants.
6 Who is the trial for? Discussion
What is the dynamic of the relationship between research teams and 
participants? How might these dynamics affect adherence? How can we 
improve trials?
7 Telling the truth
Staff role-play, 
discussion, group 
activity
Understand what factors affect if participants answer honestly, what aspects of 
the trial or relationship with staff can be changed to improve honest reporting.
8 Design your own microbicide trial Group activity
Provide participants with opportunity to make suggestions for how future 
microbicide trials should be designed.
Table 5.2.2: Focus group discussion workshop sessions
ing.
While the overall FGDWs in some cases took the entire workday, data collection periods
ranged from approximately 2 to 4 hours. The process was generally faster with Durban
participants, with FGDW implementation in Mwanza taking more time. A summary of
the FGDW sessions is given in Table 5.2.2
The FGDW began with an introduction to welcome and orient the participants on the
objectives and logistics of the day’s activities. Each participant was asked to introduce her-
self by saying her pseudonym (number) as practice for the session. During discussions,
if a participant forgot to state her number, the staff members facilitating discussions had
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been trained to state that participant’s number aloud for the audio recording.
The first session began with a “Remembering the trial” discussion during which partic-
ipants were invited to share what they remembered about the trial and its purpose, the
gels, and their trial participation. This was an important introductory step for the day, as
nearly 7 years might have passed since some of them had engaged in the past clinical trials.
The second session was an interactive educational discussion about microbicide trials that
used a simple diagram (Figure 5.2.1) to explain to participants how microbicide gel trials
are designed to identify potentially efficacious products. As the primary objective of the
FGDWs was for participants to think critically about how to improve adherence and ad-
herence reporting in future microbicide trials, it was essential for them to understand why
adherence is fundamental in microbicide trial design and how low adherence affects inter-
pretation of trial results. The diagram, which was provided to each participant, showed
how women who are not infected with HIV are recruited at the beginning of a microbi-
cide trial and then are randomised to receive either the placebo gel, which has no active
drug, or the active gel, which contains the real drug that is being tested. Through the
diagram and discussion, the participants were shown that both groups of women, those
who received placebo gel and those who received the active gel, were asked to use the gel
in the same way and also asked to use condoms. At the end of the trial, shown in the pic-
ture, the number of women who became infected with HIV was compared between the
group who used the placebo gel and the group who used the active gel. This comparison
of those infected with HIV in the two groups is used to determine if the gel is effective
at reducing HIV. To check comprehension of the participants, the facilitator proposed
different findings than those in the diagram and asked them what conclusions could be
drawn from various scenarios of observed data.
CHAPTER 5. design your own microbicide trial 162
Active Gel Arm
Placebo Gel Arm
HIV Positive
HIV Negative
HIV Negative 
Women
HIV Positive HIV Negative
Figure 5.2.1: Diagram of how a microbicide trial answers its research question
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Figure 5.2.2: Picture of results of Carraguard’s dye stain assay for vaginal applicators
Once the facilitator was satisfied that the participants understood how a candidate mi-
crobicide is assessed, the educational discussion then went on to introduce what happens
when trial participants do not use the gels very much. The participants were asked to
explain what kind of results would be observed and what conclusions trial teams could
make from the data. The participants were provided with historical information about
past microbicide trials, using the Carraguard trial as an example of a trial where partici-
pants reported high adherence (96%) and no HIV reduction effect was observed in the
data. The participants were each provided with a picture of gel applicators subjected to
the dye stain assay (DSA) (Figure 5.2.2) and it was explained that at the end of the trial,
all of the applicators were tested using this special procedure to find out if the applica-
tors had actually been inserted vaginally. The DSA showed that, despite high reporting,
adherence had been only 42%. Therefore, in actuality, trial participants’ adherence was
different from what they had reported in the trial and the actual biological effect of Car-
raguard was not clear. It was explained to the participants that once expensive trials do
not show a protective effect of a candidate gel, research is not likely to continue with that
product even though trial teams cannot be certain of its biological effect. A situation such
as this may mean women have to wait longer for a microbicide gel that is able to prevent
HIV transmission.
After it was clear the participants had a good understanding of how trials answer their
research questions and why adherence and adherence reporting are important, it was pos-
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sible to proceed to the rest of the discussions and participatory activities for the FGDWs.
The FGDW then continued into more focused data collection activities. The third ses-
sion, which covered reasons for joining the trial and gel use, was a discussion intended
to increase understanding of trial participants’ true motivations for joining and staying
in the trial, how much trial participants thought the gel had been used in the trial, how
participant motivations for joining the trial might affect adherence, and what suggestions
participants had to improve adherence in those cases. The session also sought feedback
from participants about different proposed modes of HIV prevention, such as a vaginal
ring or pill, and an alternative microbicide trial design that included a non-randomised,
no-gel arm.
The fourth session was in two parts, with a discussion and participatory activity to explore
the feelings and needs of participants, both as trial participants and as women. After dis-
cussion on what matters to them, they were broken into two groups to write down their
feelings and needs on different cards. The two groups then were asked to put their cards
together and to work as a group to categorise and sort them in any way they liked.
The fifth session involved a role-play game where participants were asked to act as either
research staff or trial participants. The objective of the session was to gain insight into
how participants viewed trial team staff and how they believed they had been viewed by
trial team staff.
The sixth session was a discussion called “Who is the trial for?” which had the objective
of understanding the dynamic of the relationship between trial participants and research
teams, how that dynamic might affect adherence, and participants’ thoughts on how tri-
als can be improved to increase trial participant motivation to use the gel.
The seventh session included a role-play performed by staff, a discussion in reaction to
the role-play, and an activity focused on telling the truth. Staff members performed two
different vignettes showing two examples of trial participants using the gel during a sex
act, and then showed how the two trial participants reported their behaviour differently:
one honestly and one dishonestly. Present participants were invited to react to the two
vignettes and then guided through a discussion about reporting behaviour at clinic visits.
Questions addressed were how difficult present participants believed it was for trial par-
ticipants to answer questions honestly, why some trial participants experienced difficulty
in doing so, and what could be changed about trials to help trial participants feel more
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comfortable answering questions honestly. Answering these questions was followed by
an activity where participants worked in groups to write ideas related to these topics on
different cards.
The eighth activity, which was the final activity of the day, was titled “Design your own
microbicide trial.” It sought to bring all of the ideas addressed during the day together
and to provide an opportunity for participants to make any suggestions they liked to im-
prove design of future microbicide trials, with a focus on how to improve adherence and
adherence reporting. Participants were divided into two groups and given flip-chart pa-
per and a set of questions to guide their discussions. The participants then presented their
ideas to the whole group.
At the end of the FGDW, once data collection had ended, participants were invited to
ask any questions they might have, in particular about conduct of the trials, upcoming
studies, or specific health information.
The above description provides an overview of the FGDW guide. Implementation of the
guide was adapted in real time to better suit the needs of each group. For example, if we
noticed that a particular group was more forthcoming with information in the discussion
format, but did not enjoy or disclose much information during an activity, we modified
the rest of the day’s sessions to focus on discussion or vice versa.
5.2.5.2 daily debriefing session
Immediately after each FGDW, a debriefing session took place with staff members that
served as the initial stage of data analysis and provided an opportunity to modify future
FGDWs for optimal implementation. A debriefing guide was used to facilitate and doc-
ument the sessions, which were audio recorded. Key points included reviewing what the
participants said (and, in the Tongaat site, translation of key terms and written work by
participants in Zulu), what was not said by participants, at what stages facilitators thought
participants might not have been forthcoming with honest information, if the objectives
of each session had been met, and what modifications for implementation would be ap-
propriate to try for the next FGDW.
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5.2.6 data processing
Standard operating procedures (SOPs) for transcription and translation were written and
provided to transcribers and translators as a part of the training process.
Tongaat audio recordings were transcribed verbatim into a text document by an inde-
pendent staff member not present at the FGDWs. Each individual speaker on the audio
recording was identified by a unique code throughout the transcript. Unique codes for
participants contained the assigned pseudonym number, the location of the FGDW, and
the FGDW session attended. For example, NO8.DUR.W3 indicates that this participant
was participant number eight, who attended the third FGDW in Tongaat, Durban, South
Africa. Once the primary transcriber transcribed the audio recordings, they listened to the
audio recording a second time to perform a quality control check of their own work and
make any corrections. A second staff member also not present at the FGDWs listened
to 100% of the recordings while reviewing the text transcripts, making corrections using
Tracked Changes as needed. A third staff member translated transcripts from Zulu to En-
glish, and performed a quality check review of their work.
Mwanza audio recordings were transcribed verbatim by an independent staff member
not present at the FGDWs. Transcripts were then translated from Swahili to English by
another staff member also not present at the FGDWs. I reviewed 100% of the transcripts
in both Swahili and English for problems or errors. Recordings were checked as needed
and corrections were made to resolve any problems.
5.2.7 data analysis
All data analysis was completed by me. My familiarity with the data began with my in-
person participation in the FGDWs and analysis began with my participation in the de-
briefing sessions and my reviews of transcripts for quality assurance. Transcripts of text
containing blocks of each language (Zulu and English; Swahili and English) were man-
aged using NVivo10 (QSR International, 2012). Information contained in demographic
forms was entered into NVivo for data management purposes.
Transcripts were coded inductively for themes that were identified from the data.137 As
transcripts were read, portions of text, in both local language and English, containing
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statements, thoughts, concepts, or meanings relevant to my research questions were high-
lighted and grouped into unique codes that represented themes. For example, a code
called “More and better education” was used to group any segments of data that con-
tained statements by participants expressing they were not provided with particular infor-
mation or had unanswered questions about aspects of trial participation, or statements
that contained explicit suggestions about how information provision could be improved
or how it “should” be. Using the software, all data coded to a particular code (or theme)
could then be reviewed together to further understand the meaning or importance of a
particular theme.
As transcripts were read and reread, codes were refined through an iterative process to
better organise and understand meaning in what participants said that was relevant to
understanding their experiences in the trials, factors affecting adherence and adherence re-
porting, and participant suggestions. Themes were often broken down into sub-themes.
Some structural codes (codes based on questions from the actual FGDW guides) were
added to aid organisation of the data. Negative cases, examples of views or situations that
were different from those more commonly expressed in the set of data, were coded as such
when examples existed.
Through the software package, NVivo, data could be viewed in different ways, such as by
theme or sub-theme, by each participant, or by each FGDW. During the coding process,
analytic memos were written within the software package, reflecting on the meaning of
what participants said, relationships between different themes identified, comparisons be-
tween different groups, and higher level or “overarching themes” relevant to the research
questions. Memos were often used to document and characterise overarching themes,
which synthesised and described relationships between themes in the data.
One hundred percent of the transcripts were coded a first time. After completion of cod-
ing 100% of the transcripts, all of the data coded into themes were reviewed and codes
were then condensed, expanded, or harmonised to help ensure that each code described
a unique concept relating to what participants said. One hundred percent of the tran-
scripts were coded a second time for quality assurance. Memos were written to note
important findings, such as questions or relationships, and to summarise findings from
themes. Themes that were relevant to the research questions were then further analysed
in the context of how they relate to microbicide trial design. More-refined overarching
themes were described in memos, which led to creating a structure for reporting the re-
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sults of this study.
5.2.8 ethical review
This qualitative study of adherence was first submitted to the London School of Hygiene
& Tropical Medicine Ethics Committee and received a favourable review. This study was
then submitted to the South African Medical Research Council Ethics Committee, and
the Tanzania Lake Zone Institutional Review Board, which both granted ethical approval.
Final ethical clearance in Tanzania was then received from the Tanzanian National Insti-
tute for Medical Research.
5.3 results
Results reported here address key barriers to adherence and accurate adherence reporting
and key suggestions for how to improve adherence and adherence reporting in future mi-
crobicide gel trials.
5.3.1 study participants
Forty-six participants (present participants) enrolled in this qualitative study. A total of 19
attended FGDWs in Durban, and 27 in Mwanza. Overall, 41 participants had participated
in MDP 301 and 5 participants had participated in VOICE. One participant in Tongaat
participated in two FGDWs, as she had been a participant in both trials; therefore, while
the number of participants in this study is 46, the number of individual women who par-
ticipated is 45. Results from the recruitment process for MDP 301 in Tongaat are shown
in Figure 5.3.1; results from the recruitment process for VOICE in Tongaat are shown in
Figure 5.3.2; and results from the recruitment process for MDP 301 in Mwanza are shown
in Figure 5.3.3. Table 5.3.1 provides information about participant characteristics.
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644
PTIDs
188 
Former participants 
called
26 
Former participants 
contacted
162
Former participants not 
reachable 
(voicemail, wrong number, 
no answer)
20
Former participants 
interested in participating
6
Former participants declined 
(moved away, working, ill)
6
Former participants not 
reachable to confirm
1
Former participant arrived 
too late
1
Former participant 
invited by her sister
14
Former participants 
participated in FGDWs
Figure 5.3.1: Recruitment results for MDP 301 at Tongaat
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176
PTIDs 
124
Former participants 
called
98
Former participants not 
reachable
(voicemail, wrong number, no 
answer)
26
Former participants 
reached
8
Former participants declined 
(moved away, working, ill)
18
Former participants 
interested in 
participating
13
Not reachable to 
confirm or no show
5
Former participants 
participated in FGDWs
Figure 5.3.2: Recruitment results for VOICE at Tongaat
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128
Former participants 
traced
2 
Former participants 
confirmed moved 
away
31
Former participants 
traced + interested in 
participating
95
Former 
participants not 
found
7
Former participants 
identified while looking for 
other participants
38
Former participants 
interested in participating
8 
Former participants not reachable 
to confirm 
6 
Former 
participants didn’t arrive 
3 
Former 
participants arrived via 
invitations from others
27
Former participants 
participated in 
FGDWs
Figure 5.3.3: Recruitment results for MDP 301 in Mwanza
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Participants Tongaat Mwanza
Number of participants (n=46)
MDP 301 (n=41) 14 27
VOICE (n=5) 5
Total 19 27
Current age range 27-51 24-73
Education level at time of trial 
participation
15 (80%) Some/completed secondary education 1 Completed  secondary  education
3 Some/completed primary education 20 (74%) Some/completed primary education
1 Illiterate 6 Illiterate
Employment at time of trial 
participation
16 (84%) No work 17 (63%)  Informal vendor
3 Employed 6 Bar or hotel worker
4 No work
Relationship status at time of 
trial participation
18 (95%) In relationship 26 (96%)  In relationship
1 Single 1 Single
Table 5.3.1: Participant characteristics
5.3.2 reasons for joining and staying in trials
5.3.2.1 need for hiv and sti protection
Some participants initially spoke of joining the trials to have a way to protect themselves
from HIV and other sexually transmitted infections. Participants discussed how HIV has
affected women more than men, how men often refuse condoms, and how they feel at risk
in their relationships due to male partners having multiple sexual partners. Women who
had multiple sex partners hoped the gel would protect them from HIV.
The man may have had sex outside there with three or even four women,
he will just force you to have sex with him; therefore when you get the gel,
maybe a little gel, you will at least be trusting yourself.
54, Mwanza
For me I enrolled in this study because I put in the gel, even if the husband
does not want to use a condom but if I know that I had put in the gel it is
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not easy to get infected with whatever disease.
49, Tongaat
...really a woman’s life is always at risk he [a husband] can go somewhere
for a job like [camps] and not come back. I do not know with whom he is
sleeping with wherever he is, he may come back with something and infect
me with it.
33, Tongaat
I had a problem that my baby’s father did not want us to go there into using
a condom. I did not trust him saying he does not eat a sweet in a paper.
28, Tongaat
5.3.2.2 health benefits and care
As discussions progressed, participants in each FGDW brought up the health benefits
of trial participation. Many participants expressed appreciation for having their health
checked on a regular basis, the confidential and free testing and treatment provided by
the study clinics, and health education. They reported feeling happy to learn about their
health status and to learn how to keep themselves healthy. That motivated them to take
care of themselves.
. . . I felt it was right in the study. . .knowing my status was also encourag-
ing. . .how to behave because things are bad outside. I like it most because
they were checking for diseases on us. . . It also encouraged us not to have un-
planned babies. . . I liked it because I found friends. Even when you came
with a problem you would be able to discuss with people. You can see that,
you will leave with no problem. I also liked money, money is part and parcel
[laughs].
42, Tongaat
. . . to see the doctor needs a lot of money; you can. . .be told that you are suf-
fering from this and this, definitely this will just cost you, in that case I was
very happy about that project because it has facilitated many people, some
people we didn’t even have the ability of going to the hospital; you are sick,
you just swallow Panadol until the day when you are very ill maybe they take
you to the hospital, that is when you will be lucky to be checked about your
health and other things but in fact you have other diseases like UTI. . .others
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had syphilis. . . therefore we got cured.
43, Mwanza
Mainly this project tempted us to check our health, it attracted us to get
that little income and to make us start our businesses, therefore we profited
health wise and economically.
60, Mwanza
This project has helped many people because you were being tested and if
you were found with a disease they treated you; if you can’t and if you are
at home they phone you, they come to visit you and they bring to you other
needs.
30, Mwanza
It was very nice because even if you were hungry we would see ourselves
eating bread and juice even when you did not bring lunch box you were able
to get something too, it was nice and get money as well when you leave. It
was very nice.
42, Tongaat
Some participants noted that the habit of checking their health and caring for themselves
is something they learned in the trial that has stayed with them over the years. Many also
discussed how they felt genuinely cared for by trial staff, found participation in the trial to
have a positive impact on their lives, and hoped another project would start so they could
participate again.
5.3.2.3 financial reasons
Money received as reimbursement for trial participation was repeatedly mentioned in the
FGDWs as a reason why women join and stay in the trials. Participants spoke about how
the reimbursements provided a way to purchase food and necessities and a small amount
of income that they would not otherwise have had.
I liked it very much it was going to happen and according to my wish it
was going to be done twice a month because after I had gotten those cents
[money] they helped me, I would go to Shoprite [supermarket] and get out
with a full plastic bag.
47, Tongaat
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I see the other reason which attracted them most was that of being given
money whenever we went there.
43, Mwanza
Some participants, however, noted they did not attend the trial visits for money or did
not think that was the reason why other trial participants joined the trials. Other partici-
pants noted that while money in some cases might not have been the primary reason for
joining or staying in the trial, the money helped them and was appreciated.
5.3.3 adherence
5.3.3.1 using the gel
When participants were asked to what extent they thought the gel was used, opinions var-
ied. Some noted that they had been using the gel, or that certain groups had been using
the gel, such as older trial participants, or those who saw themselves at risk for HIV, such
as barmaids or trial participants who did not trust their male partners.
...for example for us the barmaids, we were seeing that it was helping us every
time because we were having the gel, we were using the gel every time; now
I mean for the others, maybe they were using it occasionally, but for us, we
were working at places where there were many people; in fact it was helping
us very much.
40, Mwanza
We the older ones were using it, I think it was easy for us to use, because we
had that it [gel] may really protect us...
43, Tongaat
Two participants mentioned there could be a positive effect of the gel for women who
needed more lubrication during sex:
I see that someone is using that gel because it helps the woman during sexual
intercourse, you can’t feel even those pains; therefore that way becomes just
smooth, you don’t feel bad [uncomfortable].
32, Mwanza
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5.3.3.2 investigational nature of study gel
While some participants spoke of themselves or select groups of trial participants using the
gel, many participants spoke of low gel use in the trials. They recounted what other trial
participants had told them, what was discussed in the waiting rooms, and their challenges
and concerns with using an investigational product for each sex act or on a daily basis. The
most significant reason given for not using the gel was the fact that the gels being tested
were investigational in nature, and there was concern that the gels could harm the trial par-
ticipants. This fear is founded on the fact that informed consent forms are required44 to
state risks of clinical trial participation to prospective participants, which includes known
and unknown adverse effects of the investigational drug. The fears expressed by partici-
pants indicate that trial participants accurately understood the informed consent process
and were aware that adverse effects were possible.
I had fear at the beginning because they were saying they also do not know if
this thing is going to work or it is not going to work. . . I had a fear. . . if it gets
into my blood. . . in a way that is not right, and I go to them maybe having
rash, maybe like this and that, and when reporting they tell me that we told
you that we also do not. . .have a sure about it—we are testing it on you.
27, Tongaat
Yes. They are going to check it on us fools, why are they not checking it on
themselves?
Tongaat participant
One habit which prevents them from using the gel is that of having worries.
32, Mwanza
The gel was not used in a big quantity because others were afraid that if she
used the gel, it might bring her adverse effects.
44, Mwanza
I do not think women are using the gel. When I heard about the study I
heard about it from my friend...I even went to her house for her to show me
that product that she takes it and put it in the toilet. She is not using it.
27, Tongaat
I can say that some were not using it saying that they are scared that they are
going to get sick, they are going to have diseases in the [womb], they do not
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know what it does when stuck in there, yes only a few using it.
38, Tongaat
Participants also spoke about how community members and others not familiar with the
trial played a role in promoting the idea that the study products were dangerous, would
cause harm, and could cause illnesses such as cancer or HIV infection.
Yes the community was speaking badly about this gel. We were affected be-
cause they were saying how can we insert something that we do not know
where it was tested. There is going to be a problem with us. That is what
was discouraging us in using the gel but, because we knew what we wanted
we continued using it.
42, Tongaat
And also others were telling them that you have been implanted with HIV;
many were afraid and that is the reason others stopped.
44, Mwanza
...many thought that the gel it is the one that will give us the virus, there was
that in my neighbourhood...
44, Tongaat
Further demonstrating the centrality of the investigational nature of the drug in prevent-
ing optimal adherence in the trials, when participants were asked for suggestions on how
to improve adherence, a few participants suggested that the trial should be conducted but
should not be called “research,” and that trial participants should be told the products are
effective at preventing HIV. Present participants with these suggestions were confident
that if women were told the product does in fact prevent HIV, women would use it.
We can change the name and not say it is the study [research], we change
into something that may have been licenced because people do not feel im-
portant by that. . . this thing is being studied, they are not sure that it is work-
ing. Maybe we can change the name and not say it is research.
Tongaat participant
Now if they are studying it now they are confusing us. This is the thing that
makes a person to be reluctant.
Tongaat participant
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While it is clearly not feasible in a clinical trial not to tell trial participants that the product
is investigational, this suggestion poignantly highlights the most important barrier to gel
use stated in the FGDWs: fear of harm, given the fact that the drug’s safety and efficacy
had not yet been demonstrated.
5.3.3.3 male partners as a barrier to adherence
The second critical barrier to adherence which emerged was the effect of trial participants’
male partners. While a primary impetus for discovery of a safe and effective microbicide
was to enable women to have a product they control to protect themselves from HIV,
some participants explained that male partner knowledge and approval of using the gel
was an important factor in their ability to adhere to the study regimen.
It is true that you can be pressed by the man that you shouldn’t use many
gels, you can use it even once or once per week. Now you find many gels
remaining unused and then the days to return them are ready, you find that
many gels were not.
42, Mwanza
The male effect on adherence primarily manifested in two forms, as described by partic-
ipants in this study. The first was related to the effects that the gel had during sexual
intercourse, and culturally how those effects can be associated with infidelity. The second
was related to the expressed need of participants to provide a male partner with sex when
he demanded it, and not make him wait.
male partner reaction to vaginal differences during sex
Many participants noted that the gel, once inserted into the vagina, made a noticeable
difference that could be detected by their partners. For some, this increased lubrication
was not a positive attribute.
. . .when he enters you it becomes open, he goes in and out, it isn’t tight, it
doesn’t bring that heat.
36, Mwanza
. . . it reduces the taste or it puts some coldness instead of being warm.
36, Mwanza
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. . .he would also complain that you get wet quickly?. . .he did not like the
condom and the gel as well. He did not like both.
28, Tongaat
This increased lubrication created conflict in some relationships. Male partners noticed
the difference in their female partners and, in some cases, associated this increased lubri-
cation with infidelity, at times to the point of accusing some trial participants of being
unfaithful. This was in particular noted by participants in Mwanza.
That is why he was being surprised and said that ‘you have been having sex
with another man, you have come from having sex, why is it like this?’
60, Mwanza
...he will tell you that maybe you have had sex with other men because he
will find that there is a difference.
32, Mwanza
...they were saying that it [the gel] was bringing them problems; they were
using it but quarrels and problems never ended inside the house.
32, Mwanza
Some participants explained that partners disapproved of them using the gel and when
they chose to use the gel, it created conflict in the relationship. Trial participants who
had been in this situation had to make a choice between using the gel, which they hoped
would protect them, and not using the gel, to avoid further discord with their partners.
...he would say ‘why there are changes inside here?’ Now he had already told
you two three times, you have to stop...
42, Mwanza
...her lover said that he refused, she had to return the gel.
40, Mwanza
providing sex at the moment a male partner demands it
For some participants, the need to be ready for sex as soon as their male partners de-
manded it prevented them from using the gel during the trial. This was particularly the
case when male partners had not been informed about the gel, when trial participants’
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homes had outside latrines, and when their partners demanded sex late at night or early
in the morning. Present participants who discussed this problem noted that they had to
be ready when their partner “needed” sex, and that they were not in a position to make
him wait, as he would not be understanding if she was not able to provide sex at the time
that he wanted it. In those instances, the participants stated they were unable to use the
gel, despite wanting to.
One participant noted that after going to an outside latrine for post-sex vaginal cleansing,
...when you return your partner wants again, and you don’t have that time
of evading him, he will demand. Really it was difficult.
42, Mwanza
Another participant explained a similar situation:
When you have hidden the gel, and your husband needs you, it means you
don’t have time to prepare as you will be late, so you just have to go ahead,
and you haven’t inserted the gel.
42, Mwanza
5.3.3.4 lack of clarity and transparency about the trial
the role of adherence in answering the trial research question
Based on experiencing the educational session on how microbicide trials answer research
questions at the beginning of the FGDW (session 2), some participants raised the concern
that they thought there was a lack of clarity during the trial in which they participated
about how adherence is related to answering the question of whether or not a candidate
microbicide gel can prevent HIV transmission. They explained that as trial participants,
they were not educated in a way to help them understand why their adherence was critical
in the trial.
Education to women should be given so that she may know in detail about
the gel and the study.
60, Mwanza
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. . . it is that every participant is supposed to know the meaning of participa-
tion and research and as she is an important person in that research she will
give correct information.
41, Mwanza
. . .They should be given sufficient education like how we got education [to-
day].
43, Mwanza
. . .What is required is that. . . services should be given attentively. . .you know
someone else has little understanding and another understands quickly; there-
fore they are supposed to go step by step, I mean slowly so that someone may
understand. . . [if] someone understands quite well, even fear will go away.
32, Mwanza
While as trial participants were provided with required information in the informed con-
sent forms, such as an explanation of study procedures, risks and benefits of trial partici-
pation and other details such as the concept of placebo and randomisation, present par-
ticipants noted they were not told how microbicide trials answer their research questions
and exactly why adherence on the part of trial participants is critical to the success of the
trial and discovering a product to prevent HIV transmission.
doubts
As the microbicide gels were being tested for safety and effectiveness, many trial partici-
pants had questions about what this really meant, and also had to manage comments and
rumours from others in their lives and the community about the unknown effects of us-
ing such products. Lack of clarity and transparency during aspects of trial participation
raised questions that may have affected trial participants’ desire to use the gel or to report
honestly, as noted in the examples below related to concerns about blood draws and rela-
tionships with research staff.
. . . they [trial staff] were taking that other blood and they were not bringing
the test results, therefore they were not open, therefore it happens that you
have disbelief with that place.
43, Mwanza
CHAPTER 5. design your own microbicide trial 182
With regard to that blood for HIV we were being tested, but that blood
which they were keeping in their small bottles, we didn’t know for what dis-
ease it was going to be tested because that blood was being tested there [at
a different location]. . .but that blood in those tubes. . .we didn’t get a solu-
tion for what that blood was going to be tested.
32, Mwanza
They [people in the community] think that as we are doing the study there
is some benefit for other countries who come and take what we have done
and go to do something in other places where we do not know.
43, Tongaat
With regard to that blood, others were claiming that why are they drawing
a lot of blood from us, where is this blood being taken? Others were saying
that it was being taken to [another location] to be sold, I don’t know if it
was true, that issue of drawing blood was bringing complexity.
30, Mwanza
One participant also noted that when a trial participant feels she was not treated well by
a staff member, and leaves with complaints, it may affect adherence:
When one leaves with complaints, she thinks ‘better I stop using the gels’.
That brings a lot of fear for participants, what is needed is that they be given
courage, courage to use the gel.
39, Mwanza
5.3.4 reasons for difficulty in adherence reporting
When participants discussed reporting gel use and the discrepancy between what trial
participants report and actual gel use, there was wide agreement that it was difficult to be
honest. Present participants did express that they, as trial participants, should try to be
honest, and that being honest would be helpful to the project. They stated that they and
their fellow trial participants should understand that “it isn’t a crime” not to use the gel
and that if they told a staff member the truth, they would not “be shouted at.”
It was difficult to say I forgot the gel just say I have used it. It is something
that we were doing.
28, Tongaat
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Yes it is possible but to make yourself look like a good person and doing
everything right whereas I know that when I am at home I am wrong I am
not doing what I am told here in the study.
38, Tongaat
When asked why it was difficult to be truthful as trial participants, present participants
gave a number of reasons. Some noted that trial participants feared being perceived as
dishonest, not helpful to the project, or that they would be reprimanded.
I think that maybe she thinks that she is going to be shouted at and asked
why she did not use it.
47, Tongaat
Yes it is going to be said I am not trustworthy. I sometimes do not use it, it
is better to lie saying I am using it.
38, Tongaat
Judging a person is what causes one to lie.
42, Tongaat
The reason most often given was that trial participants feared that if they admitted they
had not used the study gel, they would be “removed” from the trial, which would mean
they would no longer have access to the health care they were receiving or the reimburse-
ment payments.
They think they will not get the money.
44, Tongaat
Let us say they have a fear of being withdrawn and that they want to be
trusted.
44, Tongaat
The reason that made the participants not to say the truth, she sees that if
she is chased away [removed from the trial] she will miss that allowance, be-
cause there is that allowance which is being given; if she will say the truth she
will be chased away and she will not get that money, therefore she tells lies.
27, Mwanza
CHAPTER 5. design your own microbicide trial 184
Someone else tells lies because maybe her husband prevents her [from using
gel], then she comes there she just decides to tell lies so that she may continue
with that project.
30, Mwanza
I have seen that maybe she has a certain income [business] because we go
there, there is fare [reimbursement], she has now become a businesswoman
so that she may get money.
43, Mwanza
Three participants noted that inaccurate reporting of gel use might not be related to any
reason in particular, except that some people are in the habit of lying and have become ac-
customed to lying in many aspects of their life, not just for reporting adherence in the trial.
. . . I mean it is someone’s habit to speak like that, it’s like to tell lies is some-
one’s habit, this one has become used to telling lies and they succeed. . .you
can’t know if this one has used [the gel] [or] this one has not used. If she
will explain to you that she has used [it], you can just believe that she has
used [the gel], but in fact she didn’t use [it].
41, Mwanza
5.3.5 design your own microbicide trial: suggestions for improv-
ing adherence and adherence reporting
The following sections gather the important suggestions present participants made about
how to improve adherence and adherence reporting in future microbicide trials. These
suggestions range from overall trial design to the physical attributes of a vaginal microbi-
cide gel. Tables 5.3.2 and 5.3.3 provide summaries of these suggestions.
5.3.5.1 trial design which includes needs of both participants
and research objectives
During the FGDWs, participants had a chance to react to the idea of different HIV pre-
vention delivery forms and an alternative trial design that included a non-randomised arm
with no gel. In this hypothetical design, women who would like to join the trial choose
if they would like to use the gel or not. Those who would like to use the gel would be
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Gel suggestions
1 Less-watery consistency
2 Less volume
3 Warming sensation/lack of “cold” feeling upon insertion
4
Greater ability to use covertly, should not be obvious to a partner that a highly 
lubricating product is being used
5 Gel applicators and boxes should be smaller and more discreet
Table 5.3.2: Suggestions to improve microbicide gel formulation
randomised to either the placebo or active gel. Those who would not like to use the gel
would remain in follow-up and would visit the research clinic regularly for HIV preven-
tion counselling, health testing, and treatment as in the gel arms. This trial design was
discussed via use of a simple diagram illustrating the design (Figure 5.3.4).
Because the workshop began with providing basic education about how a microbicide
trial is able to answer its research question, participant responses indicated they now un-
derstood how incidence of HIV in the placebo and active arms is compared at the end of
the trial, and that the participants in the no-gel arm would not directly contribute data
to answer the question of whether the gel works or not. Some expressed a positive re-
sponse to the idea of this three-arm trial, as trial participants would be able to choose if
they use the gel or not, and through this method the trial would have better ability to
ensure women randomised within the gel arms would actually be interested in using the
gel.
According to my opinion maybe this will be suitable because some women
don’t like the gel. . . if she is in this group, she can go to the group of those
who don’t like the gel.
42, Mwanza
It is better like this than to take it [gel] and not use it. At least it is better
because there is a group that will never use it. . . it is better not to take it than
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to take and throw it away.
28, Tongaat
Several participants noted that the above approach would help the research staff separate
who was joining the trial to help answer the research question or for HIV protection, and
who was joining the trial just for health checks or money.
If they divide it this way, it will be much better. . .here once they differentiate
it, those who are coming for the purpose of testing only and those who are
participating in the study will be known.
32, Mwanza
. . . it is something that can help and make it better. . . these ones choose if
they want the product, and you can have hope that because they chose it
themselves it means. . . indeed it can happen that they are using it. Maybe if
there can be a study like that with three groups.
27, Tongaat
Participants who thought such a design would not be a good solution thought so because
they believed women joining the no-gel arm would not contribute to answering the re-
search question to identify a way to prevent HIV. Others, to a lesser extent, expressed a
negative reaction to this trial design because they thought many women would choose
the no-gel arm; this reaction further demonstrated the view of many present participants
that women join the trial for reasons other than to access the candidate microbicide gel.
. . . if it will be so I think it will not be good because this is a research, if you
will have two groups [gel vs no gel] this means most of the others will go to
the group which doesn’t use the gel; now where will that group be?
32, Mwanza
. . . If you say that they should choose, most of them will go where there is no
gel.
32, Mwanza
Despite participants having opinions, when asked, about which trial arm women might
prefer to join, one participant remarked:
Until you talk with them and hear which one will like to use the gel and
which one will not like to use the gel. . .you can’t know who will want or
who will not want [the gel].
54, Mwanza
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1
Provide participants with an explanation of how a microbicide trial answers its research 
question, using simple terms and easy to understand diagrams.
2
Provide participants with an explanation of why adherence is important in the context of a 
microbicide trial answering its research question.
3
Provide participants with a simple and clear explanation of the investigational nature of 
the product, where it has been tested before, and why it is necessary to test in humans in 
this trial.
4 Offer seminars, which can be held in waiting rooms, to revisit the above topics.
5
Engage experienced participants to be ‘ambassadors’ to share their experiences with 
other participants who may have questions about participation or experience difficulties.   
6
Offer ways to engage participants' male partners to learn about the purpose of the trial, the 
investigational gel, blood draws, and study procedures. 
7
Provide participants with clear information at each blood draw about the type of testing to 
be conducted and when the results will be provided. 
8
Provide participants and invited guests with opportunities to visit clinic laboratories (and 
other areas) to learn about the trial. 
9
Use a method to test applicators for vaginal insertion, and provide feedback to particpants 
on their adherence results over follow-up.
Participant-initiated suggestions for improving future microbicide trial design 
Table 5.3.3: Participant-initiated suggestions to improve design of future microbicide trials
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Gel using group
Active 
Gel
Placebo 
Gel
Women choose if they want to be in the 
gel using group or no-gel group
No gel group
Figure 5.3.4: Diagram of a microbicide trial with a non-randomised, no-gel arm
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5.3.5.2 testing applicators for vaginal insertion
While the example of Carraguard’s applicator DSA to determine vaginal insertion of the
applicators was used at the beginning of the workshops to help explain why low adher-
ence can interfere with interpretation of null trial results, this technology was not brought
up by study staff again and was not intended to be discussed further in the FGDWs. In-
terestingly, throughout the FGDWs, and during the last activity when participants were
asked to work in groups to make recommendations for future trials, applicator testing
was repeatedly mentioned as a viable addition to microbicide trial design. Participants
stated that if trial participants can be shown results of an applicator test that demonstrates
their own use in real time, it would encourage them to use the gel correctly and be honest
in their reporting. Participants did not offer advice about procedures they might recom-
mend in response to the different levels of adherence that participants report.
In order that they may improve it I was requesting for that testing instru-
ment...when they return those boxes they should actually test them so that
they know that they have used them or not. Therefore that testing instru-
ment is needed.
32, Mwanza
The product has to have a mark [like DSA]...that the product has been used
First Tongaat FGDW, flipchart, session 8
5.3.5.3 suggestions to address adherence barriers related to male
partners
improved formulation of gel
As noted earlier, Mwanza participants in particular had recommendations about the gel
formulation. These participants recommended that it should have a less-watery consis-
tency, less volume, not be as highly lubricating, and have a warming sensation upon ap-
plication. Some thought that vaginal capsules might solve this problem or that the mi-
crobicide should be available in both formats, capsules and gel. Some acknowledged that
different bodies are different, thus what works for one person might not work for another.
Mwanza participants spoke of the importance of making these changes so that the micro-
bicide could be used covertly, which was important for some, and so that microbicide use
would not be surprising for the male partners who might notice a difference during sex
and then accuse the trial participants of having sex with other men.
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My suggestions are...medicine should continue being improved so that it
should be warm, I mean that gel should not be light [liquidy], it should
be heavy [thick].
40, Mwanza
So that when you bring it here at least it should have some certain warmth
to make the man also get the desire when she inserts it inside the vagina.
39, Mwanza
We have suggested that we should involve our partners regarding the gel so
that they may be able to completely understand that we are using the gel,
then that gel should be improved so that it may be attractive even to my
partner.
32, Mwanza
With regard to the packaging, one participant suggested the boxes should be smaller and
more discreet. Others spoke of the importance of being able to leave their appointments
and not “advertise” to community members what they had been doing at the clinic. More-
discreet packaging would not provide an opportunity for community members to spread
rumours about trial participants carrying HIV medications.
It should be improved, and its packaging, does it mean if you pack them in
boxes...? Let it be changed, it should be even in a bag which...it shouldn’t be
a burden even when we go to take them; to carry that box people really...that
appearance should improved.
52, Mwanza
explicitly consider how to engage male partners in microbicide
trials following participant request
Participants advocated for better inclusion of male partners in the research process. Many
agreed that if there were more support in the trials to engage and educate male partners,
it would be extremely helpful. They thought that male partners would likely be support-
ive of the gel and the research, thus improving a trial participant’s ability to adhere to the
study protocol and use the gel as directed.
...men should be given education on how to protect themselves against HIV
infections, they should be educated about the gel; the participants are not
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supposed to be women only and young men too need education.
30, Mwanza
...when this project starts it should involve men and women and there shouldn’t
be something like a secret; if her partner doesn’t like it, it’s better she quits, if
her partner will be ready then she should agree; particularly those with hus-
bands...if you involve him, he will understand...We have said that education
should be given openly to both sexes.
60, Mwanza
Participants suggested that male partners should be included from the beginning of the
process and that there should be opportunities for them to receive counselling on HIV,
health, the research, and the gel. Participants thought this education should be detailed
and complete, so that trial participants and their partners would not be left with doubts.
Present participants also noted that better education would also help the trial participants
themselves to have courage and strength to tell their male partners about the details of
the trial. Participants thought that once male partners were involved and understood the
purpose of the study, they would be supportive. For a coitally dependent regimen, this
support could translate into, for example, male partners wanting sex being willing to wait
for trial participants to insert the gel, thereby increasing adherence.
5.3.5.4 transparency, respect, love
Participants experienced feelings of fear stemming from multiple aspects of trial participa-
tion. They were asked to use an investigational drug that could cause adverse effects; they
heard rumours from members of the community about the gel causing health problems;
and they had to negotiate trial participation and gel use with their male partners or use
the gel covertly, not knowing how their partners would react. All of these elements might
create an environment where a trial participant’s health, safety, and well-being are at risk.
Present participants made a number of concrete suggestions on how to improve imple-
mentation of future trials that stem from the need for transparency, respect, and love. If
trial staff could create relationships and a clinic environment that embody transparency
about the research, show respect for the trial participants as people who need correct infor-
mation, and treat them with love, participants explained that fears they had would more
easily go away. They explained that knowing more details would give them strength and
courage to use the investigational products and boldness to communicate accurate infor-
mation to their partners, to advocate for their participation and use of the gel. By creating
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an environment of transparency, where information is clear and doubts of trial partici-
pants can be addressed with honestly, and by creating an environment where participants
feel respected and loved, trial participants would have more strength to be honest with
trial staff about their use of the gel. Without fear of being judged and without fear of
being removed from the trial and losing access to health care and reimbursement, which
they had valued and needed, present participants thought there could be increased accu-
rate reporting of gel use by trial participants.
more accurate and clearer education
More accurate and clear information was seen as a way of demonstrating transparency,
respect, and love within trial conduct. Participants noted that members of the research
team must have enough education and understanding about the research and the gel to
be able impart that understanding to the trial participants themselves.
Yes, research workers should be given more education so that they may give
more education to their participants.
27, Mwanza
Interestingly, this sentiment was echoed by my own RAs after I presented the “How a
microbicide trial answers its research questions” lesson to them as a part of their training.
The RAs who had been involved in prior microbicide trials (in non-clinical roles) noted
that the scientific process of comparing HIV incidence between the randomised arms had
not been explained to them clearly, and that they wished they had had that training when
they worked in their previous positions.
Participants spoke of the importance of providing clear education which could then allay
fears. More education meant explaining clearly and fully how the research question is an-
swered, what is known about the gel and its known side effects, which disease each tube
of blood was to be tested for, and when results would be returned.
I would request that when we take the participants, education is just needed.
I mean it is education that will help the people to rid themselves of the fear
and not even to fear anything.
32, Mwanza
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...these researchers, maybe they should be going to people and give them just
little seminars that when you give your blood, not that your blood is going
to be sold, that blood is going to be stored in a special place and if you want
to prove that it is your blood, we have the ability to take you...we go and
show you that here is your blood.
39, Mwanza
Present participants also wanted general procedures to be explained to trial participants as
they were happening, so trial participants would know what to expect. When aspects of
the trials were conducted in a way that was not clear to trial participants, it was confusing
and raised suspicion. As noted above, blood draws were a significant source of concern
for the participants at both sites. Another example, raised by one participant in Tongaat,
was why, after “completing” their study visit, trial participants had to wait before they
received the final approval to leave the clinic. Respecting time was highly valued by this
participant and Tongaat trial participants, and being “held” for an unknown reason was
a source of frustration.
Eh maybe you have finished here, you are sitting and told to wait for the
money you should get. You will stay maybe...30 minutes or more than 39
minutes you are sitting waiting for the money having finished everything.
That was not good to me.
32, Tongaat
Providing transparent information about trial procedures in this case would have meant
letting trial participants know that after they complete their visit procedures, their files
are reviewed by a staff member in the data room while the trial participants are still in the
clinic, in case there are any data issues that require correction or clarification. Once it is
determined that a file is satisfactory, that trial participant is given her reimbursement.
In thinking about how to help improve education within the trials, one present partici-
pant stated that trial participants who are already experienced with using the gel and have
decided that participation in the clinical trial is beneficial for them could be used to help
other trial participants who have doubts, worries, or questions.
...we who came here should be the ambassadors of those others. My friends,
we happened to use the gel and we didn’t get any adverse effects, in fact even
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during that period we had doubts, but until now we haven’t had any prob-
lem...
52, Mwanza
closeness of staff and participants
Participants in Tongaat and Mwanza spontaneously spoke of the importance of respect,
saying that research staff should respect them and that they, as trial participants, should
respect the research staff. Being clear and transparent about the trial, the gel, and proce-
dures was thought to be an important way that trial teams could demonstrate respect.
Participants at both sites also spoke about the importance of trial staff showing love, kind-
ness, and care to trial participants. Present participants thought that trial participants
and research staff should be close. Some present participants noted that when trial par-
ticipants are treated with love and respect, fears and doubts are removed and participants
feel encouraged to use the gel.
So that participants are more attracted to using the gel correctly, it is together
with the researchers to be more close to the participants, they should be open
to them and they should be friends...It is that they should be friends in the
meaning that the researcher should not fear the participant and also me the
participant should not fear the researcher so that my thoughts and hers may
be close so that we may help each other.
42, Mwanza
Like how you received us here [today], we talk nicely with love; indeed this
is the way of caring about the participants.
39, Mwanza
It is to give them [participants] respect and love and to tell them how impor-
tant they are.
Third Tongaat FGDW, flipchart, session 8
5.4 discussion
The aim of this study was to gain insight on how to improve adherence and adherence re-
porting in microbicide trials from the perspective of former trial participants. Responses
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from participants indicate that low adherence and inaccurate adherence reporting are
driven by the reality that many women in communities where microbicide trials are con-
ducted participate in trials for a number of important reasons which are not related to
interest in the study gel. Thus, there is a fundamental difference in the objectives of many
woman who agree to participate in a microbicide trial and the research objectives of trial
implementers.
5.4.1 needs of participants drive their participation in micro-
bicide trials
For many participants, the trials provided free, high-quality, confidential health services.
Participants spoke positively about being tested for a number of health issues, receiv-
ing treatment, knowing about their health, and gaining valuable education. The trials,
through reimbursements, provided a type of income that was utilised and appreciated.
Other studies have also shown access to health care and money in the form of reimburse-
ments as an important motivating factor for trial participation.114,115,116,95,117 When asked
why they thought it was difficult for some trial participants to report gel use accurately,
the most common response was that trial participants feared they would be asked to leave
the trial, thus losing access to the health care and reimbursement. This fear was also cited
as a reason for lack of honest adherence reporting in other trials. Negative responses to
the hypothetical trial design with a non-randomised, no-gel arm highlighted that some
present participants believe the gel is not the primary reason, nor a reason at all, for many
women to join trials.
5.4.2 fear of investigational nature of candidate microbicide
gels
The most important reason why participants thought the gel was not being used by trial
participants was fear of the investigational nature of the gel. This fear stemmed from
two general sources: the true nature of a clinical trial, where risks are both known and un-
known, and from rumours heard from the community. Participants made suggestions on
how to minimise fears that were perpetuated by the community, such as providing better
education, using ambassadors or peer educators, providing more male partner engage-
ment opportunities, and better transparency overall about the procedures at each stage
CHAPTER 5. design your own microbicide trial 196
of the trial. In addition to being explicitly discussed, the barrier to adherence that the
investigational nature of the study products provides was evidenced indirectly by other
statements participants made. When asked how to improve adherence in future trials,
some suggested not calling the clinical trial “research” and telling participants that the gel
“worked.” When asked for reactions to the hypothetical trial design that included one
non-randomised no-gel arm, some participants remarked that they thought that most
women would want to join the no-gel arm.
Concerns around adverse effects and unknowns about the gel will continue to be a source
of fear and cause hesitation for trial participants about using the study products. This
effect has been observed in other trials of biomedical HIV prevention methods,116,138,118
and will always be a concern for healthy participants who are asked to test a drug for effi-
cacy and safety.
5.4.3 innovative trial design for participant needs and research
needs
Acknowledging that many women join trials for reasons outside of the desire to use an
investigational gel, yet participate and report high adherence, a hypothetical trial design
with a non-randomised, no-gel arm intended to address this issue was proposed to FGDW
participants for their feedback. As many women join trials for health checks and other
means of support, this trial design would allow women to choose if they would like to
use the gel, or not, when they enrol. This trial design gives women an acceptable way to
participate without having to pretend they are using gel. Women who are interested in
using the gel would elect to do so, and would then be randomised as participants to the
placebo or active gel arm. This design seeks to improve adherence in the gel arms by elim-
inating the dilution effect11 caused by participants who do not use the investigational gel.
Some participants in the FGDWs liked the idea of this trial design and thought it would be
appropriate as women would have the freedom to choose if they use the gel or not, would
still benefit from the trial, would not waste gel unnecessarily, and would not be prevent-
ing the research from discovering a potentially effective microbicide. While this design
may improve adherence, it will certainly be more costly than a conventional trial because
more women will need to be enrolled. The feasibility of such an innovative design would
need to be assessed with formative research. Microbicide effectiveness trials are expensive,
with estimates of phase III trials costing up to $70 million USD.33,34 If multiple trials have
null results due to low adherence, considerable funds are wasted and a potentially effica-
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cious product may be eliminated from the product development pipeline. While initially
expensive, investing in a trial design that could potentially meet the needs of women in
high HIV incidence communities and also meet the needs of the research question might
be a wise investment. This possibility is worth considering. Trial teams can work with
trial populations to conduct formative research to consider various innovative trial de-
signs139 and their potential feasibility.
5.4.4 male partner effect on participant adherence
While the microbicides field has endeavoured to discover a female-controlled product
women can use to prevent sexual transmission of HIV, ironically, the field has learned
through the process of conducting microbicide trials that male partners are an impor-
tant factor in determining female trial participants’ ability to adhere to the study regi-
mens.115,116,117,127,128,131,140,141,142,143 Participants reported that trial participants who de-
sired to use the study gels as directed were sometimes not able to do so due to gender
norms and factors related to their male partners. In some cases, male partners did not like
the lubricating effect of the gel, or forbade their female partners to use the gel. In other
cases, trial participants feared using the gel because their male partners had accused them
of being unfaithful, due to the increased lubrication. In yet other cases, the need to be
ready for sex exactly at the time their partner demanded it meant there was no time for
insertion of the gel. The experiences of these trial participants indeed highlight the need
for women to have more control over their own health and additional means to protect
themselves from HIV infection.
Despite the challenges related to male partners for some trial participants, participants in
the FGDWs in this study thought that better involvement of male partners in the trial pro-
cess would likely result in agreement and support from male partners. Trial participants
would need to determine if, and when, to inform their male partners about participation
in the microbicide trial; results in this study, as well as others,116,127,131,143,121,144,145 sug-
gest that there is a greater need to inform longer-term or cohabitating male partners than
casual partners. Trials can offer a number of mechanisms to better include male partners
and support participants in informing their male partners about the microbicide trial and
the gel itself. Trial sites can offer more robust provision of HIV and health information to
both partners, joint orientation to the trial, and tours of the laboratory and clinic facilities.
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Another important aspect of male partner influence on participant adherence was related
to gel attributes. As discussed by some participants, particularly from Mwanza, the gel
consistency made it difficult to use covertly, was not always liked by male partners, and
put some women at risk for being accused of infidelity, thereby causing considerable dis-
cord within trial participants’ intimate relationships. Previous studies have reported trial
participants’ positive experiences with the gel, in that it may reduce their sexual pain or im-
prove their pleasure.146,147,148,149,129,150,151 There were participants in this study who also
mentioned positive effects of the gel; in addition, present participants were generally sup-
portive of the idea of a gel for HIV prevention and thought that negative aspects related
to its effect during sex could be addressed with improved formulation. Some amount of
lubrication was seen by some as positive, but not to the point that the ability to use the
gel covertly would be impossible. Vaginal suppositories or a dissolving microbicide film
would provide a coitally dependent form of protection but potentially with less obvious
lubrication.
5.4.5 applicator test for vaginal insertion
Another strongly supported suggested trial design element was a method to test applica-
tors for adherence. The DSA for applicators, which was developed for the Carraguard
trial, served as a pivotal moment for the microbicide field in documenting the discrep-
ancy in microbicide trials between self-reported and actual product use. The advantage
of applicator tests is they can preserve blinding and results could be reported back to
participants throughout their participation, which ideally could help improve adherence
prospectively. Biomarker testing used in anti-retroviral based trials, by contrast, cannot
be reported at an individual level due to blinding and would thus not provide individ-
ual participants with real-time feedback. Since the development of the DSA, research has
continued to progress on how to identify applicator testing methods that will be more
sensitive to identifying vaginal insertion of gel under typical field conditions within mi-
crobicide trials.152,99,153,100
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5.4.6 clearer and more complete education about the gel and
trial procedures
In this study, former microbicide trial participants discussed a strong desire to have im-
proved education about the gel, the research process, and why adherence is important.
Participants stated that they and other members of the community had had many ques-
tions and concerns about the research. Improved education could allay fears, help trial
participants feel comfortable, help their partners feel comfortable, and potentially im-
prove both adherence and adherence reporting. Tools, including simple diagrams such
as those used in this qualitative study to explain trial design and adherence, were effective
and well received by the study participants.
Interestingly, while trial teams often expend time and resources to educate local commu-
nity advisory boards (CABs) and other community entities about how research is done,
that same information is often not shared with trial participants. Rather, information
shared with trial participants tends to focus on the contents of the informed consent
form and trial procedures, rather than on a broader understanding of how and why a
clinical trial is conducted. Trial teams can ensure that these broader topics are addressed
by developing materials and adding these discussions to visit checklists. As suggested by
participants, short talks or seminars in group settings can be provided on a regular basis.
These topics can be revisited with trial participants over their follow-up to ensure clarity
around the trial and to continue to answer questions a participant might have, especially
about the investigational gel. Peer educators can also be used to help in these processes.
By following these suggestions, trial teams can create a trial atmosphere that is more trans-
parent and respectful of the trial participants as humans who have fears and who have a
need for correct and clear information.
5.4.7 transparency, respect, love
It is not surprising that participants in this study stressed the importance of transparency,
respect, and working together with research staff as key elements for a successful trial.
The history of biomedical HIV prevention research has shown that these are important
elements for trial communities and are, indeed, why respect, transparency, and mutual un-
derstanding are three of the guiding principles included in theGood Participatory Practice
Guidelines for Biomedical HIV Prevention Trials (GPP).40 These elements of coopera-
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tion and mutual understanding were lacking in some of the first PrEP trials in the field of
biomedical HIV prevention trials, which resulted in negative consequences for prospec-
tive participants, investigators, and the research effort to find an additional method of
HIV protection.42,43,154 Participants in both Tongaat and Mwanza valued the positive in-
teractions they experienced with trial staff and felt cared for. They advocated for working
closely with trial staff, as friends, and thought that when trial staff members treat trial
participants with love, it helps them to feel important and helps to remove doubts they
might have about aspects of their trial participation.
5.4.8 limitations and strengths
This qualitative study endeavoured to explore former microbicide gel trial participants’
opinions on how to improve adherence and adherence reporting in future microbicide
trials. Given the number of women who have participated in effectiveness trials of can-
didate microbicides, the sample size was small (n=46). An advantage of this study is that
it was conducted in two different countries, South Africa and Tanzania, that have very
different cultures and histories. The most notable differences observed were that partici-
pants in Tongaat highly valued time in relation to study visits not being too long, and that
in Mwanza there was more concern expressed over the physical characteristics of the gel in
relation to their male partners’ reactions. This study also included participants from two
different microbicide gel trials, although there was much greater representation of MDP
301 as only five participants in this qualitative study represented the VOICE trial.
Recruitment methods attempted to invite a representative sample of former gel partici-
pants from MDP 301 and VOICE to join the qualitative study in the respective locations
of Mwanza and Tongaat. Former participants who were contacted or able to participate
on the day of the FGDW were more likely to be women who had not moved far away
from the trial sites. Former participants who attended the day of the FGDW were also
more likely not to be formally employed compared to those who did not attend.
A potential limitation of this study is that many years had passed since participation
for some participants, particularly for those who participated in MDP 301. Therefore,
specifics about trial participation may not have been fresh in present participants’ minds,
which could lead to recall bias. While the long amount of time that passed between trial
participation and FGDW attendance may have caused some problems with recall, the fact
that this study took place well after trial participation may have increased the chance that
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participants were truthful in their responses and that they had time to reflect on their expe-
riences. More truthful responses about adherence after completion of trial participation,
compared to upon study exit, have been reported in other biomedical HIV prevention
trials.115,95
An advantage of using a group-based format to explore sensitive and stigmatised behaviours
is that individuals can talk about themselves and their behaviours in the guise of talking
about “other people.” This can result, however, in having a smaller amount of data that
appears to be first-hand accounts. Another advantage to using a group-based method for
this research is the benefit derived from the synergy amongst the participants to build
rapport and camaraderie, which facilitates discussion, speaking freely, remembering expe-
riences and feelings, generating ideas, and expressing opinions.
A unique aspect of this study was the format of focus group discussion workshops which
included both discussion and participatory activities and sought to cover the research
questions both in nuanced ways and from several angles over the course of the day. This
format provided a platform for participants to help each other remember their experi-
ences and views as trial participants from several years past, to think critically together
about what factors might contribute to aspects of adherence and adherence reporting,
and to generate suggestions or new ideas about conduct of future microbicide trials. Us-
ing a number of different methods to elicit information may also improve the chance of
gaining useful data because participants might respond differently to different techniques.
The FGDWs were longer than standard focus group discussions, which allowed partici-
pants to think about and provide input on more aspects of the research topic. A disad-
vantage of the long format was that some participants felt tired by the end of the FGDWs.
5.4.9 future microbicide gel trial design
Recent efforts to improve adherence for women in microbicide trials such as CAPRISA
004, VOICE, and FACTS 00191,90 have included adopting more participant-centred ap-
proaches to adherence counselling which address barriers to adherence and tailor coun-
selling to help participants increase gel use. While these adherence support strategies may
have shown improvements in adherence, these methods have not necessarily been effec-
tive to the extent needed to demonstrate effectiveness of the candidate microbicides, as in
the cases of VOICE and FACTS 001. The underlying assumption of these approaches is
that participants enrol in microbicide trials with the intention of using the microbicide
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gels.
Through the use of FGDWs with former participants from two microbicide trials in two
countries, this study has identified that women join microbicide trials for a number of
important reasons which are not related to using the study product, and that the largest
barrier to using the study product for participants is fear of adverse effects from a still-
investigational product. This result shows that there is a fundamental difference between
the objectives and needs of participants and the research objectives of a microbicide trial.
Without addressing these two different perspectives, it will be difficult to address low ad-
herence and inaccurate reporting of adherence in future microbicide gel trials.
As participants have expertise in the local communities where microbicide trials are con-
ducted and in trial participation, both of which trial investigators lack, former microbi-
cide trial participants can give important feedback on how to address microbicide trial
design in a way that can help harmonise the needs and objectives of participants and the
needs and objectives of the research. This is the first qualitative study to engage microbi-
cide trial participants in explicitly thinking about the design of future microbicide trials
to address the challenge of suboptimal adherence and inaccurate reporting. Former mi-
crobicide gel participants gave concrete and viable suggestions on how to improve adher-
ence and adherence reporting, and gave thoughtful reactions to an innovative trial design
with a non-randomised no-gel arm, intended to address the fundamental issue that some
women join and remain in microbicide trials without using or intending to use the micro-
bicide gel according to protocol requirements.
The field of microbicides, over many years, has endeavoured to discover a product women
can control to protect themselves from HIV. The field has searched for ways to address
the complexities of conducting vaginal microbicide trials in communities with high HIV
incidence. In addition to seeking new modes of microbicide delivery, such as rings, and
looking for ways to improve adherence and adherence monitoring through improved ad-
herence counselling and biomarker testing, it is important for research teams to examine
and appropriately address the underlying dynamics within microbicide trials. For opti-
mal results, these underlying dynamics can be addressed in the actual design of vaginal
microbicide trials. Doing so may require thinking creatively to develop new and differ-
ent ways of designing clinical trials. As this study has demonstrated, participants and
research teams can work collaboratively to consider such designs. When participants and
trial teams work together with transparency, respect, and mutual understanding,40 diffi-
cult challenges such as low adherence and inaccurate reporting can better be addressed in
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future trials.
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6 
discussion
“bring us the one thatworks.”
6
D I S C U S S I O N
This chapter provides a review of the studies undertaken within this PhD research, a sum-
mary of the key findings, an update on trials reporting primary results since the start of
this PhD research in 2012, and a discussion of the results of this research, contextualised
within microbicide trial research findings that have been published through 2015.
6.1 summary of the phd research
At the time of the start of this PhD research, 12 microbicide effectiveness trials had been
conducted, with only one which showed a decrease in HIV transmission. Adherence, at
the time, was increasingly being recognised as the Achilles heel of microbicide trials. There
was an urgent need to better understand adherence within microbicide trials and to use
this information to improve microbicide trial design so that future microbicide effective-
ness trials would be better positioned to answer their research questions.
The goal of this PhD research was to critically examine, from different perspectives, expe-
riences of past vaginal microbicide effectiveness trials, in order to better understand how
adherence and adherence assessment can be improved for future microbicide trial design.
Adherence assessment here refers to the measurement of adherence and sexual behaviour
data as well as to the analysis and reporting of those data.
This goal was accomplished by conducting three different studies, with each study look-
ing at adherence from a different perspective and addressing a different objective. A sum-
mary of each study is provided below, followed by a brief outline of the key findings.
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6.1.1 objective one
What dowe reallymean by “adherence”? A comparative study ofmeasur-
ing, calculating, and reporting adherence in five microbicide gel effec-
tiveness trials sought to critically examine how five completed microbicide effective-
ness trials measured, calculated, and reported microbicide gel adherence.
This objective was accomplished by conducting a comparative analysis of trial methods
using trial protocols, case report forms (CRFs), statistical analysis plans (SAPs), and pri-
mary results manuscripts, and by conducting a trial team survey. The comparative analysis
was undertaken to identify which source data were collected to measure sexual behaviour
and adherence, to identify how trial teams reported adherence estimates in primary results
manuscripts, and to determine how trial teams used source data to calculate the published
adherence estimates.
6.1.2 objective two
Hidden heterogeneity: Discovering adherence patterns in vaginal mi-
crobicideHIVpreventionclinicaltrials sought to examine, using self-reported
adherence data from four completed effectiveness microbicide trials, if longitudinal pat-
terns of adherence are evident and, if so, what individual-level factors were associated with
observed patterns of adherence.
This objective was accomplished by conducting latent class and latent profile analysis on
self-reported adherence data to identify patterns of adherence, followed by conducting
multivariable multinomial logistic regression to identify factors associated with patterns
of adherence.
6.1.3 objective three
Designyourownmicrobicidetrial: Opinionsofformermicrobicidetrial
participants on how to improve adherence and adherence reporting in
future microbicide trials sought the expertise of former microbicide trial partici-
pants about barriers to adherence, accurate reporting of adherence during trial participa-
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tion, and how to improve adherence and adherence reporting in future microbicide trials.
This objective was accomplished by conducting focus group discussion workshops (FGDWs)
that used participatory activities and discussions with former trial participants. Partici-
pants were engaged in concepts around microbicide trial design; asked to give their views
on trial participation, barriers to adherence, and accurate adherence reporting; and asked
to provide suggestions for future microbicide trials. Eight FGDWs in total were con-
ducted in Tongaat, South Africa, and Mwanza, Tanzania.
6.2 key findings of the phd research
6.2.1 what do we really mean by “adherence”? a comparative study
of measuring, calculating, and reporting adherence in five
microbicide gel effectiveness trials
• There was considerable diversity in methods used to collect adherence and sexual
behaviour data among the five trials. These methods used both self-reported data
and non self-reported data, different recall periods, different frequencies of data
collection, and different wording of questions.
• Trials used considerably different methods to calculate adherence estimates and
combined source data in unique ways.
• Two overall methods to calculate the final adherence estimates were identified: us-
ing the total number of sex acts in the trial as the denominator, with the numerator
being gel use, or using the number of participants as the denominator, with the
numerator being average adherence calculated from participants’ adherence over
follow-up.
• Unclear or ambiguous wording was present in some of the questions used to collect
source data from participants.
• Trial documentation and publications lacked clarity in exact methods used to cal-
culate adherence estimates.
• Means or medians used to characterise overall adherence in trials did not provide
meaningful information about how adherence might have varied over time or in
different groups of participants.
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• Adherence questions which ask about non-adherence first may help participants
feel more comfortable to answer questions honestly. (Finding from trial team sur-
vey)
• Inclusion of self-reported adherence by participants is essential for trial staff to
know if participants understand the study regimen or are having problems with
product use. (Finding from trial team survey)
• Both biomarkers and a strong social science component are important for future
successful microbicide trial implementation. (Finding from trial team survey)
6.2.2 hidden heterogeneity: discovering adherence patterns in
vaginal microbicide hiv prevention clinical trials
• Using self-reported data, different trajectories or patterns of adherence to microbi-
cide gels were observed in all four trials.
• The patterns of adherence were similar among the four trials.
• Latent class and latent profile analysis is a useful method to understand the longi-
tudinal nature of adherence patterns in coitally dependent microbicide trials.
• Latent class and latent profile analysis can be used with inexpensive self-reported
data or with other adherence data that are collected longitudinally over follow-up.
• Using multivariable multinomial logistic regression, certain individual-level factors
were found to be associated with adherence patterns in all four trials.
• Older age versus younger age was associated with consistently reporting high ad-
herence in all four trials.
• Site was associated with different patterns of adherence in all four trials; this find-
ing indicates that culture or staff characteristics may be influencing adherence and
adherence reporting.
• Participant report of male partner dislike or refusal of gel use was associated with
membership of trajectories that had decreasing reported adherence. The effect size
of this association was large, and evidence for this association was strong in two out
of the four trials in the final adjusted analyses.
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6.2.3 design your own microbicide trial: opinions of former mi-
crobicide trial participants on how to improve adherence
and adherence reporting in future microbicide trials
• Women join and stay in microbicide trials for their own needs, which are not nec-
essarily related to interest in using the investigational product.
• Access to free, high-quality health care was an important reason for joining and
staying in trials.
• Access to money, through reimbursements provided by the trial, was an important
reason for joining and staying in trials.
• Being cared for and valued was a reason participants stayed in trials.
• Fear of adverse effects or harm from the investigational product is the most impor-
tant reason why some participants did not use the gel in accordance with instruc-
tions.
• The lubricating effect of the gel was noticeable to regular male partners during sex.
• Participants reported that male partners can act as barriers to using the gel.
• Some participants reported that the lubricating effect of the gel caused regular male
partners to suspect that they were having sex with other men.
• Fear of this suspicion or direct accusation created barriers for some participants to
use the gel as directed.
• Participants reported that the need to provide sex to male partners at the time it
was demanded was a barrier to using the gel as directed.
• Fear of removal from the trial, and thus loss of perceived benefits such as health
care and reimbursements, was the primary reason for reporting gel use when the
gel had not been used.
• An innovative trial design with a non-randomised, no-gel arm was seen as a good
option by some participants to address low adherence in microbicide trials because,
as some reported, some women who join trials will never want to use an investiga-
tional gel.
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• Participants who expressed concern about this trial design with a non-randomised,
no-gel arm did so because they thought that many woman would choose the no-gel
arm.
• Applicator testing, such as the DSA, and reporting of those results, was strongly
recommended by participants for inclusion in future microbicide trials.
• A gel formulation that offers lubrication but is less noticeable to male partners was
requested by participants in Mwanza, Tanzania.
• To improve gel adherence, trials should explicitly include methods for male partner
engagement, with participant consent.
• Participants reported that they were not provided with explicit information about
how trials answer their research question and the mechanism by which their adher-
ence can affect trial results.
• A simple diagram showing the trial process, and how the number of women in-
fected with HIV by the end of trial follow-up is compared across study arms, was a
simple and effective way to teach participants how trial teams answer the question
of whether an investigational gel can prevent HIV transmission for women.
• Participants reported that they were not always given clear information about trial
processes while they were taking place, and this raised doubts about the research.
• For future trials, participants request an atmosphere of transparency, respect, and
love between research teams and trial participants.
6.3 summary of microbicide effectiveness trials reporting be-
tween 2013 and 2016
Prior to the start of this PhD research, 12 microbicide trials had been conducted, with only
CAPRISA 004 reporting a statistically significant reduction in HIV incidence. During
the period of conducting this PhD research, four microbicide trials reported results, two
testing 1% tenofovir gel and two testing a vaginal ring containing dapivirine for monthly
use. The two coordinated trials of the dapivirine ring reported results while writing up
this thesis. The sections below provide a brief description of those four trials and their
results.
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6.3.1 aspire trial
The Microbicide Trials Network’s (MTN) A Study to Prevent Infection with a Ring for
Extended Use (ASPIRE, MTN 020), was a randomised, double-blind, placebo-controlled
phase III trial to test the effectiveness and safety of a four-weekly vaginal ring filled with
dapivirine (25 mg), used to prevent HIV infection in healthy women.125 Dapivirine is a
non-nucleoside reverse transcriptase inhibitor. The trial enrolled 2629 participants, aged
18–45 years; was conducted in Malawi, South Africa, Uganda, and Zimbabwe; and fol-
lowed participants for a minimum of 1 year. The trial started in August 2012 and com-
pleted in June 2015. The dapivirine ring was found to reduce HIV-1 infection by 37%
(95% CI 12–56). Adherence was measured quarterly using plasma samples. Adherence
was defined as dapivirine levels of greater than 95 pg/mL, which indicated at least 8 hours
of continuous use. Residual drug levels were also assessed in rings after the first year of
the study. A level of less than 23.5 mg of dapivirine remaining in the used vaginal ring
was defined as adherence; this amount indicated that at least 1.5 mg of dapivirine was re-
leased, which indicated some use during the month. Eighty-two percent (82%) of plasma
samples detected dapivirine at concentration levels of greater than 95 pg/mL. These analy-
ses indicated that better adherence was associated with improved HIV protection. While
overall the trial found a reduction in HIV incidence, HIV protection was not observed
in women aged between 18 and 21 years. Both adherence and biologic effects are believed
to have contributed to this finding. The dapivirine ring was also found to be safe.125
6.3.2 ipm dapivirine ring study
The International Partnership for Microbicides’s (IPM) Ring Study126 was a randomised,
double-blind, placebo-controlled phase III trial to test the effectiveness and long-term
safety of a 4-weekly vaginal ring filled with dapivirine (25 mg), used to prevent HIV infec-
tion in healthy women. A total of 1959 women were enrolled in South Africa and Uganda.
The trial began in April 2012 and was scheduled to end in December 2016. Due to the
HIV prevention results of the ASPIRE study, the Ring Study reported their results early.
The Ring Study found the dapivirine ring was able to reduce HIV incidence by 31% (95%
CI 1–52). The Ring Study also found that HIV protection was less in women aged 21 and
younger. The ring was also found to be safe in this study. Adherence was measured by
testing the amount of dapivirine in plasma samples collected each month, and the amount
of residual dapivirine in used rings, collected every month. These analyses indicated that
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better adherence was associated with improved HIV protection. Due to the beneficial
findings of the ASPIRE study together with the Ring Study, all participants in the Ring
Study were provided with dapivirine rings for the remainder of their participation.126
6.3.3 voice
The MTN’s Vaginal and Oral Interventions to Control the Epidemic (VOICE) study was
a 5-arm, randomised, placebo-controlled phase IIb trial to assess daily use of 1% teno-
fovir (TFV) vaginal gel, or oral tenofovir disoproxil fumarate (TDF), or oral tenofovir–
emtricitabine (TDF/FTC) against HIV infection. Women in South Africa, Uganda, and
Zimbabwe were enrolled. The trial began in 2009, and results were reported in February
2015. At the start of this PhD research, VOICE was an ongoing trial actively collecting
data.136
In September 2011, the DSMB recommended that the oral TDF arm be suspended due
to futility, followed by a recommendation in November 2011 that the TFV gel arm be
suspended for futility. The TDF/FTC and oral placebo arms continued until trial com-
pletion in August 2012. In the final analysis, no study product was found to affect HIV
incidence compared to the placebo arms (TFV gel vs placebo gel HR 0.85; 95% CI 0.61–
1.21). The mean proportion of quarterly plasma samples with TFV detected was 25%, and
the mean proportion of vaginal swab samples with TFV detected was 49%. Adherence
assessed by FTFIs for TFV gel and placebo gel in the past week were 90% and 90%, re-
spectively. Applicator counts conducted at the clinics indicated 83% and 84% adherence,
respectively. The mean rates of adherence via ACASI for TFV gel and placebo gel were
88% and 89%, respectively. As evidenced by the biomarker data for TVF, poor adherence
was identified as the cause of the inability of the trial to demonstrate an HIV prevention
effect. The VOICE trial team also reported that the daily use regimen for this population
was not ideal.114 Tenofovir gel was deemed safe in this clinical trial.
6.3.4 facts 001
The Follow-on African Consortium for Tenofovir Studies (FACTS) 001 study was a phase
III, randomised, placebo-controlled trial of peri-coital use (BAT 24 regimen) of 1% teno-
fovir gel against transmission of HIV. This trial was intended to confirm the results of
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CAPRISA 004 and was conducted in nine sites in South Africa over 27 months, with
2059 women aged 18–30.124 The trial was conducted between October 2011 and August
2014. The primary results of the study did not show a protective effect of before and after
sex gel dosing to prevent HIV transmission (incidence rate ratio 1.0; 95% CI 0.7–1.4). The
gel was found to be safe. Adherence was measured as an estimate of the percent of sex acts
covered, calculated by inspected returned used applicators and self-reported number of
sex acts. Adherence was estimated to be 50–60% of sex acts per month covered by gel. In a
pre-specified case cohort sub-study, quarterly cervical vaginal lavage (CVL) samples were
used to measure tenofovir levels and found that tenofovir was associated with a reduction
in HIV incidence in those who reported sexual activity in the past 10 days (HR 0.48; 95%
CI 0.23–0.97).124
A unique aspect of FACTS 001 was that the trial team aimed to recruit young women,
with the oldest age for eligibility being 30 years old. Seventy percent (70%) of the partic-
ipants were less than 25 years of age. Eighty-nine percent (89%) of the study population
was single, and 61–63% were living with their parents or siblings, which may have meant
that sex was occurring outside of the home and thus might have made adherence addi-
tionally challenging for this population.
6.4 the changing hiv prevention landscape
During the period of this PhD research, much progress has been made in the field of
biomedical HIV prevention. In 2015, the World Health Organization (WHO) released
Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for
HIV,155 which recommends that oral PrEP containing TDF be offered to individuals at
substantial risk of HIV infection, as a part of HIV combination approaches, and defines
substantial risk as HIV incidence of greater than 3 per 100 person-years. Recommend-
ing oral PrEP adds to the combination of HIV prevention options being rolled out and
scaled up globally; these include male and female condoms, voluntary medical male cir-
cumcision, HIV testing, and ARV initiation when testing HIV positive.
WHO guidelines must be adopted by individual countries and then scaled up to make
prevention options, such as oral PrEP, available to residents in need. Oral PrEP may be
an excellent option for women who see themselves at risk for HIV and would like to take
an oral pill on a daily basis to protect themselves from HIV. Currently, research results to
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support coital or “on demand” dosing of oral PrEP for women do not exist.
While new WHO recommendations are being adopted and scaled up globally, research
must continue to identify more HIV prevention options which women can control them-
selves, and particularly ones which can be effective when used just around the time of sex.
While the new WHO recommendations are milestones in biomedical HIV prevention re-
search, they will also make the clinical trial landscape more challenging to identify novel
methods.156
6.5 discussion of phd research results in context of recommen-
dations for future trials
This section provides a discussion of the key findings in this PhD research within the
context of recommendations for future microbicide trial design. This discussion is organ-
ised into sections describing trial planning, trial implementation, and results analysis and
reporting. While topics are discussed within one of the three stages of the trial life-cycle,
some of the topics, in reality, span more than one category. Relevant research results from
biomedical HIV prevention trials, published through 2015, are included where appropri-
ate. A summary of recommendations for future microbicide trial design is provided in
Table 6.5.1.
6.5.1 trial planning
6.5.1.1 overall design of trials needs to marry objectives of par-
ticipants and objectives of research teams
Results from the qualitative study in this PhD research found that women join and stay
in trials for a number of important reasons that may not be related to using a drug whose
efficacy at preventing HIV is unproven and whose complete safety is unknown.
Participants in this qualitative study reported that it was difficult for some participants to
honestly report their adherence because they thought doing so would put them at risk for
being removed from the trial and thus lose the benefits and financial reimbursements they
were receiving. Discrepancies in self-reported adherence data compared to biomarker or
applicator data from recent biomedical HIV prevention trials for women have shown
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Recommendations for improving microbicide trial design
Trial planning
•Trial design needs to consider participant objectives and perspectives
•Conduct formative research and community engagement to consider innovative trial design ideas
•Improve gel formulation: less watery consistency, warming sensation, ability to use more discretely, and more discreet packaging
•Questions about adherence should ask about non adherence first
•Include more careful wording of questions on CRFs which clearly refer to the information being asked
•Recruitment of participants should balance those likely to adhere and those in populations of higher HIV incidence
•Hire staff with excellent interpersonal skills who share trial values of respect and transparency
•Train all staff on the science of microbicide trials
•Provide clear and specific information in statistical analysis plans about how adherence will be estimated
•Conduct formative research for designing a male engagement plan
Trial implementation
•Use a simple diagram showing the microbicide trial process to teach participants how microbicide trials answer their research questions
•Create diagrams which show the chain of custody for blood samples, including bloods which are stored or used for confirmatory testing 
in central laboratories
•Explain trial procedures to participants while they are happening, including any reasons for delays.
•Checklists should include that staff have informed participants of the purpose of each tube of blood collected, and when results will be 
given.
•Provide a comprehensive male engagement programme which offers opportunities for engaging male partners throughout trial follow-
up.
•Include questions in visit checklists about new male partners and whether the participant would like support disclosing trial participation.
•Offer "open days" for male partners at the study clinic to describe the purpose of the trial and to provide information about the gel and 
trial procedures.
•Create and use a peer educator programme to assist with adherence.
•Include a technology for applicator testing to identify applicators expelled vaginally.
•Provide applicator-testing results to participants on a regular basis.
•Provide sites with ongoing information about adherence, explore site differences in adherence, take corrective actions as necessary.
Trial results analysis and reporting
•For adherence data, use an analysis approach which shows patterns of adherence over time, such as latent class and latent profile 
analysis.
•Use multinomial logistic regression to look at factors associated with different patterns of adherence.
•Methods and results sections of publications should include clear information about adherence estimation, and any deviances from 
planned analyses.
•Adherence results in publications should include analyses which describe microbicide use over time.
Table 6.5.1: Summary of recommendations for future microbicide trial design
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that participants consistently overreport their adherence. CAPRISA 004 found that ad-
herence based on self-reported last sex act alone resulted in an estimate of 82% adherence,
whereas estimates of adherence which were derived from self-report and applicator counts
resulted in an estimate of adherence of 72.2%.157 The VOICE trial also found evidence
that participants overreported their own adherence. A sub-study of 158 active gel users
found an estimated 65% had not used the gel in the past 7 days, according to pharmacoki-
netic (PK) data taken from vaginal swabs. For the same period of 7 days, self-reported
adherence in FTFIs indicated non-adherence was only 2%. When ACASI was used to ask
the same questions, non-adherence was estimated to be 6%.88
FEM-PrEP, a phase III trial of once daily oral FTC/TDF pills for women, experienced
poor adherence which led to trial closure due to futility. Using self-reported data, 95% of
participants reported they had usually or always taken their study pill. Using pill counts,
it was estimated that participants took pills for 88% of the days on trial.94 Plasma and
intracellular drug concentrations among a sub-cohort showed that only 12% of the sub-
cohort had achieved good adherence throughout their participation and 23% had rarely,
if ever, taken their study pills; 60% of participants had fluctuating adherence throughout
the trial.96 In a FEM-PrEP follow-up study with 224 former trial participants, 31% stated
they overreported adherence while in the trial. Sixty-nine percent (69%) of those who re-
ported that they had overreported their adherence during trial participation said they did
so because they were worried they would be terminated from the trial.95
participant objectives
The VOICE trial team found, in two separate qualitative studies related to VOICE, that
participants joined and stayed in trials for quality health services, free treatments, regular
HIV testing, and reimbursements.114,115,116 FEM-PrEP also found that participants stated
they joined and stayed in trials for health care services, such as regular HIV and pregnancy
testing, free check-ups, contraceptives, and treatment for common ailments, as well as re-
imbursements.95,117 MDP 301 also heard reports from participants that women joined to
know their HIV status, to receive physical exams, and that some joined and remained in
trials for reimbursements, which in South Africa, due to a regulatory guideline, greatly
exceeded the cost of travel to and from the clinic.118
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participant fear
Critical to the improvement of microbicide trial design is to understand that many par-
ticipants have concerns about using an investigational product or do not intend to use
it. Results from VOICE were similar to findings in the qualitative study within this PhD
research, where some participants expressed fear of experiencing side effects or harm from
the experimental products. A quotation from a participant in the VOICE D study states
“Why don’t they do the research on themselves? They do it on us. I do not use that thing,
I just put it there. I do not insert it. Why do they not use it? What if it causes a problem
to us?”116 This sentiment was expressed by participants in this PhD research. The FEM-
PrEP trial found that participants were willing to be more truthful after trial completion.
In a follow-up study, it was found that the investigational nature of the drug accounted for
47% of participant non-adherence. The trial team concluded that apprehension around
the investigational drug and potential side effects was a substantial contributor to non-
adherence in their trial.117 They noted that “alternative study designs or procedures may
be needed in future studies to provide women an opportunity to receive the benefts of
a study without being enrolled, reserving enrolment and study product distribution for
participants who are more likely to adhere.”117 The trial team also observed that “Improve-
ments to adherence counselling and participant self-reports will only be benefcial if study
populations enrol in such trials with some interest in taking the study product.”138
Recent research findings suggest that when participants know the product is effective and
are enrolled in open label studies of oral PrEP, their adherence is improved158 and esti-
mates of effectiveness are even higher than in phase III trials.159 As microbicide research
results indicate that adherence is suboptimal due to participants’ concerns about the in-
vestigational nature of the products, it would be expected that open label studies with
products whose effectiveness has been demonstrated would likely result in higher adher-
ence by participants, resulting in improved rates of HIV incidence reduction.
need for innovative design
In thinking about how microbicide trials can be designed to better answer their research
questions, research teams need to consider that the way they design and run clinical trials
is from a particular perspective, which is their own perspective, and to consider that their
own perspective is different from the perspective of participants who are asked to join
these trials in sub-Saharan Africa. Trial funders, sponsors, and implementers have been
trained to see a clinical trial as a scientific study where individuals are asked to volunteer to
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use an experimental product in accordance with a specific protocol; in exchange for time
and inconvenience, those volunteers are provided with a type of reimbursement.
Recent research using qualitative methods has shown that trial participants in biomed-
ical HIV prevention trials have a different perspective. Many women in these settings
see a clinical trial as a way to receive health care and money to help improve their lives.
While research teams are often aware that participants in trial communities would like
to be provided with long term income and health care, research teams also know that
provision of these is not possible within the context of clinical trials. This creates an on-
going tension between trial implementers and communities where microbicide trials are
conducted. Years of research has shown that researchers continue to design microbicide
trials in a similar fashion which does not fully integrate the realities of participants’ per-
spectives into trial design, and, prior to when this PhD research commenced, sometimes
misunderstood the underlying reasons why adherence may be low. Research teams need
to work harder to design microbicide gel trials that will be able to answer their research
questions in the context of how women being asked to participate perceive these trials. As
shown in the findings of the qualitative study in this PhD research, one possibility would
be to explore a trial whose design includes the option for women to join and receive the
benefits they would like, and assign the gel only to women who explicitly would like to
use it. While it is unlikely that trial funders would initially agree to such a trial design,
the results from VOICE and FACTS 001 provide merit to the argument that innovation
in trial design is warranted. The findings of this PhD research showed that trial teams
can work together with former microbicide participants to brainstorm and consider dif-
ferent innovative options for trial design. These consultations and collaborations should
take place at the formative stage of research, in accordance with the GPP guidelines.40
Meaningful understanding and integration of the underlying reasons for low adherence
and true engagement with former trial participants and communities around innovative
ways to consider trial design may result in more creative solutions than what trial teams
may have expected was possible.
6.5.1.2 gel formulation
Overall, results from microbicide studies provide good evidence that the gels have been
received well by participants. Participants have reported that the gel has made sex more
pleasurable, decreased pain from sex, increased libido, and, in the context of trial partic-
ipation, has increased intimacy and dialog with male partners. Results have also shown
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that gel use fits into vaginal practices in some areas.160,161,146,147,148,149,129,150,151
The qualitative study in this PhD research focused on understanding barriers to adher-
ence and barriers to accurate reporting of adherence. Results from this study indicate
that negative male partner response or fear of negative male partner response had a neg-
ative effect on some participants’ ability to use the gel in accordance with the protocol.
This issue was brought up as a factor by participants in Mwanza, Tanzania. Participants
in Mwanza noted that the increased lubrication was noticeable to their regular male part-
ners, and that some male partners who were not informed in advance about the gel or trial
participation perceived the increased lubrication to mean their partners were having sex
with other men. Participants reported that this led to conflict in some relationships, some
participants dropping out of the trial, and some participants not being able to adhere to
gel use in accordance with the protocol. These experiences caused some participants in
Mwanza to suggest that the gel formulation be modified so that it was not as easily de-
tectable to male partners. They suggested the consistency of the gel be thicker, less runny,
and have a warming sensation rather than a coldness. Even with these reported problems
with the gel, participants in the qualitative study within this PhD research expressed in-
terest in and hope for a gel that could prevent HIV transmission. Some participants also
acknowledged that the lubricating effects of the gel could help reduce pain during sex, and
that different people have different needs and preferences.
Results found in this PhD study do not contradict the findings of other studies where re-
sults reported dominant themes around increased pleasure and benefits from the lubricat-
ing effects of the gel. Rather, the findings in this PhD research, which included 46 former
microbicide trial participants, add to the body of data about women’s experiences with in-
vestigational microbicide gels in clinical trial settings. This PhD study focused on barriers
to adherence, and thus the discussions were focused on problem-solving. As women were
no longer enrolled in the trials, they also may have been more willing to disclose problems
with adherence. While the VOICE team found that participants were not more willing to
disclose non-adherence at study exit compared to during regular follow-up visits,162 they
did find that participants presented with their own PK results in a follow-up study were
able to acknowledge product non-use and provide reasons for lack of adherence.114
Remembering the context of the evolution of the microbicide field is important in ex-
amining the breadth of reactions to microbicide gels. Initially in the microbicide field,
there was concern that a lubricating gel might not be acceptable in parts of Africa, espe-
cially in locations where “dry sex” had been reported as preferred.148 Questions around
CHAPTER 6. discussion 220
the feasibility of a vaginal microbicide for HIV prevention in African settings were fo-
cused on whether such a product would be acceptable to users. The field was surprised
when a considerable amount of data, particularly from MDP 301, indicated that the gel
was not only acceptable but also appreciated and perceived as highly beneficial by trial
participants. These results were unexpected, and exciting for the feasibility of vaginal mi-
crobicide development.
While participants who experienced relationship conflicts around gel use would be more
likely to withdraw or be lost to follow-up, results from studies have not been universally
positive. An analysis of qualitative data from MDP 301 participants in Johannesburg
found that 51% of cases of intimate partner violence (IPV) reported due to trial participa-
tion were attributed to partner dissatisfaction with the gel,141 for reasons similar to those
reported by participants in Mwanza. Results from the pilot study of MDP 301 recruiting
320 women in South Africa, Tanzania, Uganda, and Zambia found that male partners
in Tanzania liked the gel less than in other locations due to the increased lubrication.163
VOICE and CAPRISA 004 also found that participants reported fear that the extra lubri-
cation might cause suspicion or complaints by male partners,116,164 and reports of male
resistance to gel use were documented in the Carraguard trial.140
The combined experiences of microbicide gel use by different participants provides fur-
ther evidence that a single HIV prevention technology or strategy will not be appropriate
for the diverse population of humans. Individuals have different needs, and the needs of
each individual change as their circumstances change through life. A range of HIV preven-
tion options and a range of female-controlled HIV prevention options are an appropriate
public health response to the HIV epidemic. A vaginal ring might be an appropriate so-
lution for some women. Those who benefit from additional lubrication might prefer a
vaginal gel. Others who want a product they can use covertly and only around the time
of sex might prefer a less-lubricating formulation such as a vaginal film or capsule.
Overall, evidence from the body of microbicide gel trials is strong that women liked the
gels tested and would like to have HIV prevention methods available to them that they
can control and that are effective and safe. The vaginal ring is likely to be the first method
approved by regulatory agencies and rolled out to communities. While the availability
of any effective female-controlled HIV prevention method will be a major benefit for
women globally, this method does not address a number of important needs for some
women. A ring will not meet the needs of women who would like a coitally dependent
regimen, a ring will not meet the needs of women who would like an HIV prevention
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method which has the added effect of lubrication, reducing pain during sex and making
sex more pleasurable, and a ring will not meet the needs of women who would not like
to expose their bodies to an anti-retroviral drug on a continuous basis. These are all rea-
sons why the biomedical HIV prevention community must continue to work to identify
a coitally dependent vaginal gel for HIV prevention.
6.5.1.3 design of questions on crfs
Results from the comparative study in this PhD research showed that the wording of
some questions designed to gather data on sexual behaviour and adherence were ambigu-
ous, and this ambiguity may have led to different interpretations by different participants.
Results from the trial team survey indicated that, in order to reduce social desirability bias,
questions on product use should be asked in a way that begins with the assumption that
some non-use will occur.
Including clear language such as the number of days, 7 or 30, rather than ambiguous terms
like “week” and “month” are recommended. Adherence questions introduced with per-
missive statements acknowledging that it is not possible for everyone to have perfect adher-
ence are also recommended. These questions can be followed by questions on the number
of times in a particular period of time when product use was not possible. Questions that
ask about product use over a series of sex acts or days may be more easily answered by
asking participants about their last sex act, followed by asking about the sex act prior to
that one, and so on. Terms and their translations should be validated before being used in
forms. For example, vaginal sex can be clarified by statements such as “when a man puts
his penis in your vagina.” Trial teams can also consider using triangulation forms that
can help reconcile data from different adherence collection methods. Trial teams should
conduct formative research and pilot questions to verify questions are understood in the
way trial teams intended.
6.5.1.4 recruitment of participants
The latent structure analysis in this PhD research has shown that older participants report
higher adherence. This has been observed in other studies as well.120,121,122,123 Data from
multiple studies also suggest that younger participants, who may have lower adherence,
may also be more at risk for HIV infection.123,1 The reality of biomedical HIV preven-
tion trials is that groups who typically have lower adherence to study products are also
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the same groups who have the highest rates of HIV incidence, and are therefore essential
to include in trials in order to meet their research objectives. Trial teams can use the body
of data about participant attributes, and their relation to both HIV risk and adherence,
to recruit prospective participants so the overall composition includes a balance of par-
ticipants who may be more likely to use the gel and who are also likely to have a higher
incidence of HIV infection.
6.5.1.5 recruitment and training of staff
Participants in the qualitative study of this PhD research spoke of the importance of
friendly, transparent relationships between participants and staff. The MDP 301 trial
team, in its analysis of data from using mixed methods to capture adherence data, ac-
knowledged the importance of interpersonal skills of staff members, as well as their train-
ing, in obtaining accurate results.70 The importance of staff selection, training, and su-
pervision is critical to successful clinical trial implementation. Its importance, however, is
often overlooked and not discussed thoroughly in the literature.
Future trials should invest the time and resources it takes to ensure that staff being hired
have excellent interpersonal skills and have values that align with treating participants
with respect and making them feel welcome, comfortable to answer sensitive questions,
and happy to discuss trial procedures candidly to improve trial transparency.
6.5.1.6 statistical analysis plans
Results from the comparative study in this PhD research showed that there was a lack of
clarity in trial materials about analysis of adherence data. Given the central importance of
adherence to microbicide trial interpretation, trial teams should take care to define plans
for adherence analysis and clearly describe those in the statistical analysis plans before trial
data are analysed, in order to avoid selective reporting of data.
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6.5.2 trial implementation
6.5.2.1 male partner engagement
Both the qualitative and the latent structure studies in this PhD research found that male
partners have an effect on participants’ abilities to use the gel in accordance with the pro-
tocol. A large body of data including both qualitative and quantitative data now shows
that successful participation in microbicide trials by women can be affected by male part-
ners.127 Findings from studies have shown that participants overwhelmingly prefer to
tell their partners about gel use during microbicide trial participation. Results have also
shown that adherence can be improved when male partners are aware of gel use or provide
support, and that negative reactions by male partners can lead to suboptimal adherence,
conflict, and intimate partner violence. These results are discussed below.
The VOICE trial, through a qualitative study with participants in Johannesburg,115,116,128
found that male partners directly and indirectly affected participant trial participation
and gel use, and that this was true for both gel users and tablet users. Some participants
were afraid of male partner reactions to trial participation, expecting they would refuse or
react negatively. Other participants found that they were eventually able to gain approval
after telling their partners about the study and the benefits of participation. Male part-
ner discontent influenced participants’ willingness to use products, in some cases made
use difficult for participants, and in other cases promoted clandestine use.116 Women who
reported living in a supportive or understanding environment reported fewer problems
with using their products.116 The site in Kampala, Uganda, found that partners who came
to the study clinic played a supportive role in product use.131
The Carraguard trial, in examining qualitative data from two sub-studies140 during the
phase III trial, found that participants largely preferred to communicate involvement in
the trial to their male partners. The timing and nature of discussions, however, depended
on the motivation for disclosure. Some participants chose to disclose trial participation
to promote positive trust-building aspects of the relationships, while others disclosed to
avoid negative consequences within the relationship if they did not disclose. A minority
of participants chose not to disclose, and this was more common in relationships with
non-regular partners. Based on experiences reported by participants, male partner en-
gagement fell into three broad categories: active support, non-interference, and active
resistance.140
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MDP 301 results from South Africa also found that male partners were a factor for women
enrolled in the trial.141,142 In Johannesburg, a qualitative study of 150 participants found
that 129 decided to tell their partners about their trial participation, either for reasons of
trust and respect or out of fear of negative repercussions in the relationship or to avoid
conflict. This study also found that 52% of IPV reported by participants was attributed
to trial participation, due either to gel use or aspects of trial requirements and participa-
tion.141 In KwaZulu-Natal, participants preferred to tell their partners about gel use: 60%
had discussed microbicides with their male partners within 4 weeks of participating in the
trial, and 84% had done so after 52 weeks of participation. The MDP 301 trial team found
a significant association between younger age and discussing gel use with male partners
after 4 weeks of trial participation.142
FEM-PrEP, looking at ARV pill use in women rather than gel use, found similar results to
vaginal gel trials with regard to the influence of male partners on trial participants’ use of
study products. In this trial, participants’ pill-taking behaviour was negatively affected by
both perceived and actual discouragement by male partners, and some participants chose
to hide their trial pills due to fear of a negative response.117 In looking at factors that fa-
cilitated adherence in the trial, the trial team found that partners who were aware of trial
participation could play a role in facilitating participant adherence to pills.165
CAPRISA 004, the only microbicide gel trial to find a significant reduction in HIV trans-
mission, found a modest but significant relationship between adherence and disclosure
of gel use to male partners, with participants who disclosed gel use having 4.2% (p=0.03)
increased adherence.143 A total of 67.3% (569) of participants who completed a partner
disclosure questionnaire at study exit reported that they had disclosed gel use to their last
sex partner. While women in both the disclosing and non-disclosing groups were similar
in age, marital status, and income, women who disclosed were more likely to be living
with their regular partner. Trial results indicated a trend that participants who disclosed
had lower incidence of HIV infection.143
Using a special questionnaire at study exit about partner change,121 HPTN 035 found
that self-reported gel use at last sex act was more likely to be reported by participants with
ongoing partners as opposed to participants with new partners. In addition to lower self-
reported adherence, this study found that participants with new partners had higher HIV
incidence. The HPTN 035 trial team concluded that specific counselling should be of-
fered to participants for when they change partners.121
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An older HIV prevention trial, the Methods for Improving Reproductive Health in Africa
(MIRA) trial, tested a diaphragm used with a lubricating (non-microbicidal) gel for HIV
prevention and was one of the first HIV prevention trials to report data about the relation-
ships between product adherence and male partners.144,72 In an ancillary study looking at
male partner influence on trial participation, the trial team found that most participants
(96.3%) stated they asked permission from their male partners to join the trial. Of those
women, 70% were concerned that if they did not ask permission they would face conflict
in their relationship. Women who reported telling their partner about study product use
every time they had sex were more than twice as likely to consistently use study products
(AOR 2.28, 95% CI 1.55–3.35). The trial team found that participants who stated they
would “face problems at home” by not first asking permission to join the study were less
likely to be consistent users (AOR 0.70, 95% CI 0.51–0.96). The study also found that a
participant’s perception of her partner’s view of study products affected adherence: par-
ticipants who reported that their partner strongly liked the diaphragm were more than
twice as likely to be consistent diaphragm and gel users (AOR 2.27, 95% CI 1.64–3.15).144
A separate analysis looking at predictors of product use in the trial found that consistent
use of diaphragm was associated with being less likely to have experienced IPV (AOR,
0.38; 95% CI 0.15–0.95). This analysis also showed that participants whose partners al-
ways knew when they used the diaphragm were 2.18 times (95% CI 1.06–4.49) more likely
to be consistent users compared to sometimes users.145
In the past different trial teams have tried various partner engagement strategies and have
found this issue difficult to tackle. The types of strategies and whether they were imple-
mented comprehensively as a programme have not been well documented in the litera-
ture; nor has evaluation of such strategies. It is clear from a wide range of research results
that male partner influence is a critical factor in participant adherence. Future trials will
need to do more than include a number of male partner engagement strategies. Rather,
they will need to create robust, comprehensive programmes for male partner engagement
from the start of the trial and continuing through follow-up, as participants can have
multiple partners and change partners over time. The plan can be designed during the
formative research process. Trial procedures can include informing participants at the
start of the trial about partner involvement support mechanisms, in case they would like
to inform a partner and receive support in that process. Participants can be informed of
experiences of past microbicide gel trial participants, for example that most found their
regular partner was able to notice a difference when having sex with the gel, that most
participants eventually chose to inform their regular male partners about the gel, and
that telling partners has helped some participants receive support from partners for us-
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ing the gel. Participants can then be informed about a range of support mechanisms to
help participants tell their male partners about the study. These can include provision of
study information materials targeted at partners and provision of invitations for partners
to come to the trial clinic to meet with a trial team member, with or without the partici-
pant. The trial team could host special seminars or “open days” at the clinic, during nights
or on weekends, that would explain the purpose of the trial and what the gel is, and in-
clude a tour of the clinic and laboratory while explaining trial procedures. In particular,
tours should offer detailed explanations about blood tests and blood processing. For par-
ticipants who have partners who are too busy to visit the clinic, trial teams could offer to
visit participant homes to speak directly with partners, upon invitation from participants.
Visit checklists can include specific questions about whether the participant would like
support around disclosing to male partners, or if she would like support on how to use
the gel without disclosing. As participants may have different needs and different partners
over time, it is important that visit checklists, used at regular intervals, include questions
about whether participants would like support in informing partners. If couples who
use and like the gel are identified over time, they could be asked to be peer educators and
receive special training on how to support other participants who would like to disclose
to male partners. A critical component of a comprehensive support programme is to en-
sure that participants understand disclosure is their decision, and that the trial team will
support them in whatever choice they make.
6.5.2.2 clarity and transparency in trial conduct
how trials answer their research questions
Results from the qualitative study in this PhD research identified that, from the perspec-
tive of participants, there was a lack of clarity about how microbicide trials answer their
research questions and the mechanism by which participant adherence affects trial results.
Due to the complicated nature of microbicide trials and their required procedures, trials
over the years have increasingly invested resources in providing easy to understand ma-
terials for participants. Ethical requirements of clinical trials state that informed consent
(IC) forms must provide information about the trial purpose, benefits, risks, and required
procedures (among other information).44 There is no requirement to tell participants
how trials answer research questions. Before the microbicide field understood the extent
to which low adherence was affecting trial results, providing this additional information
would not have been a priority. As participants in the qualitative study reported that un-
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derstanding how the trials work and how their own adherence can affect trial outcomes,
this section examines the information they did receive, and provides recommendations
for information that can be included in future trials.
Microbicide trial teams have found that that additional supportive materials are helpful
to ensure that participants correctly understand what participation means. More recently,
trial teams have begun to typically prepare materials in the form of booklets or table-top
flipcharts with culturally appropriate illustrations and simple language. In addition, trial
teams may include questionnaires to test the comprehension of prospective participants
to ensure that the contents of the IC forms have been correctly understood and that par-
ticipation is voluntary.
Upon examination of the IC forms for MDP 301 and VOICE, and results of the qualita-
tive study in this PhD research, it is indeed evident that participant materials are focused
on trial procedures but do not explain the mechanism of how a trial answers its research
question. The IC materials for MDP 301 screening state that the purpose of the trial is to
find a new way to prevent sexual transmission of HIV, and that PRO 2000 is being tested
for both effectiveness at prevention HIV and safety. It explains that PRO 2000 is an ex-
perimental drug and that it is not known if the drug prevents HIV transmission. The
form states, “Another gel which has been specifically matched is a dummy gel known as a
‘placebo’. This dummy gel has no activity against HIV.” The form explains that the gels
look alike and that chance will determine if the participant receives the PRO 2000 gel or
the dummy gel. The form then states, “You will receive the same type of gel throughout
the trial. NO-ONE KNOWS WHICH GEL THEY ARE ON, including the study staff.
This is the best and only way to test the gels to see if they prevent HIV infection.” The
form then continues to explain the specific procedures of trial participation and other re-
quired information. At the end of the form, a section entitled “What will happen to the
results?’ explains that “After the study has been completed the results will be analysed.”
The form then states that participants will be informed of which gel they used. The en-
rolment IC form has a section called “A reminder about the purpose of this trial” which
states, “The question we are trying to answer is ‘does 0.5% or 2% PRO 2000/5 gel pre-
vent HIV?”’ The form then states, “The best way to answer this question is in a clinical
trial, where women are allocated by chance to 0.5%, 2% or placebo (dummy gel with no
activity against HIV). This way, the risk factors that are linked to HIV, such as not using
condoms, are evenly balanced across the three groups.”
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The accompanying animated booklet provides clear explanations of study procedures
from the perspective of the participant. Based on these materials, which are centrally pro-
vided by the trial and can be tailored at local sites, it would not be possible for a participant
to understand how the trial answers its research question or why product use at each sex
act would be important. While concepts of randomisation and placebo are mentioned,
there is no statement that tells participants that the way trial teams learn if PRO 2000 is
effective or not at HIV prevention is to compare, at the end of the trial, the number of
women who get HIV in the group that used PRO 2000 with the number of women who
get HIV in the trial that used the placebo gel. Unless this is stated explicitly, it is not possi-
ble for a lay person to understand how a clinical trial is able to know if an investigational
gel prevents HIV transmission. Participants, therefore, would also not understand why
their adherence was critical.
The VOICE IC materials, compared to the MDP 301 materials, provide more detailed ex-
planations of the trial and trial procedures, using clear language. The enrolment IC form,
under “Purpose of the study,” explains that the trial is testing three products for effective-
ness at preventing HIV as well as testing the safety of the products. It explains that the trial
drugs are experimental and what is already known about the drugs. The IC form states
it is not known if the drugs prevent HIV. Under “Study groups,” the form explains that
there are five groups in the trial and that women will be allocated by chance. It explains
that two types of placebo exist for the trial (oral and gel), and that these products look like
the actual product but do not have any ingredients that prevent HIV. The form explains
that all groups are important to the study and then provides more detailed information
about expected use of products and study procedures. At the very end of the form, in
the “New information” section, there are two statements about what is known about the
study gel from the CAPRISA 004 and from TDF/FTC from the iPrEx trial. The state-
ment about the gel says, “The results of CAPRISA 004 showed that women who received
tenofovir gel had a lower risk of getting HIV during the trial, compared to women who
received the placebo gel.” This is the only statement in the document that could help a
woman understand what results at the end of a trial would look like, but does not explain
how the VOICE trial will answer its research question. This statement also comes near the
end of the form, on page 11, while discussing results of a different trial and not the trial
the participant is providing consent to join. The animated booklet/flip chart provides
clear and helpful information for participants about trial participation. When discussing
“study groups,” the booklet explains what placebos are and states that “you may wonder
why” some participants are given the actual drugs while others are given placebos. The
booklet then states, “the placebo gel and placebo tablets are needed to help researchers
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understand the effects of Tenofovir and Truvada. No one will know which women are
using Tenofovir or Truvada, and which are using placebo, until the study is finished. The
researchers will then compare the women who used Tenofovir or Truvada to the women
who used the placebo to find out if the Tenofovir or Truvada prevented women from
getting HIV.” This explanation also does not state exactly what is being compared and
how, although it provides somewhat more information than what is provided in any of
the other documents.
Because the purpose of the qualitative research in this PhD research was to seek sugges-
tions from former microbicide trial participants on how to improve adherence and ad-
herence reporting, it was essential that they understood why adherence is important in
microbicide trials. Participants were first provided with a clear explanation of how mi-
crobicide trials answer their research questions. This explanation was clear enough that
participants could answer for themselves what would happen if adherence was low in
the trial. Participants in the qualitative study found this explanation helpful, and it was
recommended that such explanations be included in future microbicide trials so that par-
ticipants are more empowered to understand how their behaviour affects trial outcomes.
How a trial answers its research question is most easily explained and understood using a
diagram that illustrates the trial process. The following description provides a list of key
elements that should be included in such a diagram so the trial process is transparent to
those who volunteer to participate. The diagram is read from the top of the page to the
bottom of the page. A group of women at the top of the diagram is labelled “HIV nega-
tive women.” This illustration shows participants the starting point. The diagram is then
divided into two equal groups by arrows; half of the women are going to one side and half
to the other side. One group is labelled “Active gel” and the other group of women, on
the other side, is labelled “Placebo gel.” Here, the concepts of placebo and randomisation
can be explained, as well as the prevention package that goes along with each type of gel.
After being assigned to use a particular gel, participants will continue with their normal
lives, using the gel as directed and attending study visits.
The picture also shows that participants are followed up over time; at the bottom of the
diagram, the group of participants on the active gel arm is divided into two groups that
have different numbers of participants. One group is labelled “HIV positive” and the
other group is labelled “HIV negative.” The number of HIV positive women is notice-
ably lower than the number of HIV negative women. On the other side of the diagram,
the placebo arm is divided into two groups: those who are HIV positive, and those who
CHAPTER 6. discussion 230
are HIV negative. For illustration purposes, the HIV positive group should clearly in-
clude more women than the number of HIV positive women on the active gel side. What
can then be explained to participants is that the number of women who become positive
in the two groups is compared; thus, participants can see for themselves that because ev-
erything else was the same, the difference in HIV infection must have been due to the
special ingredients in the active gel, which in turn shows that the active gel was effective at
preventing HIV transmission. The diagram can then be used as the basis for discussion of
different outcomes in HIV results and what the interpretations could be. The concept of
adherence can then be introduced, and participants can be asked what HIV results would
look like if no one used the gel.
clarity in procedures at each stage of trial participation
Trial teams over the years have increasingly included culturally sensitive materials to help
participants understand the purpose of blood draws, how much blood will be taken, and
how blood specimens will be handled. Both MDP 301 and VOICE developed and used
such carefully created materials. Participants from both trials in the qualitative study
within this PhD research raised concerns about not knowing why certain test tubes of
blood were drawn, not always knowing where the blood was taken to, and sometimes not
receiving the test results. These circumstances raised doubts in the participants’ minds
about the research; moreover, such doubts can easily be exacerbated by rumours in the
community. While some trial teams have been careful to be clear about these procedures
due to the sensitive nature of blood draws in Africa, it is also important to remember that
most of this information is provided to participants at screening and enrolment and may
not necessarily be repeated or reinforced throughout the trial. Participants are provided
with a substantial amount of information at the beginning of the trial, and they may for-
get some of those details as time passes. Also, as time passes, participants may start to
have doubts or questions which they did not have at the start of the trial. Trial teams
can mitigate negative consequences of participant doubt by creating a structure of com-
munication that helps procedures appear transparent to participants throughout the trial
process.
Results from this research indicate that participants would like to know about each proce-
dure as it is happening. This updating can create an atmosphere of greater transparency
and trust. Visit checklists can include a section for informing participants about what
each test tube of blood will be tested for and when the results will be ready. Trial teams
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can create simple diagrams that show the local chain of custody for blood, where each
tube of blood is tested, and where it is stored. Tubes of blood which are sent to a central
laboratory for confirmatory testing or for blood storage do not necessarily give rise to a
test result being reported back to participants, which can be confusing for participants.
Therefore, it is important for trial teams to create explanatory materials and diagrams to
explain confirmatory testing and blood storage.
6.5.2.3 inclusion of applicator testing and feedback to partic-
ipants
Different approaches to applicator assessment have been used in trials and continue to
be under development. As discussed earlier in this thesis, Carraguard developed a special
DSA to detect vaginally inserted applicators. HPTN 035 and VOICE did not ask partici-
pants to return used applicators. MDP 301 did ask participants to return used applicators.
Participants in the qualitative study in this PhD research strongly suggested the use of a
system in which used applicators could be distinguished from unused applicators, and
suggested that those results be provided to participants on an ongoing basis over follow-
up. Participants felt these procedures would help microbicide trial participants both to
have improved adherence and to be more likely to report their gel use accurately. These
results are echoed by findings in other biomedical HIV prevention trials for women. For
example, the VOICE trial team found that providing participants with their PK results in
the follow-up study, VOICE D, was acceptable and elicited more honest responses from
participants. In addition, the VOICE D study participants suggested that participants
should be provided with real-time adherence feedback.114,162 The FEM-PrEP trial also
concluded that real-time adherence feedback which preserves blinding could prevent so-
cial desirability bias and should be included in future trials.95,138 While provision of in-
dividual drug levels to participants can only be implemented after study exit in a blinded
trial, the advantage of systems to assess applicators is that results can be provided to par-
ticipants over follow-up, as they do not break blinding.
CAPRISA 004 asked participants to return used applicators. Fifteen months into trial
implementation, the trial team initiated a standardised protocol to differentiate empty
applicators from vaginally inserted empty applicators. The protocol, Visual Inspection of
Returned Empty Applicators (VIREA), was then used until trial completion.166 Results
of implementing the protocol showed that more-accurate assessment of applicator use
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was possible. Participants self-reported that 93.4% of returned applicators had been used;
however, using VIREA, the research team found that only 77.5% of the empty applica-
tors had been used. An increased risk of HIV (HR 1.9; 95% CI 1.1–3.5) was found among
participants who had fewer than half of the empty returned applicators determined to be
used by VIREA. While this method requires visual inspection which is subjective, has a
learning curve, and requires training and quality assurance monitoring, it is inexpensive
and can be completed in trial clinics in real time, which in turn enables research teams
to provide participants with adherence feedback in a prospective manner. The trial team
also found that asking participants not to wipe or wash used applicators and return them
to the clinic in provided strip-lock bags was feasible.166
More sophisticated methods of measurement are in development, such as viewing used
applicators under ultraviolet light (UVL)152,99 and swabbing used applicators to detect
DNA and protein biomarkers for vaginal insertion and semen exposure.153 A study com-
paring UVL reading, visual inspection, and the DNA and protein biomarkers found that
the DNA and protein biomarker method had better sensitivity and specificity than UVL
or visual inspection, which were both found to be subjective and to have a learning curve
for readers.100 While testing for DNA and protein biomarkers for vaginal insertion per-
formed better according to sensitivity and specificity, they are labour-intensive processes
that require expensive equipment and supplies. Technological progress in developing im-
proved ways to test applicators, as well as other ways to assess adherence,167,168,114,166,169 are
exciting steps towards improved adherence measurement. Advantages of new technolo-
gies will have to be balanced with feasibility and cost—factors which will likely change
over time.
6.5.2.4 feedback adherence data to participants and sites over
follow-up
To facilitate improving adherence prospectively, trial teams can analyse real-time adher-
ence data. These results can be reported back to participants as a platform to discuss ad-
herence and trial participation. This can be integrated into a comprehensive adherence
program, which also asks participants at selected points in time if they have any questions
about blood draws, problems with partners, influence from other individuals or commu-
nity members, or procedures that are not clear. Individual participant adherence can be
provided to participants, or results of analyses such as latent structure analysis can be used
to describe adherence. Analyses can be conducted with data, such as looking at differences
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in adherence by site; these differences can be explored to understand potential reasons for
differences, and corrective actions taken.
6.5.3 trial results analysis and reporting
6.5.3.1 analysis
The results of this PhD research have shown that trial results are typically reported as
overall averages, which do not appropriately convey the reality of adherence of trial par-
ticipants, as this changes over time. The latent structure analysis in this PhD research
showed that adherence data analysed over time reveals different patterns of adherence in
the trial population, which conveys more information than reporting averages alone, even
with self-reported data. This research has also shown that multinomial logistic regression
can help identify which factors are associated with different patterns of adherence. Both
of these methods are inexpensive and can be used with self-reported or biomarker data.
6.5.3.2 results reporting in publications
Due to the benefit of understanding adherence patterns gained through latent structure
analysis, it is recommended that trials use this method to report adherence information,
in addition to providing averages or static estimates. If space limitations restrict full de-
scriptions of adherence analyses in primary results publications, trial teams can use the
option of supplemental online information that many publications now offer. Methods
and results sections of publications should be clear and transparent about how adherence
calculations were made. If adherence calculations deviate from SAPs, this should be stated
and the reasons given.
6.6 limitations and strengths
The research chapters of this thesis (Chapters 3, 4, and 5) describe in detail the limitations
of the particular studies. This section provides a summary of key limitations of this PhD
research and discusses the strengths of the research.
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6.6.1 limitations
Overall, the main limitation of this research is that the trials and data included largely draw
from second generation microbicide trials, whereas the field has moved on to test microbi-
cides with ARVs, which allows greater ability to use biomarkers for adherence estimation.
Third generation microbicide trials have been designed in the context of knowing that
adherence in microbicide trials may be low while self-reported adherence may be high.
Third generation trials have more carefully considered adherence counselling, measure-
ment, and estimation. While CAPRISA 004 was included in the comparative study of
this PhD research, the other five trials were second-generation microbicide trials.
The main limitation of the latent structure analysis is that all of the adherence and be-
havioural data used in the analysis were self-reported. Results of the study are therefore
subject to both recall bias and social desirability bias. It is likely that estimates of adher-
ence are inflated compared to actual adherence. Another limitation of the latent struc-
ture analysis is that participants who missed study visits or were lost to follow-up did not
contribute adherence data to the models. Those participants may represent a group of
women who are more likely to have lower adherence than participants who attended reg-
ularly and completed the trials. These limitations may have resulted in latent structures
that are biased in the direction of showing more adherence at each of the time points.
The qualitative study within this PhD research was small, with only 46 participants, and
was conducted in two locations. For the majority of participants, a long time had elapsed
between microbicide trial participation and participation in this study, and the partici-
pants who did participate in the qualitative study represented individuals who were still
living in the vicinity of the trial sites. These women may be different in a number of ways
from those who are no longer living in the same areas or not able to attend on the days of
the FGDWs.
6.6.2 strengths
A strength of this PhD project is that it critically examined adherence in vaginal micro-
bicide gel trials as a trial design issue from three perspectives, using three different types
of data and three different analytical approaches. This project used data sources that in-
cluded trial implementation and reporting materials, quantitative adherence data from
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microbicide trials, and qualitative data from former microbicide trial participants, in or-
der to understand ways to improve the design of future microbicide trials for improved
adherence, improved estimation of adherence, and improved reporting of adherence.
The comparative study was the first study to compare exactly how a selection of micro-
bicide trials calculated and reported adherence and to link this process to statistical anal-
ysis plans and source questions on CRFs. This study identified issues with wording of
questions used to collect data from participants and gaps in explanations about analysis
methods in SAPs and publications. This study found that trials described adherence in
primary results manuscripts as means or medians, despite adherence data being collected
throughout follow-up. This study, which was comprehensive in that five microbicide tri-
als were included in its analysis, found that there was considerable variability in how trial
teams collected adherence data and estimated and reported adherence.
The latent structure study was the first study to use latent class analysis and latent profile
analysis to identify patterns of adherence across four different microbicide trials using self-
reported adherence data that, on average, appeared consistently high. This study demon-
strated that latent structure analysis is a feasible method to analyse and characterise the
longitudinal nature of adherence data in microbicide trials. This study showed that pat-
terns of adherence appear to be similar across four different microbicide trials, and that
age and site are associated with different patterns of adherence. This study also found
that male partner disapproval of the gel was associated with trajectories of adherence that
decreased over trial follow-up.
The qualitative study included in this PhD research was the first study to engage former
microbicide trial participants in participatory activities to think explicitly about future
microbicide trial design with respect to improving adherence and adherence reporting.
This study created and used a novel approach, called focus group discussion workshops,
to combine methods such as focus group discussions, participatory activities, and small
group work to engage former microbicide trial participants with limited education in
thinking about how to design future microbicide trials so adherence and adherence re-
porting can be improved. This study, which was designed from the perspective of micro-
bicide trial participants, developed materials so participants could understand the science
behind clinical trials and low adherence, and thereby make constructive contributions to
the clinical trial design process. This study revealed that participants have their own ob-
jectives for joining microbicide trials that may not be related to using an investigational
product. Successful microbicide trial implementation will benefit from trial designs that
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consider and include the reasons why women join and stay in trials. This study showed
that trial teams can work with former trial participants and other stakeholders to consider
the feasibility of creative trial designs to improve future implementation of microbicide
trials.
6.7 conclusion: identifying a microbicide gel
The microbicide field was born out the need for women to protect themselves from HIV
without having to rely on male cooperation to use condoms. HIV disproportionally af-
fects women, who often do not have choice about how and when they have sex. Structural
factors perpetuate environments where women have less autonomy than men. A range
of methods for HIV prevention which women can use themselves is urgently needed.
Multiple effectiveness clinical trials have tested coitally dependent candidate microbicide
gels, with disappointing results. Low adherence has likely played an important role in
many of these trials being unable to accurately characterise the biological efficacy of the
candidate products. This PhD research has examined the complex nature of adherence
and adherence assessment in microbicide trials from three different perspectives, with the
goal of making concrete recommendations for future microbicide trial design to increase
the chance of demonstrating effectiveness of candidate products. This PhD research has
shown there are improvements to be made in how trialists plan, conduct, analyse, and
report results of microbicide trials.
Results of this PhD research have shown that the imbalance of power in intimate re-
lationships affects even the ability of trials to identify an effective microbicide, as trial
participants’ adherence can be affected by male sexual partners. Results of this research
have also shown that women in the settings where effectiveness microbicide trials are con-
ducted join trials for their own reasons, and not necessarily for the reasons that micro-
bicide trialists initially assumed. Trial participants may have doubts about using an in-
vestigational product whose effectiveness and safety are not yet proven, and the presence
of these doubts has affected adherence in past microbicide trials. Identifying an effective
product for HIV prevention for women requires better understanding of the lives and
perspectives of the women being asked to join the trials, as well as incorporating that un-
derstanding in future clinical trial design.
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It is important that donors and sponsors of microbicide trials understand the reality of
microbicide trials, which involve the complicated nature of sex and intimate relationships,
within the context of a world that provides fewer freedoms and opportunities for women
than it does for men. Rather than continuing to use standard clinical trial design ap-
proaches, innovative trial design ideas should be considered. While this consideration re-
quires investing time and resources into formative research and stakeholder engagement,
it will increase the chance of obtaining scientifically valid research results which can then
be used to improve the health of populations. The results of this research show that par-
ticipants and research staff can work together to develop and consider innovative trial
designs which better include women’s perspectives and increase the chance of identifying
an effective HIV prevention microbicide for coital use.
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